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 ABSTRACT 
TIMOTHY P. MORAN: Characterization of Dendritic Cells Transduced with Venezuelan 
Equine Encephalitis Virus Replicon Particles as Therapeutic Cancer Vaccines  
(Under the direction of Jonathan S. Serody and Robert E. Johnston) 
Cancer vaccines seek to harness the specificity of T and B lymphocytes for reduction of 
tumor burden, as well as prevention of recurrent disease by establishing immunological 
memory.  Because of their ability to initiate adaptive immune responses, dendritic cells 
(DCs) presenting tumor antigens have frequently been used as cancer vaccines.  
Unfortunately, induction of therapeutic responses in cancer patients has been sporadic, 
suggesting that current DC vaccines are unable to surmount tolerance against tumor antigens.  
The transduction of DCs with recombinant viral vectors may be a viable strategy for 
augmenting the ability of DC vaccines to break tolerance, as this approach can be used to 
efficiently deliver tumor antigens to DCs in the context of an immunostimulatory viral 
infection.  Therefore, we have investigated the potential of DCs transduced with Venezuelan 
equine encephalitis virus replicon particles (VRPs) as cancer vaccines.  VRPs could 
efficiently transduce human and murine immature DCs ex vivo, leading to high-level 
transgene expression, DC maturation, secretion of proinflammatory cytokines and efficient 
presentation of VRP-encoded antigens to T cells.  VRP-transduced DCs (VRP-DCs) 
expressing a truncated neu oncoprotein stimulated neu-specific T cell and antibody responses 
and induced regression of established tumors in nontolerant mice.  In contrast, VRP-DCs 
failed to induce robust antitumor responses in mice tolerant to neu, and were likewise unable
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 to inhibit tumor growth.  Depletion of CD4+CD25+ regulatory T cells (Treg) improved the 
effectiveness of VRP-DC vaccines in tolerant mice, demonstrating that VRP-DCs alone were 
unable to overcome Treg activity.  Furthermore, provision of tolerant mice with neu-specific T 
cells from nontolerant mice did not augment vaccine efficacy, indicating that tolerogenic 
mechanisms are dominant over effector T cell activity.  These results demonstrate that while 
highly immunogenic, virally-activated DCs cannot break tolerance against self/tumor 
antigens.  Moreover, these findings imply that potent DC vaccines alone are unlikely to 
induce therapeutic antitumor immunity unless additional measures are undertaken to inhibit 
immunoregulatory mechanisms. 
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CHAPTER ONE 
INTRODUCTION
DENDRITIC CELL BIOLOGY   
 
Discovery of dendritic cells (DCs) 
DCs were originally described by Steinman and Cohn as a “novel cell type” found in 
peripheral lymphoid organs of mice (279).  The cells comprised a minor population (1.0-
1.6%) of the murine spleen and were morphologically distinct from granulocytes, 
macrophages and lymphocytes.  While these cells were heterogeneous in morphology, they 
were predominantly characterized by branching cellular processes extending from the cell 
body, and were thus referred to as “dendritic” cells (279).  DCs were phenotypically and 
functionally characterized as:  i) being a glass adherent and low-density cell population, ii) 
having little endocytic activity in comparison to macrophages; iii) having a low ex vivo 
proliferative capacity but a high in vivo turnover rate as determined by uptake of 3H-
thymidine; iv) lacking lymphocyte or monocyte surface markers; and v) originating from 
bone marrow-derived precursors (279-281). 
While initially described in the spleen, it soon became clear that DCs were also present in 
several other lymphoid and nonlymphoid tissues.  In rodents, DCs were identified in multiple 
tissues, including the epidermis (where they are referred to as Langerhans cells) (259), heart 
(122), lungs (262), lamina propria (230), peripheral lymph nodes (279), and thymus (13).  In 
humans, DCs were first identified in the peripheral blood, where they comprise <0.1% of 
mononuclear cells (300).  DCs were subsequently found in several other human tissues, 
including tonsils (123), lung (262) and skin (245).  Thus, DCs are dispersed throughout the 
body in both lymphoid and nonlymphoid compartments, an attribute that is essential for their 
sentinel function. 
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 DC subsets 
DCs were initially described as a population of cells with a heterogeneous morphology, 
although it was unknown if this equated to different functional subpopulations as seen for T 
lymphocytes.  With the advent of fluorescence-activated cell sorting (FACS), it became clear 
that DCs could be subdivided into different populations based upon the expression of specific 
cell surface markers (61).  Furthermore, the various DC subpopulations appeared to have 
varied functions.  However, it was not clear whether the different DC subpopulations 
represented distinct activation stages of a single lineage of cells or were derived from 
different precursor populations.  Current evidence suggests that a mixture of both models is 
involved in the development of the different DC subpopulations (269).   
Mature murine DCs are classically characterized by expression of CD11c (the αX integrin 
subunit of complement receptor 4) and moderate to high expression of MHC class II 
molecules (200).  DCs also express various levels of the T cell costimulatory molecules 
CD40, CD80 (B7.1) and CD86 (B7.2) (3, 128).  Other markers that have been useful for 
differentiating DC subpopulations include CD11b (the αM integrin subunit of complement 
receptor 3), CD4, CD8 (αα homodimers) and CD205 (DEC-205) (3, 128, 152).   
In the murine spleen, two major populations of DCs have been routinely identified:  DCs 
that express CD11b but are negative for CD8αα (CD8- DCs), and DCs that express CD8αα 
but lack CD11b expression (CD8+ DCs).  In addition, CD8- DCs can be further divided into 
CD4+ and CD4- subtypes (3, 128).  CD8- and CD8+ DCs have been historically referred to as 
myeloid and lymphoid DCs, respectively, which was based upon their proposed 
hematopoietic lineage of origin (5, 142).  However, several studies have shown the ability of 
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common myeloid and lymphoid precursors to give rise to all types of DCs, indicating that 
DC development is more complex than originally proposed (195, 269, 313).   
In addition to the three DC populations found in the spleen, murine skin-draining lymph 
nodes also contain two other DC subtypes:  CD11b+CD4-CD8loCD205hi and CD11b+CD4-
CD8-CD205+ cells (128, 269).  The former represent Langerhans cells (LCs) from the 
epidermis, while the latter are likely derived from interstitial DCs that have migrated to the 
lymph node.  Recently, a sixth population of DCs has been described in mouse spleen and 
lymph nodes (8).  These cells, referred to as plasmacytoid DCs, are CD11clo and express the 
unconventional markers CD45 (B220) and Ly6C.  While plasmacytoid DC precursors do not 
morphologically resemble typical DCs, they can differentiate into functional antigen 
presenting cells (APCs) and secrete copious amounts of type I interferon (IFN) following 
viral infection. 
Besides expressing different surface markers, the DC subtypes of the spleen also appear to 
have distinct functions.  While both CD8+ and CD8- DCs can stimulate T cell proliferation, 
the type of T cell response induced appears to depend upon the subclass of DC presenting the 
antigen (192).  Injection of antigen-bearing CD8+ DCs resulted in the secretion of TH1 
cytokines [i.e. interleukin (IL)-2 and IFN-γ] by CD4+ T cells in the draining lymph node.  In 
contrast, stimulation of CD4+ T cells by CD8- DCs resulted in the secretion of TH2 cytokines 
(i.e. IL-4 and IL-5).  The ability of CD8+ DCs to stimulate TH1 responses was dependent 
upon high level IL-12 secretion by these DCs, whereas CD8- DCs only produced minimal 
levels of IL-12 following activation (192, 236).  The DC subpopulations also differ in their 
ability to capture and present antigen to T cells.  CD8+ DCs, but not CD8- DCs, are capable 
of cross-presenting cell-associated antigen to CD8+ T cells in vivo (68).  Consistent with their 
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cross-priming ability, CD8+ DCs are also responsible for inducing tolerance against 
exogenous antigens in the peripheral lymphoid system (20).  Furthermore, CD8+ DCs appear 
to be responsible for initiating CTL responses against several different types of viruses, 
regardless of the inoculation route (21). 
In humans, the identification of different DC subsets is hindered by a lack of fresh tissue 
specimens other than peripheral blood.  Finding human equivalents to the different murine 
DC populations has also been difficult since human DCs do not express CD8αα.  However, 
DCs in the human thymus do appear to resemble their murine counterparts in that they 
primarily express lymphoid rather than myeloid markers (301).  It is well known that human 
peripheral blood contains at least three different DC precursors:  CD34+ stem cells, CD14+ 
monocytes and CD123+CD45RA+ plasmacytoid cells (269).  CD34+ stem cells are usually 
found at low numbers in the peripheral blood, but are enriched in umbilical cord blood or 
bone marrow.  In the presence of granulocyte/macrophage-colony stimulating factor (GM-
CSF), tumor necrosis factor-α (TNF-α) and transforming growth factor-β (TGF-β), CD34+ 
cells can be differentiated into CD1a+ DCs with a LC-like phenotype characterized by 
expression of Birbeck granules, CD207 (Langerin) and E-cadherin (45, 286).  CD34+ stem 
cells can also give rise to DCs that lack Birbeck granules and resemble interstitial or dermal 
DCs (45).  CD14+ monocytes can differentiate into CD11c+CD11b+ immature DCs after 6-7 
days of culture in the presence of GM-CSF and IL-4 (255).  These cells can be further 
differentiated into functionally mature DCs by treatment with monocyte-conditioned media, 
TNF-α, CD40L or lipopolysaccharide (LPS) (22, 255).  The final precursor—
CD123+CD45RA+ plasmacytoid cells—was one of the few cell types identified in humans 
before mice (116).  These cells are most notable for their ability to secrete large amounts of 
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type I IFN following stimulation with viruses (270).  However, plasmacytoid cells can 
differentiate into DCs when cultured in the presence of IL-3 and CD40L (116).  To date, 
most studies of human DC populations involve in vitro culture of precursors in the presence 
of exogenous growth factors, and therefore more research is needed to verify the in vivo 
relevancy of these experiments. 
 
DC function 
The immunological role of DCs was first hinted at when DCs were identified as the 
primary stimulators of the mixed leukocyte reaction (MLR)—being at least 100-fold more 
potent than lymphocytes or macrophages (282).  The observation that DCs were potent 
stimulators of the MLR suggested that DCs may be specialized for initiating lymphocyte-
dependent immune responses.  Indeed, DCs were subsequently shown to be capable of 
priming naïve antigen-specific CD4+ T helper (146) and CD8+ cytotoxic T lymphocytes 
(CTL) (148).  The ability of DCs to activate T cells is dependent upon several functional 
attributes of DCs, including antigen capture and processing, migration to T cell areas of 
lymphoid tissues, high-level expression of proteins involved with antigen presentation and T 
cell stimulation, and secretion of immune-modulating cytokines. 
 DCs are the prototypic APC, meaning that their main function is to capture antigen from 
the environment and then process the antigen into peptides for presentation to T 
lymphocytes.  To aid in this process, DCs are strategically deployed throughout cutaneous 
and mucosal sites in an immature state.  Upon migration into peripheral tissues, DCs begin 
sampling the extracellular environment for antigens via macropinocytosis, phagocytosis and 
receptor-mediated endocytosis (12, 254).  DCs possess several molecules that assist in each 
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of these mechanisms of antigen capture.  Immunoglobulin Fc and complement receptors 
allow the capture of antigen-antibody complexes or the phagocytosis of opsonized microbes.  
Lectins, such as CD206 (mannose receptor), CD207 and CD209 (DC-SIGN), recognize 
specific carbohydrate domains present on microbes or glycosylated antigens, leading to 
engulfment of the antigen (107). 
 Upon antigen capture, DCs must determine whether the antigen is from an insidious 
foreign entity, such as a pathogenic microbe, or the antigen is an innocuous self-protein from 
a normally dying cell.  This fateful choice will ultimately determine how the antigen is 
presented to T cells.  To aid in this decision, DCs can express an array of germ line-encoded 
receptors that recognize pathogen-associated molecular patterns (PAMPs) found on many 
microbes.  These receptors—known as Toll-like receptors (TLR) due to their homology with 
the Drosophila Toll protein—can discriminate multiple PAMPs on microbial molecules, 
including zymosan and peptidoglycan (TLR2); viral double-stranded RNA (TLR3); LPS 
(TLR4); flagellin (TLR5); viral single-stranded RNA (TLR7-8); and bacterial or viral DNA 
containing unmethylated cytosine-guanosine motifs (TLR9) (2).  TLRs are transmembrane 
proteins with an extracellular domain composed of leucine-rich repeats involved with ligand 
binding, and an intracellular region containing a Toll/IL-1 receptor (TIR) domain (1).  Upon 
ligand binding, most TLRs dimerize and recruit the adapter protein MyD88 through TIR-TIR 
domain interactions, which in turn recruits the kinase IRAK-4.  IRAK-4 initiates a cascade of 
downstream signaling events that culminate in the translocation of nuclear factor kappa B 
(NFκB) to the nucleus, resulting in the transcription of genes involved with inflammation and 
cell survival.  Some TLRs also utilize a MyD88-independent pathway involving either 
TIRAP (TLR4) or TRIF (TLR3), which results in IRF3 or late-stage NFκB activation (1).   
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Regardless of the signaling pathway used, activation of TLRs ultimately informs the DC 
that the endocytosed antigen is likely from a pathogen, and should therefore be presented in a 
stimulatory manner to T cells.  The process of DC maturation is thus initiated, which 
involves a coordinated series of events.  Although cells may transiently increase 
macropinocytosis immediately following TLR activation (308), the endocytic capacity of 
DCs is eventually down-regulated (254, 255).  Endocytosed antigen is then processed and 
loaded onto intracellular MHC class II molecules, which are rapidly relocated to the cell 
surface (254).  Remarkably, DCs can discriminate what antigen to present at the level of the 
phagosome, which is dependent upon the concurrent presence of TLR ligands with the 
endocytosed antigen (28).  The presentation of antigen is accompanied by increased 
expression of cell-adhesion molecules (i.e. ICAM-1 and LFA-3) and costimulatory molecules 
(i.e. CD40, CD80 and CD86), both necessary for optimal stimulation of T cells (48, 178, 
255).  Finally, activated DC can secrete proinflammatory and immune-modulating cytokines 
such as TNF-α, IL-6, IL-1β and IL-12p70.  These cytokines are not only involved with 
molding the ensuing T cell response (e.g. IL-12p70 induction of TH1 responses) (135), but 
can also inhibit the activity of suppressor T cells, thus facilitating effector T cell activity 
(229). 
 Once the DC has captured antigen, it must then transport the antigen to the regional lymph 
node where naïve or memory T cells await.  Migration of antigen-bearing DCs to the lymph 
nodes is dependent upon maturation-induced expression of chemokine receptor CCR7, which 
allows DCs to enter afferent lymphatic vessels and traverse to the draining lymph nodes (97).  
Upon entering the lymph node, DCs migrate to the paracortical areas of the lymph node and 
position themselves around high-endothelial venules (9).  Here, DCs transiently and 
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randomly interact with 500-5000 T cells per hour—an amazing yet necessary process if the 
DCs are to encounter the rare antigen-specific T cell (32).  Once a T cell recognizes its 
cognate antigen presented by a DC, stable contacts are formed for up to 12 hours, during 
which time the T cell becomes activated and secretes IL-2 and IFN-γ (199).  The T cell 
eventually disengages from the DC and begins the process of cellular expansion, during 
which it will embark down a pathway of differentiation into either an effector or memory 
cell. 
 The above description of how DCs initiate T cell responses was predicated upon the 
encounter of the DC with a microbe-associated antigen.  However, what happens when a DC 
encounters a self-antigen?  Studies in the 1990s demonstrated that bone marrow-derived 
APCs could capture and present antigen from dying pancreatic islet cells under steady-state 
conditions (173, 174).  Interestingly, cross-presentation of antigen to reactive CD8+ T cells 
resulted in T cell deletion rather than activation, suggesting that APCs may be responsible for 
maintaining peripheral tolerance (174).  In agreement with this finding, studies by Steinman 
and Nussenweig demonstrated that targeting antigen to immature DCs led to antigen-specific 
T cell anergy or deletion (30, 125).  Other studies have demonstrated that presentation of 
antigen by immature DCs can induce the development of IL-10 secreting T cells with 
regulatory properties (69).  Taken together, it appears that presentation of antigen by DCs in 
the absence of maturation cues results in T cell tolerance.  However, the erroneous 
presentation of self-antigen by mature DCs does not necessarily lead to irrevocable 
autoimmunity, as these DCs can induce expansion of regulatory T cells capable of 
suppressing the immune response (318).    
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DENDRITIC CELLS AND CANCER IMMUNOTHERAPY 
 
A brief history of cancer immunotherapy 
The hypothesis that the immune system could control carcinogenesis was postulated as 
early as 1909 by the esteemed German scientist Paul Ehrlich (79).  In the 1950s and 1960s, 
several studies demonstrated that carcinogen-induced tumor cells could be recognized by the 
immune system of syngeneic mice (219).  In 1953, Foley observed that removal of 
methylcholanthrene-induced sarcomas from mice led to a state of immunological memory 
against the tumor, as these mice were now resistant to subsequent challenge with the same 
sarcoma (94).  Other studies demonstrated that the transfer of sera or lymphoid cells from 
tumor-bearing mice to naïve syngeneic animals would result in protection from subsequent 
tumor challenge (219).  These observations suggested that immunogenic molecules of 
unknown identity were present on transformed cells, which could lead to tumor rejection.  
These molecules were thus referred to as tumor-specific transplantation antigens (158).  
Based upon these early studies of tumor immunity, Burnett developed the tumor 
“immunosurveillance” hypothesis, which postulates that the immune system of higher 
vertebrates is essential for recognizing and eliminating transformed cells throughout life (39).   
 Over the next several years, the immunosurveillance hypothesis was a contentious topic.  
While it was generally accepted that the immune system was important in controlling tumors 
spawned by oncogenic viruses, its ability to restrain the development of spontaneous tumors 
of epithelial origin was debatable.  Studies in the 1970s using thymectomized mice, mice 
treated with anti-lymphocyte sera, or athymic nude mice did not yield convincing data that 
supported tumor immunosurveillance (79).  Therefore, the notion of tumor 
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immunosurveillance went out of vogue for nearly 20 years.  In the mid 1990s, new studies 
using gene-targeted mice deficient for IFN-γ, perforin, or recombination activating gene-2 
added credence to the immunosurveillance hypothesis, as these mice develop more 
spontaneous- and chemically-induced tumors than their wild-type counterparts (263).  These 
studies also supported the rationale that the immune system could be harnessed to eradicate 
neoplastic cells, an idea known as cancer immunotherapy. 
 One of the earliest examples of cancer immunotherapy was described by William Coley in 
the 1890s (227).  Coley treated several sarcoma patients with a formulation of bacterial 
derivatives, known as “Coley’s toxin,” resulting in tumor regression in about 10% of cases.  
Coley’s work eventually led to the use of Bacille Calmette-Guérin (BCG) for tumor 
immunotherapy, which is still a standard treatment for superficial bladder cancer.  In 
retrospect, it is likely that Coley’s toxin contained TLR ligands that primarily activated 
constituents of the innate immune system—an important component of tumor immunity (34). 
 The ability to coerce the adaptive immune system to specifically target tumor cells 
became realistic in the 1980s and 1990s with the discovery of several antigens that were 
either solely or preferentially expressed by spontaneous tumors (299).  These tumor-
associated antigens (TAAs) are often derived from mutated or overexpressed oncogenes or 
tumor-suppressor genes, which include ras, p53 and c-erbB-2 (neu).  Other TAAs are derived 
from alternatively glycosylated proteins, such as the mucin MUC-1, or aberrantly expressed 
fetal genes such as carcinoembryonic antigen (CEA).  In particular, malignant melanomas 
express a plethora of TAAs, ranging from proteins involved with melanocyte differentiation 
(i.e. MART-1, tyrosinase, and gp100) to proteins that are normally expressed in testicular 
tissue (i.e. MAGE-1 and LAGE) (246).   
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Armed with this new knowledge of TAAs, researchers performed several clinical trials 
aimed at inducing therapeutic tumor immunity against these proteins.  Multiple strategies for 
immunizing patients against TAAs have been employed, including MHC class I-restricted 
peptides, irradiated tumor cells, DNA plasmids, and recombinant viral vectors (89).  
Unfortunately, cancer vaccines have been generally ineffective in the clinical setting.  A 
recent review by Rosenberg et al. claimed that the objective response rate for 440 patients 
enrolled in cancer vaccine studies was only 2.6% (248).  While the exact number has been 
debated by other scientists, the overall success rate of cancer vaccines has been undeniably 
low. 
 
DCs as cancer vaccines 
 It was recognized in the 1980s that DCs possessed a unique ability to prime naïve CD8+ 
and CD4+ T cells.  The enhanced immunostimulatory capacity of DCs is due to several 
factors, including highly efficient capturing and processing of antigen; high level expression 
of intracellular MHC class II molecules, which are quickly relocated to the cell surface 
following maturation; expression of an arsenal of costimulatory molecules, including CD40, 
CD80, and CD86; and secretion of immunomodulatory cytokines such as IL-6, IL-12p70 and 
type I IFN (12).  It was not long after their discovery that researchers proposed the use of 
DCs for tumor immunotherapy.  It seemed reasonable that these potent APCs might be 
capable of activating and expanding tumor-specific T cells in patients.  At that time, though, 
the clinical use of DCs as cancer vaccines seemed impractical, since DCs were present at 
very low frequencies in peripheral blood (<0.1% of leukocytes) and appeared to be 
terminally differentiated cells that were incapable of expansion (300). 
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 Sources of DCs for Immunotherapy.  The use of DCs as immunotherapeutic reagents moved 
closer to reality when methods for isolating and expanding DCs from precursors were 
developed in the early 1990s—first in mice and then in humans.  In 1992, Inaba et al. 
described a method for expanding murine DCs from precursors in the blood and bone 
marrow in the presence of GM-CSF (144, 147).  The functionality of these DCs was 
confirmed in a subsequent study where the DC precursors were pulsed with killed BCG 
mycobacterium in vitro (143).  The DCs were capable of endocytosing the bacterium, and 
then processing and presenting BCG-derived epitopes to primed T cells in vitro.  
Furthermore, injection of BCG-loaded DCs into naïve mice primed BCG-specific T cells in 
the draining lymph node, although it was not demonstrated that the adoptively transferred 
DCs had directly presented the antigen.  Several other methods for generating large numbers 
of DCs from murine bone marrow precursors have been published (33, 189, 196, 275), 
although in general, most of these methods are based upon the protocol originally described 
by Inaba et a.l in 1992.  One notable difference is the addition of IL-4 during the culturing 
process, which minimizes the outgrowth of granulocytes and macrophages and increases the 
yield of fully differentiated DCs (196, 275). 
 The generation of large numbers of DCs from human peripheral blood precursors was 
originally described by Banchereau and colleagues in 1992.  The authors demonstrated that 
CD34+ hematopoietic stem cells isolated from peripheral blood could be expanded and 
differentiated into CD1a+ cells with a LC-like morphology after 12 days of culture in the 
presence of GM-CSF and TNF-α (44).  Parallel studies by Schuler and colleagues 
demonstrated that the addition of IL-4 further enriched the DC yield by suppressing the 
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growth of monocytes (244).  Unfortunately, the normal frequency of CD34+ cells in 
peripheral blood is very low (<0.1%), and therefore patients must be treated with drugs that 
mobilize bone marrow precursors and subsequently undergo leukopheresis to generate 
sufficient numbers of CD34+ stem cells for ex vivo culture and differentiation into DCs (95).  
Appreciable numbers of human DCs can also be generated from peripheral blood CD14+ 
monocytes  (22, 255, 326). Human monocytes cultured for 6-7 days in the presence of GM-
CSF and IL-4 differentiate into immature DCs; the cells can be further matured with TNF-α 
or monocyte-conditioned media.   
DCs generated from either CD14+ monocytes (mono-DCs) or CD34+ stem cells (CD34-
DCs) have been used in several clinical trials (64 and see below).  While there is no data to 
suggest that one population of DCs is therapeutically superior to the other in patients, some 
researchers have described differences in the ability of mono- or CD34-DCs to stimulate 
antigen-specific T cells (87, 204).  However, a recent comparison of DCs derived from either 
monocytes or CD34+ cells from the same individual found that while mono-DCs expressed 
higher levels of CD86 and HLA-DR, both mono- and CD34-DCs were functionally 
equivalent in an allogeneic MLR (290).  However, the yield of DCs was greater when using 
CD34+ cells as a precursor population, suggesting that CD34-DCs may be preferable when 
large numbers of DCs are required. 
 
Preclinical and clinical evaluation of DC vaccines.  Several in vitro studies in the 1980s had 
demonstrated that DCs were the principle APC responsible for priming antigen-specific 
CD4+ and CD8+ T cells (278).  Based on this finding, Inaba et al. demonstrated that murine 
splenic DCs pulsed with antigen could induce primary T cell responses following injection 
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into naïve syngeneic mice (145).  This was one of the first studies to support the notion of 
using antigen-pulsed DCs for immunotherapy.  Earlier studies had suggested that antigen-
pulsed APCs could induce tumor-specific immunity in animals, but the role of DCs in the 
APC population was not directly evaluated (112, 265).   
The first report of antigen-pulsed DCs used specifically for the induction of tumor 
immunity in vivo was published in 1994 by Flamand et al. (93).  The authors demonstrated 
that immunization with splenic DCs pulsed with idiotypic antibody as a tumor antigen could 
protect mice from challenge with lymphoma cells.  Shortly thereafter, Mayordomo et al. 
demonstrated that vaccination with peptide-pulsed DCs generated from bone marrow 
precursors could induce prophylactic and therapeutic tumor immunity in three different 
animal tumor models, although two of the tumors expressed model antigens (196).  Several 
other researchers have published similar findings regarding the ability of DCs to induce 
tumor immunity in vivo (49, 223, 235, 277, 328).  While these results were encouraging, the 
relevancy of both the tumor antigen used and the animal model in which the vaccinations 
were performed was conveniently disregarded.  Furthermore, most of the studies evaluated 
the ability of DC vaccines to protect mice from subsequent tumor challenge rather than their 
ability to inhibit growth of established tumors. 
Preclinical studies describing DCs as potential immunotherapeutic agents for cancer 
generated significant excitement in the medical community, and quickly led to several 
clinical trials.  The results from an initial patient study were published by Hsu et al. in 1996 
(136).  This study involved four patients with follicular lymphoma who had been previously 
treated with chemotherapy.  Tumor biopsies from the patients were used to generate tumor-
specific (and therefore patient-specific) idiotype antibody.  The idiotype antibody was used 
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to pulse DCs that had been isolated from peripheral blood mononuclear cells (PBMCs) by 
density centrifugation.  The antigen-pulsed DCs were then injected intravenously into the 
patients.  The patients received 3-4 monthly DC vaccinations, and were also boosted with 
soluble protein every two weeks following each DC vaccination.  All vaccinations were well 
tolerated, and all of the patients developed proliferative PBMC responses to their respective 
idiotype antibodies.  Evaluation of the patients after completing the vaccine regimen 
indicated that one patient was in clinical remission, one patient had a minor response with 
some regression of diseased lymph nodes, and the other two patients exhibited no significant 
change in disease.  While this study only included four patients, it supported the clinical use 
of DC vaccines for the treatment of cancer. 
 Since the original DC vaccine trial reported by Hsu et al., several more studies have been 
undertaken to evaluate the efficacy of DC vaccines in other types of cancer, including breast, 
colon, prostate, renal and malignant melanoma (11, 64, 67, 168, 209, 284).  It has often been 
difficult to compare the results of different DC clinical trials, since the studies differ in the 
type of cancer that is being treated, the origin and maturation of the DCs being used, the type 
and source of tumor antigen, the immunological assays used to measuring tumor-specific T 
cell activity, and even the criteria used for evaluating clinical responses.  Overall, the clinical 
response rate for DC vaccines has been low, yet is potentially higher than that seen with 
other vaccine regimens.  Focusing on melanoma alone, a recent review by Rosenberg et al. 
reported that DC vaccines have resulted in a 9.5% remission rate, compared to a mean of 
3.1% for peptides, viral vectors and tumor cell vaccines combined (248).  One must also 
remember that the majority of DC vaccine trials have been performed in patients with 
extensive and refractory disease, and therefore complete tumor regression following any type 
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of treatment would be highly extraordinary.  Instead of seeing the low success rate of DC 
vaccines as a deterrent for their use, some researchers have viewed it as an argument for the 
development of improved DC vaccines (10). 
 
Virally-transduced DCs as cancer vaccines 
 One of the most frequently used methods for loading DCs with tumor antigens is to pulse 
the DCs with MHC class I-restricted peptides—typically those restricted to HLA-A2 
molecules (95).  This method is often preferred because it is relatively simple to generate 
clinical-grade peptides of 8-10 amino acids in length.  Most tumor antigen-derived peptides 
were originally identified via acid elution of peptides present on the surface of tumor cells, or 
through the use of mathematic algorithms that predicted sequences with high-binding 
affinities for MHC class I molecules (64).  While dozens of MHC class I-restricted peptides 
have been mapped for several different tumor antigens, this approach for antigen loading has 
several drawbacks.  First, MHC class-I restricted peptides can only be used for patients of a 
specific MHC haplotype.  Second, focusing the immune response against only one or two 
MHC class I-restricted peptides can select for tumors with mutations in those specific 
peptides, thus leading to immune escape.  Third, the use of MHC class I-restricted peptides 
precludes the involvement of MHC class II-restricted CD4+ TH cells in the nascent anti-tumor 
response.  Antigen-specific CD4+ T cells are necessary for the licensing of DCs through 
CD40-CD40L signaling, thus resulting in more efficient activation of CD8+ CTL (23).  
Additionally, CD4+ TH cells are required for the activation of tumoricidal macrophages and 
the generation of T-dependent antibodies against tumor antigens (60, 140).  While inclusion 
of CD4+ T cells in the anti-tumor response could be achieved by pulsing DCs with MHC 
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class II-restricted peptides, relatively few CD4+ TH cell epitopes have been characterized for 
tumor antigens. 
 Because of the limitations associated with MHC class I-restricted peptides, several 
alternative strategies for loading DCs with tumor antigens have been employed, including 
pulsing DCs with recombinant protein or killed tumor cells (223, 235, 296), transfecting DCs 
with tumor messenger RNA (mRNA) (212), or fusion of DCs with tumor cells (111).  These 
approaches have some benefits, but are also plagued with certain drawbacks.  DCs pulsed 
with recombinant protein do not induce significant CD8+ T cell responses, since uptake and 
cross-presentation of soluble protein on MHC class I molecules is typically inefficient (68).  
Cross-presentation of exogenous antigen can be enhanced, however, by feeding DCs antigen-
antibody complexes (239) or antigen-heat shock protein complexes (272).  Using whole 
killed tumor cells or tumor cell lysates as an antigen source is potentially advantageous 
because both known and unknown tumor antigens could be delivered to DCs.  Unfortunately, 
tumor cell lysates can also contain immunosuppressive proteins that inhibit DC activation 
(90), and apoptotic cells have been shown to suppress DC maturation (257).  Furthermore, 
loading DCs with killed tumor cells relies on the availability of either primary tumor isolates 
or closely related tumor cell lines.  Similar to pulsing DCs with killed tumor cells, 
transfection of DCs with tumor mRNA, or fusion of DCs with tumor cells, can lead to 
presentation of unidentified but potentially immunogenic epitopes.  However, these methods 
carry the risk of presenting self antigens that are not specifically associated with the tumor, 
which could lead to autoimmunity (132).  Finally, most of these methods for antigen delivery 
do not result in DC maturation, and therefore codelivery of maturation stimuli is required.  
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 The use of viral vectors for the delivery of antigens to DCs has several theoretical 
advantages.  First, viral transduction can be significantly more efficient that other physical 
methods of gene delivery, such as electroporation or chemical transfection (7).  Second, viral 
vectors can be used to deliver intact tumor antigens containing both MHC class I- and  II-
restricted epitopes (319, 322, 330).  The presentation of multiple epitopes would induce a 
broader T cell response, thus decreasing the likelihood of tumor immune escape through 
mutations in immunodominant epitopes.  Third, viral vectors can be used in patients of all 
MHC haplotypes.  Fourth, viral vectors can induce DC maturation through stimulation of 
TLRs (i.e. TLR-3, 7, 8 and 9) or cytoplasmic viral recognition proteins (i.e. RIG-I or Mda5) 
(156).  DC maturation can occur via direct activation of the NFκB pathway by viruses, or 
indirectly through autocrine or paracrine secretion of type I IFN (133).  Fifth, viral vectors 
can induce secretion of type I IFN, which can enhance the activity of innate immune 
effectors such as macrophages and NK cells (129, 194).  Furthermore, type I IFN can act 
directly on CD4+ and CD8+ T cells to augment clonal expansion (124, 167) and can enhance 
the cross-presentation of antigen to CD8+ T cells (179).  Finally, viral vectors have been 
shown to inhibit the activity of regulatory T cells and thus lower the threshold for breaking 
tolerance (320). 
 Several different viral vectors have been evaluated for ex vivo-transduction of human 
DCs.  Some of the more promising and clinically relevant virally-derived vectors are 
described here. 
 
Adenovirus.  Adenoviral (Ad) vectors are non-integrating DNA vectors that can 
accommodate large fragments of heterologous DNA (~37 kb) (314).  Ad vectors can 
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transduce murine DCs and human mono-DCs ex vivo, although a very high MOI (>1000) is 
required for efficient transduction (~95%) due to low expression of the coxsackievirus and 
Ad receptor by DCs (7, 240).  Strategies to enhance DC transduction efficiency by altering 
the tropism of Ad vectors have met with some success (295).  Transduction of human DCs 
with Ad vectors does not significantly disrupt DC maturation or antigen presentation (240, 
325).  Human DCs transduced with recombinant Ad vectors encoding tumor antigens 
activate CTLs specific for several tumor antigens in vitro, including MART-1 (40), p53 
(215), and CEA (56).  Multiple preclinical studies have evaluated the efficacy of Ad-
transduced DCs as tumor vaccines in mice (314). These studies have generally shown that 
Ad-transduced DCs induce appreciable CD4+ and CD8+ T cell responses against tumor 
antigens, and can partially inhibit the growth of established poorly-immunogenic tumors 
(155).  To date, no clinical trials have been performed with Ad-transduced DCs. 
 
Vaccinia virus.  Vaccinia virus (VV) is a member of the Poxviridae family of viruses, which 
are large double-stranded DNA viruses of ~200 kb in size.  Replication-defective VV vectors 
have been shown to transduce human immature and mature DCs with moderate efficiency 
(mean 30.9% at an MOI of 2.5) (151).  Furthermore, human DCs transduced with VV vectors 
were capable of stimulating melanoma-specific CTL in vitro (76).  However, VV appears to 
inhibit DC maturation and induces apoptosis, likely due to the multiple immune-modulating 
proteins expressed by poxviruses (82).  Despite the derogatory effects of VV on DCs, VV 
vector-transduced human CD34-DCs have been evaluated in a phase I clinical trial (70).  Six 
stage IV melanoma patients received four injections of 1 x 108 VV-transduced DCs over a 
two month period.  Treatments were well tolerated and melanoma-specific CD8+ T cells were 
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detected in four or five patients.  One patient receiving adjunct surgery also demonstrated a 
partial clinical response. 
 
Retroviruses and lentiviruses.  Retroviral vectors are most often associated with gene therapy 
due to their stable integration in the host genome, but they have also been utilized for 
transduction of human DCs.  The major limitation of retroviral vectors is their inability to 
transduce non-dividing cells, thus precluding their use for transducing mono-DCs.  However, 
retroviruses can be used to transduce proliferating CD34+ precursors, which can then be 
differentiated into DCs (291).  Transduction efficiency is relatively limited (10-20%), but 
transduced DCs are functional and can stimulate both CD4+ and CD8+ T cells specific for the 
vector-encoded antigen (177, 330).  Unlike classical retroviral vectors, lentiviral vectors have 
the capacity to infect both dividing and quiescent cells, including human mono- and CD34-
DCs (118).  Transduction efficiency of human DCs ranges from 20-99%, depending upon the 
source of the DCs and the maturation status (78).  Human DCs transduced with lentiviral 
vectors do not exhibit significant functional deficits, and can stimulate tumor-specific CD8+ 
T cells in vitro (91, 288).  In vivo studies in mice have indicated that lentiviral-transduced 
DCs are superior to peptide-pulsed DCs at inducing immunity against a model tumor antigen 
(127).  Furthermore, transfer of CD34-DCs transduced with a lentiviral vector encoding 
green fluorescent protein (GFP) induced GFP-specific T cell responses in non-human 
primates (172).  Based on these studies, vaccination with lentiviral vector-transduced DCs 
may be a promising strategy for tumor immunotherapy.  However, issues with large-scale 
production and questionable safety of lentiviral vectors are significant barriers to clinical 
application (78). 
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 Alphaviruses.  Alphaviruses are single-stranded, positive-sense RNA viruses of ~11 kb in 
length and belong to the Togaviridae family of viruses (see below for a detailed description).  
While studies by MacDonald and Johnston had shown that alphaviral vectors derived from 
VEE could target murine DCs in vivo (190), the ability of an alphaviral vector to transduce 
human DCs ex vivo was first reported by Gardner et al. in 2000 (104).  Using replicon 
vectors derived from Sindbis virus (SIN), the authors identified a single mutation in the E2 
glycoprotein that conferred tropism for human mono-DCs (18% transduction efficiency at an 
MOI of 50).  Transduction of human immature DCs with SIN replicons resulted in DC 
maturation, but the ability of transduced DCs to stimulate human T cells was not assessed.  
Vectors derived from Semliki Forest virus (SFV) have been used to infect murine DCs ex 
vivo, although the virus had to be treated with a synthetic polymer for efficient transduction 
(53).  SFV-infected DCs have also been evaluated for tumor immunotherapy.  Vaccination of 
mice with murine DCs pulsed with SFV replicons encoding IL-12 or IL-18 resulted in 
prolonged survival in a metastatic brain tumor model (316, 317), although the DCs were used 
primarily for adjuvant activity rather than for antigen presentation.  The major limitation of 
current alphaviral vectors is their inefficiency at transducing DCs—an attribute that is likely 
due to type I IFN sensitivity rather than an inability to target DCs (250). 
 
Other viruses.  Vectors derived from human herpes simplex virus (HSV) can be engineered 
to encode large fragments of heterologous DNA and can efficiently transduce a variety of 
cells, including DCs (90% transduction at MOIs of 1-5).  However, HSV infection inhibits 
maturation of DCs and is highly cytopathic (202, 253), thus limiting its utility as a viral 
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vector.  Vectors derived from adeno-associated viruses (AAV) have also been used to 
transduce human mono-DCs, although the transduction efficiency varied widely (2-55%) at 
an MOI of 100.  AAV-transduced DCs did not exhibit any functional deficits, and were 
capable of stimulating CD4+ and CD8+ T cells specific for vector-encoded tumor antigens in 
vitro (55, 289). 
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VENEZUELAN EQUINE ENCEPHALITIS VIRUS 
 
Overview of Venezuelan equine encephalitis virus (VEE) 
 VEE is a member of Togaviridae family of viruses, and specifically falls within the 
alphavirus genus.  VEE can be further classified as a New World alphavirus, which also 
includes Eastern and Western equine encephalitis viruses; these viruses have the potential to 
cause febrile disease and encephalitis in equines (i.e. horses, donkeys and mules) and 
humans.  Old World alphaviruses include SIN, SFV, Ross River virus (RRV), Chikungunya 
virus, and O’nyong-nyong virus.  Human infection with Old World alphaviruses is often 
characterized by fever, rashes and/or arthralgias.  All alphaviruses are transmitted by 
arthropod vectors, and are thus capable of replicating in both vertebrate and invertebrate 
hosts (88).     
 VEE is normally an enzootic infection, cycling between mosquitoes and small rodents in 
subtropical regions of the North and South America.  However, certain serotypes of VEE, 
namely I-AB and I-C, can cause epizootics/epidemics (305).  Epizootic VEE infection of 
equines was initially described in the 1930s in northern South America, with the virus being 
first isolated in 1938 (17, 171).  Although the ability of VEE to infect humans had been first 
reported in 1943 in two laboratory personnel working with the virus (43), the virus was not 
identified as a cause of human epidemics until the 1950s (256).  From 1938 to 1972, 
epizootic/epidemic outbreaks of VEE occurred every 5-10 years throughout northern South 
America, Central America, Mexico and even the southern United States.  During this time, 
the development of vaccines against VEE—first from formalin-inactivated virus, and then 
from a live-attenuated virus (TC-83)—significantly reduced epidemics amongst livestock 
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(305).  No major outbreaks were reported after 1972 until 1992, when epizootic disease 
reappeared in western Venezuela (242).  Not long after, one of the largest epizootic/epidemic 
outbreaks involving up to 100,000 people in Venezuela and Columbia occurred in 1995 
(306).  The ability to cause epizootic/epidemic disease, along with the potential to be used for 
biological warfare, has made VEE a focus of intensive research. 
 
VEE structure and replication 
 VEE is an enveloped, single-stranded, positive-sense RNA virus.  The genome of VEE is 
11,477 nucleotides in length and contains a 5’ methylguanosine cap and a 3’ polyadenylated 
tail.  The genome is divided into two regions:  the 5’ two-thirds encodes the nonstructural 
proteins (nsP1-4) involved with viral replication, while the 3’ one-third encodes the structural 
proteins (capsid, E3, E2, 6K and E1) required for virion assembly (285).  The RNA genome 
has significant secondary structure, and is encased in a T=4 icosahedral nucleocapsid 
consisting of 240 copies of the capsid protein (57).  The nucleocapsid is surrounded by a 
lipid bilayer derived from the host cell plasma membrane, which also contains the viral 
glycoprotein spikes projecting outward from the viral core in a T=4 icosahedral symmetry 
(225).  Recent cryoelectron micrographs of other alphaviruses indicate that the E1 
glycoprotein lies tangential to the plasma membrane surface and forms an icosahedral 
scaffold, while the E2 glycoprotein predominantly forms the protruding spikes (181, 234). 
 No single receptor has been definitively identified for VEE.  Because of its wide tropism 
for both vertebrate and invertebrate cells, it is likely that VEE either uses a ubiquitously 
expressed and evolutionarily conserved receptor, or uses multiple receptors for binding and 
entry.  Some candidate receptors for VEE include the laminin-binding protein (187), heparin 
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sulfate (25) and c-type lectins (159).  In vitro passage of VEE can lead to mutations in the E2 
glycoproteins resulting in the use of heparin sulfate as a receptor (25, 66).  While heparin 
sulfate-binding VEE exhibits enhanced viral binding and penetration in vitro, these viruses 
have reduced virulence in vivo, arguing against heparin sulfate as a natural receptor.  Recent 
studies by Klimstra et al. have identified the c-type lectins DC-SIGN and L-SIGN as putative 
receptors for Sindbis virus (159)—an observation that is likely relevant for other 
alphaviruses.  Carbohydrate modifications of the virus appeared to be important for binding 
to DC-SIGN, since virus produced in insect cells or mammalian cells defective in enzymatic 
glycosylation, and therefore lacking complex carbohydrates, exhibited higher infectivity of 
DC-SIGN-expressing cells.  However, it was not clear if the enhanced infectivity of DC-
SIGN-binding viruses was due to more rapid binding and internalization, or rather to 
enhanced replication through down-regulation of the antiviral response.  The latter is 
supported by observations that binding of pathogens to DC-SIGN can inhibit DC activation 
(108). 
 After binding to its receptor on the cell surface, VEE is internalized into coated vesicles 
through an endocytic pathway.  As the pH of the endosomes decreases, the E1 glycoprotein 
undergoes conformational changes resulting in fusion of the viral envelope with the 
endosome (181, 234, 285).  While most of the knowledge concerning alphavirus entry was 
gleaned from studies of SIN and SVF, recent studies have suggested that VEE may enter 
cells somewhat differently.  Using retrovirus pseudotyped with VEE envelope glycoproteins, 
Kolokoltsov et al. demonstrated that the viruses exited the endocytic pathway at the late-
endosome stage and were resistant to cholesterol depletion (166).   In contrast, SFV has been 
shown to exit early-endosomes in a process that is highly dependent upon cholesterol in the 
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host membrane (35).  It is also possible that VEE may enter cells through a mechanism that is 
independent of membrane fusion and endocytosis, as recently demonstrated for SIN by 
Dennis Brown and colleagues (226). 
 Upon entry into the cytoplasm, the viral genome is uncoated from the nucleocapsid and is 
directly translated by host ribosomes into a polyprotein consisting of nsP1-3 or nsP1-4, 
depending on whether the ribosome reads through an opal stop codon located between nsP3 
and nsP4 (285).  The nonstructural proteins mediate the processes of viral replication and 
transcription, and possibly interact with cellular proteins to modulate host cell translation.  
nsP1 possesses guanine-7-methyltransferase and guanyltransferase activities, and is also 
involved with attachment of the viral replicase complex to cell membranes.  nsP2 is a 
multifunctional protein, with helicase and NTPase activity in the N-terminus region and thiol 
protease activity in the C-terminus region; the latter is responsible for proteolytic processing 
of the nsP precursor protein.  Interestingly, a significant proportion of nsP2 is found in the 
nucleus, where it can interact with host nuclear proteins and possibly modulate host cell 
transcription and/or translation (203).  nsP3 is a phosphoprotein that has an essential but 
unknown role during viral replication.  nsP4 is the core viral RNA-dependent RNA 
polymerase responsible for viral replication and transcription (285). 
 Following the initial translation of the viral genome, the nsP polyprotein is first cleaved in 
cis at the nsP3/4 site to yield a complex consisting of P123 and nsP4, which is thought to 
initiate minus-strand synthesis (268, 285).  Minus-strand synthesis dominates during the first 
3-4 hours following infection, but then becomes undetectable as positive-strand synthesis 
arises.  The cessation of minus-strand synthesis is due to continued processing of the P123 
into nsP1 and P23, and finally into all four individual nsPs (180).  The individual nsPs, along 
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with several putative host factors, form the replication complex, which is thought to be 
confined to the cytoplasmic surface of endosome-derived vesicles known as cytopathic 
vacuoles type I (98).  The replication complex produces new positive-sense genomic RNA by 
binding to a promoter in the minus-strand complementary to the 5’ untranslated region of the 
genome.  The replicase complex also drives transcription of a 26S subgenomic mRNA 
encoding the structural polyprotein downstream of a strong promoter located after nsP4.  
Subgenomic mRNA is made in significant excess to full-length genomic RNA, resulting in 
production of large amounts of capsid and viral glycoproteins (285).  The capsid protein is 
self-cleaved from the structural polyprotein, while the PE2 (a precursor protein composed of 
E2 and E3) and E1 glycoproteins are proteolytically processed in the endoplasmic reticulum 
by host furin-like proteases.  The processed E1 and E2 viral glycoproteins are transported 
through the Golgi complex to the plasma membrane, undergoing several posttranslational 
modifications during the voyage including glycosylation (161).  As mentioned above, the 
type of carbohydrates added to the glycoproteins differs between vertebrate and invertebrate 
host cells, and may ultimately dictate tropism for the virus. 
 During virion assembly, the capsid protein specifically interacts with a packaging signal 
sequence in the nonstructural gene region, which results in selective encapsidation of full-
length genomic RNA rather than subgenomic RNA (285).  The nucleocapsid then interacts 
with the intracellular domain of E2 at the plasma membrane, resulting in envelopment of the 
nucleocapsid and budding from the cell.  Budding involves binding of preformed 
nucleocapsid to the glycoproteins, resulting in the release of an infectious virion from the 
cell. (105).  Infected mammalian cells eventually die by apoptosis, which is likely caused by 
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a combination of inhibition of host-cell translation and direct cytotoxic effects of viral 
structural proteins (88). 
 
Pathogenesis of VEE 
 Infection of humans or equines with VEE results in a variety of clinical manifestations, 
ranging from fever to fatal encephalitis.  Enzootic serotypes of VEE are typically avirulent in 
equines, causing little or no disease.  In contrast, epizootic serotypes can cause significant 
mortality in equines (305).   In humans, the severity of disease is most dependent upon the 
age of the patient and the serotype of the virus (81).  After a 2-5 day incubation period, 
humans infected with VEE can present with fever, malaise, vomiting and severe retro-orbital 
headache.  Symptoms typically subside within one week; although some patients may go on 
to develop neurological sequelae including convulsions, somnolence, confusion and coma.  
Death occurs in less than 1% of cases, and is often accompanied by meningoencephalitis, 
cerebral hemorrhage and/or necrotizing vasculitis (81, 88, 305).  Interestingly, VEE causes a 
profound peripheral lymphopenia in humans and other mammals—a clinical sign often 
associated with other acute viral infections (81).  This finding may result from the action of 
IFN-α/β, which can directly deplete lymphocytes (197) or induce lymphocyte retention in 
peripheral lymphoid tissues through a mechanism involving CD69 and sphingosine 1-
phosphate receptor-1 (267). 
While VEE can infect a range of animals, studies involving mice have proven most 
valuable for deciphering the pathogenesis of VEE.  Pathological studies in the 1960s 
demonstrated that mice exhibit a two-phase disease following peripheral challenge with 
VEE:  an initial phase of replication in peripheral lymphoid and myeloid tissue followed by a 
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neurotropic phase that eventually resulted in death by 6-7 days post-infection (pi) (110).  
More recent studies by Grieder et al. using a virus (V3000) derived from a molecular clone 
of an isolate from the original Trinidad Donkey strain have more thoroughly described VEE 
pathogenesis in mice (114).  Following foot pad inoculation, V3000 replication was detected 
in the draining popliteal lymph node within 4 hours.  By 12 hours pi, virus was isolated from 
serum and nearly every visceral organ, including, spleen, heart, lung, liver, kidney and 
adrenal glands; pancreas and thymus had detectable virus by 18 hours pi.  Viral RNA was 
only detected in a subset of tissues (i.e. lymphoid tissue, heart and pancreas), suggesting that 
viral replication was primarily limited to specific cell types.  Viral titers in the peripheral 
tissues peaked between 24-48 hours pi, and virus was eventually cleared from the periphery 
by 3-4 days pi.  By this time, however, V3000 had already invaded the central nervous 
system (CNS), with virus first detected in the brain at 2-3 days pi.  Penetration of the CNS 
likely occurs through infection of olfactory neuroepithelium or the trigeminal nerve (52).  By 
6 days pi, viral RNA was detectable throughout most of the brain and was accompanied by 
severe neuropathology.  Infected animals uniformly died by 6-7 days pi.  Grieder et al. and 
others also characterized the pathogenesis of several viruses with mutations in the E1 and/or 
E2 glycoproteins (6, 66, 114).  These mutants all had reduced virulence upon footpad 
inoculation, and exhibited marked differences in viral dissemination, thus providing tools for 
further dissecting the mechanisms of VEE pathogenesis. 
  As mentioned above, VEE replicated in lymphoid tissues shortly after footpad 
inoculation.  However, the identity of the originally infected cells was unknown.  In 2000, 
MacDonald and Johnston used a double-promoter V3000 encoding GFP (dpV3000-GFP) and 
VEE replicon particles (VRP, see below) to demonstrate that the virus initially infected 
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DCs—specifically LC from the epidermis (190).  At 12 hours following foot pad inoculation 
of dpV3000-GFP, GFP was detected in cells within the paracortex of the lymph nodes.  
These cells morphologically resembled DCs, and also expressed CD205 but were negative 
for the lymphocyte markers B220 and CD5.  Inoculation of mice with VRP encoding GFP, 
which undergo only one round of replication, demonstrated that the initially infected cells 
had a LC-like morphology.  While the cells expressed CD205 and MHC class II, they did not 
stain positive for the DC marker CD11c.  Moreover, the authors did not evaluate the cells for 
expression of the LC marker CD207 (Langerin) or the presence of Birbeck granules.  Finally, 
increasing the inoculum of VRP resulted in infection of CD11c+ and CD11b+ cells in the 
paracortex, suggesting that other DC populations may be targeted at higher viral loads.  
Based upon this study, a model for early VEE pathogenesis was proposed.  Following the 
transfer of VEE to a mammalian host from a mosquito bite, the virus initially infects LC at 
the site of inoculation.  Infected LC then migrate to the peripheral draining lymph node, 
where viral replication continues and eventually spreads to other lymphoid and non-
lymphoid cells. 
With regards to immune control of VEE infection, both the innate and adaptive immune 
systems are essential.  Early studies in hamsters demonstrated that induction of type I IFN 
prior to challenge with virus precluded the establishment of infection, although sensitivity to 
IFN was dependent upon the viral strain (150).  Mice genetically deficient in the receptor for 
IFN-α/β die within 24-48 hours after VEE infection, further underscoring the importance of 
the innate immune system in controlling early viral replication (115, 309).  The adaptive 
immune response appears to be important for clearance of virus from the periphery through 
the production of VEE-specific IgM that is independent of T cell help (51).  While antibody 
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responses are not sufficient to prevent neuroinvasion and death during primary infection with 
wild-type VEE, they are likely essential for protection following vaccination (88).  The role 
of CD8+ CTL in VEE immunity has not been extensively investigated, but a recent study 
failed to identify VEE-specific CTL in infected mice, suggesting that CTL activity may not 
be involved with viral clearance (154).  Besides conferring protection against infection, the 
immune system can also potentiate disease by causing immunopathology in the CNS, as 
witnessed for SIN and SFV (86).  While VEE induces some immunopathology, the virus can 
also cause lymphocyte-independent destruction of the CNS in SCID mice, although the 
pathology of disease resembles a spongiform encephalopathy rather than fulminant 
encephalitis (51). 
 
VEE replicon particles (VRP) 
 The advent of reverse genetics allowed the development of stable cDNA clones of RNA 
viruses and facilitated their genetic manipulation.  The generation of full-length cDNA 
clones of several alphaviruses has allowed the development of expression vectors for 
heterologous genes.  This can be accomplished by one of two ways (298).  The first method 
involves the generation of attenuated yet propagating “double-promoter” viruses, which 
contain a second 26S subgenomic promoter downstream of the native E1 gene that drives 
expression of a heterologous gene.  Since these vectors can form new progeny, they result in 
sustained antigen expression.  However, they also carry the risk of developing mutations or 
undergoing genetic recombination, which could result in the formation of wild-type virulent 
virus.   Furthermore, these vectors will produce large amounts of structural proteins, which 
can increase the likelihood of anti-vector immunity and interfere with immunological 
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responses against the vector-encoded immunogen.  The second method entails the 
development of non-propagating “replicon” vectors.  Replicon vectors are created by 
replacing the structural genes with a heterologous gene, resulting in a replicon mRNA.  If the 
structural genes are then supplied in trans, and modified so that they do not contain the cis-
acting packaging sequences, then the replicon mRNA can be packaged into new virions 
termed replicon particles.  These replicon particles can only undergo a single round of 
replication, since they lack the structural genes necessary for the synthesis of new virions.  
The benefit of this approach is that vector is incapable of producing new virus, which greatly 
enhances safety.  However, antigen synthesis is transient since it will only be produced in the 
initially infected cell. 
 The development of alphaviral replicons was first described by Xiong et al. using SIN 
(315).  Replacement of the structural genes with chloramphenicol acetyltransferase (CAT) 
resulted in high level production of heterologous protein following transfection of cells with 
in vitro-derived transcripts.  Infection of the cells with Sindbis virus, which provided the 
structural genes in trans, resulted in the packaging of the CAT-encoding replicon RNA into 
infectious particles.  Not long after, Liljestrom and Garoff described a procedure for 
generating SFV replicons using packaging-deficient helper RNAs encoding the structural 
genes (182).  Additional studies demonstrated that vaccination of mice with recombinant 
SFV replicons encoding influenza nucleoprotein resulted in both cell-mediated and humoral 
immunity (327).  
 In 1997, Pushko et al. described a method for generating VEE replicon particles (VRP) 
from the attenuated viral mutant V3014 (238).  Using a bipartite helper system in which the 
capsid and glycoproteins were expressed on different RNA constructs, Pushko et al. 
 33
demonstrated the production of high-titer VRPs with no detectable contamination of 
recombinant propagating virus.  The authors also showed that vaccination of mice with VRP 
encoding influenza hemagglutinin (HA) induced a strong antibody response and conferred 
protection against mucosal challenge with influenza virus.  Moreover, previous vaccination 
with a VRP encoding Lassa virus nucleocapsid did not interfere with anti-HA antibody 
responses generated by subsequent immunization with HA-VRP, suggesting that anti-vector 
immunity was not an issue with VRP vaccination in mice.  It was argued that VEE replicons 
may be ideal vaccine vectors due to their ability to replicate in lymphoid tissues, thus 
providing antigen at the site of immune initiation.  Furthermore, multiple attenuating 
mutations in the glycoproteins had been described, which could be incorporated into VRP for 
additional safety.  
 Subsequent studies demonstrated that like replication-competent VEE vectors, vaccination 
with recombinant VRP could induce mucosal IgA responses (121, 294) and CTL activity 
(302, 311) in mice.  In addition, VRP have been shown to be superior to SIN replicons at 
inducing antigen-specific CD8+ T cells in a head-to-head comparison (231).  Furthermore, 
vaccination of non-human primates with recombinant VRP conferred partial or complete 
protection against SIV (65, 153) or Marburg virus (131), respectively.  VRP have also been 
evaluated as vectors for tumor immunotherapy.  Velders et al. demonstrated that vaccination 
with VRP encoding the human papillomavirus 16 (HPV16) E7 gene (E7-VRP) induced 
antigen-specific CTLs (302).  Prophylactic vaccination with E7-VRP protected mice from 
challenge with an E7-expressing tumor cell line.  More importantly, therapeutic vaccination 
with E7-VRP completely inhibited the growth of established tumors.  Interestingly, 
vaccination with irrelevant GFP-VRP also inhibited tumor growth, which demonstrated 
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potential adjuvant activity of VRP but also exposed the low threshold for induction of tumor 
immunity in this system.  Tumor immunotherapy studies involving VRP encoding the neu 
oncogene have also been performed, and will be described in detail below.    
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IMMUNOTHERAPY AGAINST HER-2/NEU 
 
Overview of HER-2/neu 
The neu oncoprotein was originally discovered as a 185 kilodalton phosphoprotein 
expressed at high levels in several neuro/glioblastoma cell lines derived from 
ethylnitrosourea-treated rats (222, 264).  The protein was shown to share homology with the 
retrovirus-associated oncoprotein v-erbB (derived from avian erythroblastosis virus locus B) 
and the epidermal growth factor (EGF) receptor (c-erbB-1) (59, 258).  Molecular cloning of 
the neu cDNA demonstrated that the oncogene encoded a transmembrane protein that was 
closely related to the EGF receptor (14).  The oncoprotein was thus named c-erbB-2, with the 
human form of the protein often referred to as HER-2 (derived from Human EGF Receptor).   
HER-2/neu is one of four members of the erbB receptor family, which also includes the 
EGF receptor (HER-1/c-erbB-1), HER-3/c-erbB-3, and HER-4/c-erbB-4 (218).  The erbB 
receptors are expressed primarily by cells of mesodermal or ectodermal origin.  The four 
receptors share a common structure, consisting of an extracellular ligand-binding domain, a 
single transmembrane domain, and a cytoplasmic domain with tyrosine kinase activity.  
There are multiple ligands for the erbB receptors, which can be divided into four groups: 
ligands that only bind c-erbB-1 (i.e. EGF, transforming growth factor-α, and amphiregulin); 
ligands that bind either c-erbB-1 or c-erbB-4 (betacellulin, heparin-binding EGF, and 
epiregulin); ligands that bind only c-erbB-3 [neuregulin-1 and -2]; and ligands that bind only 
c-erbB-4 (neuregulin-3 and -4) (321).  To date, no ligands specific for c-erbB-2 have been 
identified.  However, c-erbB-2 has potent tyrosine kinase activity, and likely potentiates the 
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signaling of other ligand-bound erbB receptors by heterodimerization.  Indeed, c-erbB-2 is 
the preferential heterodimerization partner for ligand-bound c-erbB-3 (113).  
Signaling via the erbB receptors is highly complex and depends upon several factors, 
including the type of ligand bound, the specific erbB receptors expressed, the type of homo- 
or heterodimers formed, the specific adapter proteins associated with the receptors, and the 
rate of receptor endocytosis (321).  In general, binding of ligand to the extracellular domain 
of an erbB receptor induces receptor homo- or heterodimerization, resulting in activation of 
the tyrosine kinase catalytic site and subsequent autophosphorylation of tyrosine residues in 
the cytoplasmic domain.  The phosphorylated tyrosine residues act as docking sites for 
several adapter proteins that initiate intracellular signaling pathways, including the mitogen-
activated protein kinase and the phosphatidylinositol-3-OH/Akt pathways.  These pathways 
ultimately modulate expression of genes involved with cell survival, proliferation and 
migration (321).  erbB signaling is also salient during development, as illustrated by the 
embryonic lethality of null mutations in all of the individual erbB receptors (218). 
 Shortly after its discovery, it was noted that the neu oncogene was amplified and 
overexpressed in various human tumor cell lines, suggesting that HER-2/neu may be 
involved with the development of cancer (99, 260).  It was presumed that amplification of 
neu leads to increased HER-2/neu concentration on the cell surface, thus increasing the 
spontaneous formation of receptor homodimers.  Transforming mutations in the 
transmembrane region that increase the spontaneous homodimerization of HER-2/neu have 
been identified in rodents (307); however, no similar mutations have been routinely 
recognized in cancer patients.  Although recent studies have identified mutations in the 
tyrosine kinase domain of c-erbB-2 in a minority of patients with non-small cell lung cancer, 
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these mutations were not associated with amplification of the gene (283).  Overexpression of 
HER-2/neu also increases heterodimerization with coexpressed erbB family members, which 
significantly augments the signaling capacity of these receptors and increases their 
tumorigenic potential (218).   
The relationship between neu amplification and human breast cancer was first published 
in 1987 by Slamon et al. (273).  The authors identified neu amplification as a negative 
prognostic factor for human breast cancer, which was subsequently confirmed in several 
large studies (249).  Current data indicates that HER-2/neu is overexpressed in about 15-30% 
of all cases of breast adenocarcinoma (41).  HER-2/neu is also overexpressed in several other 
types of malignancies including ovary, pancreas, gastric, kidney and lung cancer and 
multiforme gliomoblastoma (141). 
 Several transgenic mouse models have been developed for studying the role of neu in 
tumorigenesis.  These transgenic mice have also proven invaluable for tumor vaccine studies, 
since they provide a model for evaluating vaccine efficacy under conditions of 
immunological tolerance.  The first neu transgenic mouse was described by Muller et al. in 
1988 (208).  The authors developed transgenic mice (FVB/neu-T) on the FVB/N genetic 
background that expressed a mutated and constitutively activated form of rat neu (neu-
transforming or neuT) under the murine mammary tumor virus (MMTV) promoter.  
Overexpression of the neu-T protein had a profound affect on tumorigenesis, as female 
FVB/neu-T mice uniformly and synchronously formed tumors in all mammary glands by 14 
weeks of age.  A year later, Bouchard et al. generated similar transgenic mice on a BALB/c 
background, with neu-T expression driven by the MMTV long terminal repeat (31).  In 
contrast to the results of Muller et al., these mice developed mammary tumors stochastically 
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between 5-10 months of age.  In 1992, Guy et al. generated transgenic FVB/N mice that 
expressed the wild-type rat neu protein (neu-nontransforming or neu-N) under the MMTV 
promoter (120).  Unlike FVB/N mice expressing neu-T, FVB/neu-N mice developed focal 
tumors after a long latency period.  At one year of age, 30% of FVB/neu-N mice remained 
tumor-free, whereas all of the FVB/neu-T mice had developed tumors by 14 weeks of age.  
Subsequent studies demonstrated that tumor formation in FVB/neu-N mice was frequently 
associated with somatic mutations in the neu gene, resulting in increased tyrosine kinase 
activity and transforming potential (271).  A neu transgenic mouse on the BALB/c 
background was characterized by Boggio et al. in 1998 (29).  These mice were derived from 
a transgenic CD-1 male breeder that expressed neu-T under control of the MMTV long 
terminal repeat, thus resulting in accelerated tumor growth (185).  Unlike FVB/neu-T mice, 
which only formed tumors in mammary tissue, BALB/neu-T mice form multifocal 
adenocarcinomas in breast tissue, salivary and Harderian glands and the epididymis by 33 
weeks of age.  Most recently, Piechocki et al. developed transgenic mice on the C57BL/6 
background that expressed human c-erbB-2 under the whey acidic protein promoter 
(B6/HER-2) (232).  B6/HER-2 transgenic mice did not develop spontaneous mammary 
tumors, but were immunologically tolerant to HER-2/neu, making them an acceptable model 
for evaluating HER-2/neu vaccines.          
 
Strategies for HER-2/neu immunotherapy 
Monoclonal antibody (mAb) therapy.  Because HER-2/neu is overexpressed on the cell 
surface of many cancers, it appeared to be an ideal target for mAb therapy.  Early studies 
using mAb specific for rat neu demonstrated that antibody treatment inhibited growth of neu-
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overexpressing tumor cell lines both in vitro and in vivo (74, 75).  Subsequent studies using 
anti-HER-2/neu mAb generated in mice showed similar results for human tumor cell lines, 
although the exact mechanism of action was unclear (139).  Because murine antibodies are of 
little clinical use due to their immunogenicity in humans, a “humanized” version of a murine 
anti-neu antibody was created by cloning the antigen-binding domains of a murine IgG2a 
mAb into the human IgG1 backbone (42).  Phase II clinical trials utilizing this recombinant 
antibody, which is referred to as trastuzumab (Herceptin), demonstrated that treatment of 
metastatic breast cancer patients with trastuzumab alone resulted in a 15% objective response 
rate (58).  A phase III randomized clinical trial showed that when given with first-line 
chemotherapy, trastuzumab significantly increased the objective response rate and survival in 
patients with HER-2/neu-overexpressing metastatic breast cancer, although cardiac toxicity 
was an uncommon but serious side effect (274).  Based on these studies, the United States 
Food and Drug Administration approved the use of trastuzumab either alone or in 
conjunction with chemotherapy for the treatment of metastatic breast cancer with HER-2/neu 
overexpression.  While trastuzumab has shown promising results in the clinic, the overall 
objective response rate is relatively low and resistance to the drug frequently occurs after one 
year of treatment (210).     
 
Peptide/protein immunization.  While several studies demonstrated the anti-tumor effects of 
manufactured antibodies against HER-2/neu, it was not clear if HER-2/neu was normally 
immunogenic in cancer patients.  An early study of breast cancer samples described a 
positive correlation between HER-2/neu amplification and lymphocyte infiltration, 
suggesting that cellular immunity against HER-2/neu may exist (292).  The presence of anti-
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neu immunity in cancer patients was first characterized by Disis et al. in 1994, who described 
the presence of neu-specific antibodies and CD4+ T cells in patients with HER-2/neu+ breast 
cancer (71).  An important implication of this report was that immune responses against an 
overexpressed self antigen could exist in the absence of apparent autoimmunity, which 
supported the notion that self proteins could be successfully targeted for vaccination.   
Induction of neu-specific T cell responses by vaccination could conceivably be 
accomplished with either whole protein or MHC-restricted peptides.  An early study by Disis 
et al. reported that immunization with neu-derived peptides, but not whole protein, could 
overcome tolerance and induce T cell responses in rats (72).  Thus, early efforts to vaccinate 
against HER-2/neu primarily employed immunogenic peptides.  The first MHC class I-
restricted peptide was identified in 1993 by Ioannides et al., who described CTLs from 
ovarian cancer patients that recognized an HLA-A2-restricted epitope corresponding to 
amino acids 971-980 of HER-2/neu (149).  Shortly thereafter, an immunodominant HLA-A2-
restricted nonapeptide—E75 (amino acids 369-377)—was discovered (92).  Since then, 
several more HER-2/neu-derived epitopes restricted to both MHC class I and II molecules 
have been identified (16). 
Several clinical trials evaluating the immunogenicity of neu-derived peptides have been 
undertaken.  While vaccination with HER-2/neu peptides was uniformly safe, induction of 
meaningful neu-specific T cell responses was typically absent.  Zaks and Rosenberg showed 
that immunization of patients with E75 and incomplete Freund’s adjuvant could induce E75-
specific CD8+ T cells, but these T cells failed to recognize neu-expressing tumor cells (324).  
Similarly, injection of E75 peptide with GM-CSF could induce E75-specific T cells, but the 
responses were short-lived and were undetectable by 5 months after vaccination (163).  
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Studies involving the addition of MHC class II-restricted T helper cell epitopes to the vaccine 
formulation have fared slightly better.  Knutson et al. demonstrated that immunization with 
peptides containing both MHC class I and II epitopes resulted in the induction of neu-specific 
CTLs that could lyse neu-expressing tumors (164).  Furthermore, neu-specific CTLs could be 
detected up to a year after vaccination.  These clinical trials clearly demonstrate that vaccines 
containing HER-2/neu-derived peptides can elicit neu-specific T cell responses in cancer 
patients.  However, no objective clinical responses in vaccinated patients have been reported 
to date (15). 
As noted above, vaccination with whole protein failed to break tolerance against HER-
2/neu.  However, targeting neu protein to the MHC class I presentation pathway of 
professional APCs may help address the ineffectiveness of whole protein vaccination.  
Several strategies for targeting neu to APCs have been employed, including the incorporation 
of neu protein into hydrophobized polysaccharides complexes (119), the combination of neu 
with heat shock proteins (193), and the generation of chimeric CD152-neu molecules (243).  
These strategies have yet to be tested in the clinical setting. 
 
Whole tumor cell vaccines.  The use of neu-overexpressing tumor cells for inducing neu-
specific immunity has been primarily restricted to preclinical animal models.  In 1999, Cefai 
et al. characterized an allogeneic vaccine consisting of BALB/c fibroblasts transduced with 
the neu protein (47).  This vaccine could prevent the formation of tumors in FVB/neu-T 
mice.  Nanni et al. described the efficacy of an allogeneic neu-expressing tumor cell vaccine 
in BALB/neu-T mice (213).  When combined with systemic injections of IL-12, the vaccine 
significantly inhibited the development of spontaneous tumors through an IFN-γ-dependent 
 42
mechanism.  In 2000, Jaffee and colleagues described an irradiated neu-expressing 3T3 cell 
vaccine that had been transduced with GM-CSF (3T3neuGM).  The vaccine was highly 
immunogenic in nontolerant syngeneic FVB/N mice, but was only slightly efficacious at 
inhibiting growth of adoptively transferred neu+ tumor cells in tolerant FVB/neu-N 
transgenic mice (241).  Subsequent studies have demonstrated that the efficacy of 
3T3neuGM vaccines can be enhanced when combined with anti-neu mAb or chemotherapy 
(191, 312). 
Although whole cell tumor vaccines have shown promising results in preclinical models, 
their actual use in the clinical setting is hampered by a frequent unavailability of autologous 
tumor cells (276).  While allogeneic tumor cells can be used, they often lead to allospecific 
rather than tumor antigen-specific T cell responses.  In addition, allogeneic tumor vaccines 
may lack neoantigens present in the patient’s own tumor.  Nonetheless, clinical trials using 
allogeneic tumor cells for vaccination against neu have been recently described (73).  
Allogeneic vaccines were well tolerated and even appeared to induce tumor-specific T cell 
responses in some instances, although it was not clear whether the T cell responses were 
directed against alloantigens or against neu.  Furthermore, no clinical responses were 
observed.   
 
DC vaccines.  Both preclinical and clinical studies have evaluated the ability of DC vaccines 
to induce neu-specific immunity.  Methods for loading DCs with antigen include pulsing 
with HER-2/neu-derived peptides (37, 67, 168, 261), viral transduction (54, 80, 201, 252, 
330), and transfection with tumor-derived RNA (207). 
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 Several preclinical evaluations of DCs loaded with HER-2/neu-derived peptides have 
been performed.  In 2000, Serody et al. evaluated the immunogenicity of DCs pulsed with 
either wild-type or modified GP2 peptides (amino acids 654-662) in transgenic A2Kb mice, 
which express a chimeric MHC class I molecule containing the α1 and α2 domains of human 
HLA-A2 and the α3 domain of murine H2-Kb (261).  The authors found that DCs presenting 
the modified GP2 induced better CTL responses in comparison to DCs presenting the wild-
type peptide.  The route of delivery of the DC vaccine did not seem to affect the magnitude 
of the immune response, but DC vaccines given intradermally resulted in more rapid 
induction of CTL activity.  Interestingly, weekly DC vaccination appeared to diminish the 
overall CTL response, which could be avoided if the vaccine was given every three weeks.  
While this study yielded important data concerning the logistics of DC vaccination, it did not 
evaluate the activity of DC vaccines in tolerant mice.  Recent studies by Lustgarten et al. 
examined the ability of peptide- or whole tumor-pulsed DCs to inhibit the growth of 
preexisting tumors in A2Kb × FVB/neu-N mice, which are tolerant to neu (62, 188).  
Multiple DC vaccinations resulted in modest inhibition of tumor growth; this could be 
slightly enhanced with adjunct anti-OX40 antibody and IL-2 therapy. 
Few virally-transduced DC vaccines have been studied in relevant animal models for neu 
immunotherapy.  In 2001, Chen et al. described the vaccination of FVB/N mice with DCs 
transduced with adenovirus encoding neu (54).  DC vaccination resulted in protection from 
challenge with neu+ tumors and even suppressed growth of established tumors when given 
therapeutically.  However, the authors did not test the efficacy of the vaccine in tolerant neu 
transgenic mice, although a recent study published in 2006 showed that prophylactic 
vaccination with adenovirus-transduced DCs slightly delayed the formation of spontaneous 
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tumors in FVB/neu-N transgenic mice (50).  The most compelling data concerning the 
efficacy of virally-transduced DCs for neu immunotherapy was published by Sakai et al. 
(252).  In this study, DCs from BALB/c mice were transduced with Ad encoding the 
extracellular-transmembrane domains of rat neu (neuET).  Vaccination with Ad-transduced 
DCs delayed spontaneous tumor formation in BALB/neu-T mice and reduced the number of 
mammary tumors.  Furthermore, vaccination induced appreciable anti-neu IgG responses, but 
only low-level CD8+ T cell responses.  Unfortunately, the authors did not assess vaccine 
efficacy when given therapeutically to mice with established tumors.       
  Human DCs have also been transduced with viral vectors encoding the HER-2/neu 
protein or derivative peptides.  Transduction of CD34-DCs with retrovirus encoding HER-
2/neu was only moderately efficient (~15%), but resulted in processing and presentation of 
HER-2/neu-derived epitopes to both CD8+ CTL and CD4+ T helper cells (330).  
Transduction of mono-DCs with recombinant influenza virus encoding the E75 epitope was 
also inefficient, yet the transduced DCs were capable of stimulating E75-specific CTL clones 
that exhibited some lytic activity against a HER-2/neu+ tumor cell line (80).   
The immunogenicity of DCs presenting epitopes from HER-2/neu has been evaluated in 
the clinical arena.  In 2000, Brossart et al. vaccinated metastatic breast cancer patients with 
mono-DCs pulsed with either MUC-1- or HER-2/neu-derived peptides (37).  Two of six 
patients receiving HER-2/neu peptide-pulsed DCs developed neu-specific CD8+ T cells.  
However, no clinical responses were noted.  In 2002, Kono et al. vaccinated gastric 
carcinoma patients with mono-DCs pulsed with E75 peptide alone (168).  Six of nine patients 
developed neu-specific T cells, although cytolytic activity was only present in two of the 
responders.  One of the patients who developed neu-specific T cells with cytolytic activity 
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had a partial clinical response.  A more recent trial was published by Dees et al. in 2004 (67).  
In this study, patients were treated with CD34-DCs pulsed with either wild-type GP2 or an 
altered GP2 peptide with enhanced binding to HLA-A2.  Two of ten patients developed 
modest GP2-specific CD8+ T cell responses, but no cytolytic activity was measured.  
Interestingly, two separate patients exhibited partial clinical responses.   
 
Recombinant viral vectors.  The use of a recombinant virus expressing neu was first reported 
in 1987 by Bernards et al. (26).  The authors used a VV vector encoding rat neu to induce 
protective anti-neu antibody responses in rats, resulting in protection from challenge with 
xenogeneic 3T3 cells expressing neu.  Since then, other viral vectors encoding neu proteins 
or peptides have been evaluated primarily in nontolerant animal models. 
 In addition to their use for transduction of DCs (see above), recombinant Ad vectors have 
also been used to directly immunize animals.  Palmer et al. described the efficacy of 
intratumor inoculation of Ad vectors encoding a kinase-dead mutant of rat neu in wild-type 
mice (224).  The vector appeared to inhibit tumor growth through induction of neu-specific 
immunity and through direct cytolytic effects on tumor cells.  Another study in 2005 
demonstrated that xenogeneic vaccination with an Ad vector encoding neu slightly delayed 
tumor formation and decreased the mean number of tumors formed in BALB/neu-T mice 
(103).  In that same year, Park et al. observed that multiple vaccinations with Ad encoding 
neuET significantly delayed autochthonous carcinomas in BALB/neu-T mice (228).  
However, vaccination had to be initiated early (7 weeks of age) for any observed efficacy.  
Interestingly, inhibition of tumor growth did not require CD8+ T cells, but instead required T 
helper-dependent antibody responses. Another DNA viral vector evaluated for neu 
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immunotherapy was derived from murine polyomaviruses (293).  A single vaccination with a 
recombinant polyomavirus vector encoding neuET significantly delayed spontaneous tumor 
formation in BALB/neu-T mice; however, the clinical relevance of murine polyomavirus is 
unclear.    
 VRP encoding rat neu (neu-VRP) have been evaluated in three different studies.  The first 
use of VRP for neu immunotherapy was reported by Nelson et al. in 2003 (214).  Using a rat 
animal model, the authors demonstrated that prophylactic vaccination with neu-VRP 
protected 50% of rats from challenge with a neu-expressing tumor cell line.  Vaccinated rats 
also rejected a second tumor challenge, suggesting that neu-specific immunity was present.     
However, neu-specific T cell responses were not directly measured, and it was not clear if the 
tumor cell line used in the study was MHC-matched.  A subsequent study by Lachman and 
colleagues demonstrated that therapeutic vaccination with neu-VRP alone was ineffective at 
inhibiting tumor growth in wild-type BALB/c mice (83).  However, adjunct treatment with 
either doxorubicin or paclitaxel modesty inhibited tumor growth.  A follow-up study in 2005 
demonstrated that repeated vaccination of FVB/neu-T mice with neu-VRP prevented 
spontaneous tumor formation up to 240 days of age, whereas all control mice had developed 
tumors by 140 days of age (304).  However, therapeutic vaccination of tumor-bearing mice 
was not evaluated. 
 
Adoptive cell therapy (ACT).  The adoptive transfer of tumor-specific T cells has been of 
great interest, since it is one of the few immunotherapeutic strategies that has induced tumor 
regression in patients with advanced disease (77).  The isolation and ex vivo expansion of 
high-avidity T cells that maintain the capacity to home to tumors and exert effector function 
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have been generally difficult, although new methods based on the use of alternative 
lymphoproliferative cytokines such as IL-15 have been promising (106).  To increase the 
repertoire of neu-specific lymphocytes, human T cells have been genetically modified to 
express anti-neu antibody receptors, which can function as artificial T cell receptors (233).  
In xenogeneic animal models, human T cells expressing membrane-bound anti-neu chimeric 
receptors migrated to tumor sites and exerted anti-tumor activity.  However, genetic 
manipulation of T cells can potentially lead to cellular transformation, which may limit their 
clinical application. 
 
Barriers to successful HER-2/neu immunotherapy 
 Despite the use of multiple vaccination strategies, the overall success rate for inducing 
clinically relevant immunity against HER-2/neu in cancer patients has been dismal.  This 
may be surprising to some, since several preclinical studies (see above) have shown 
induction of robust immune responses against neu and even regression of neu-expressing 
tumors.  However, most of these studies have been performed in nontolerant animal models, 
where the threshold for inducing tumor immunity is significantly low.  In studies that did use 
tolerant mice, most vaccinations were performed in young mice prior to tumor 
development—a scenario that is far from the reality of the clinic, where most cancer patients 
are elderly, present with established disease, and have been extensively preconditioned with 
chemotherapy and radiation.  For tumor immunotherapy to be successful in this patient 
population, a better understanding of the barriers to successful vaccination is required.  A few 
of the known impediments are described below. 
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Tumor-specific inhibitory factors.  There are many mechanisms by which malignant cells can 
interfere with tumor immunity, including down-regulation of MHC class I molecules or 
immunogenic antigens, secretion of anti-inflammatory mediators, and expression of cell 
surface molecules that can directly inhibit NK or T cells (157).  Most of these strategies for 
immune evasion have been observed for HER-2/neu-overexpressing tumors.  Loss of HER-
2/neu expression is the most straightforward way for HER-2/neu+ tumor cells to avoid 
immune recognition.  However, because of the essential role of HER-2/neu-signaling in 
tumor growth and metastasis, it was thought that loss of HER-2/neu would result in “unfit” 
variants that contribute little to disease.  Nonetheless, studies in mice treated with anti-neu 
antibodies identified HER-2/neu antigen-loss variants with malignant potential, suggesting 
that somatic mutations conferring HER-2/neu independency may arise (162).  Down-
regulation or loss of MHC class I expression has also been identified in patients and mice 
with HER-2/neu+ tumors (184, 216).  Interestingly, HER-2/neu itself may be directly 
involved, as induced expression of HER-2/neu in tumor cells resulted in the down-regulation 
of proteins involved with the MHC class I presentation pathway (130).  HER-2/neu signaling 
can induce secretion of vascular endothelial growth factor (VEGF) (160), and HER-2/neu 
expression has been associated with production of indoleamine 2,3-dioxygenase (206); both 
can have potent inhibitory effects on immune cells.  Finally, spontaneous tumors in neu 
transgenic mice were shown to express CD95L (FasL), which correlated with apoptosis of 
tumor-infiltrating T cells (46).  In summary, multiple tumor-derived factors could conspire 
against successful neu-specific immunotherapy. 
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Paucity of HER-2/neu-specific effector T cells.  Most self-reactive T cells are centrally 
deleted in the thymus through the process of negative selection.  Yet it is clear that some self-
reactive T cells can avoid thymic selection and escape into the periphery (217, 220).  
Fortunately (or unfortunately for tumor vaccinologists), the functional avidity of self-reactive 
T cells in the periphery is usually low, and these cells remain phenotypically naïve due to 
antigen ignorance (169).  However, self-reactive T cells can potentially be converted into 
potent effector cells capable of causing autoimmune disease or tumor immunity—a process 
in which DCs likely play a pivotal role (186).  It has thus been the goal of tumor vaccines to 
recruit the endogenous pool of self-reactive T cells for the elimination of cancer cells.         
 The ability to induce effective anti-neu T cell responses in mice and humans tolerant to 
HER-2/neu has been difficult.  Tolerant neu transgenic mice generally lack high-avidity 
CD8+ T cells specific for neu (85, 188).  Vaccination alone does little to expand the 
repertoire of neu-specific T cells in these mice, although combination therapy with certain 
chemotherapeutic drugs can enhance the expansion of high-affinity T cells (84).  CD8+ T 
cells specific for the immunodominant epitope E75 have been identified in patients with 
HER-2/neu-overexpressing tumors, but these cells are of low frequency (27).  While neu-
specific CD8+ T cells can be expanded ex vivo using peptide-pulsed APCs, they often lack 
the ability to recognize and kill HER-2/neu+ tumors (163, 324).  Some investigators have 
attempted to circumvent tolerance to HER-2/neu through the use of modified heteroclitic 
peptides (261, 303).  This strategy may recruit cross-reactive T cells that escaped central 
deletion and would not be subject to the same regulation as normal neu-specific T cells.  
However, studies in melanoma patients have indicated that T cells specific for heteroclitic 
peptides are often deficient at recognizing native peptide presented by tumor cells (287). 
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 In the event that neu-specific CD8+ T cells with high avidity can be efficiently expanded 
by vaccination, this may still be insufficient for effective immunotherapy.  While tumor-
infiltrating lymphocytes are typically considered a positive prognostic factor, malignant 
lesions can continue to growth even in the presence of infiltrating tumor-specific CD8+ T 
cells (205).  Furthermore, a study by Rosernberg et al. showed that tumors can progress 
unabated in melanoma patients with large numbers of melanoma-specific CD8+ T cells (247).  
These studies strongly suggest that immune inhibitory mechanisms will trump CTL 
responses in cancer patients, and therefore strategies that “inhibit the inhibitors” are needed.       
 
Regulatory T cells.  The identification of T cells that could suppress immune responses was 
first made by Gershon et al. in 1972 (109).  Subsequent work by North and colleagues 
demonstrated that these cells could inhibit antitumor immunity in animals (24).  However, 
the confusion regarding the existence of I-J specific T cells led to a decade with little work 
performed evaluating the function of these cells.  In 1995, Sakaguchi and colleagues 
described the presence of CD4+ T cells that constitutively expressed CD25, the high-affinity 
IL-2 receptor, and could inhibit immune responses (251). 
Regulatory CD4+ T cells are thought to come in two basic varieties:  “natural” cells that 
are purposely selected in the thymus, and “induced” cells that acquire suppressor function in 
the periphery.  Natural regulatory T cells (Treg) are characterized by expression of CD25 (the 
α chain of the IL-2 receptor) and the transcription factor FoxP3 (134).  Other markers that are 
preferentially expressed on Treg (but also on activated effector T cells) include CTLA-4, 
GITR, and Lag-3 (138).  While CD25 may be expendable for the development of Treg (96), 
FoxP3 is not, as humans and mice deficient in the FoxP3 gene lack Treg and quickly succumb 
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to a fatal lymphoproliferative disorder (38, 310).  In vitro, Treg appear to suppress effector 
cells indiscriminately through a cell-contact dependent mechanism.  In vivo, though, Treg may 
employ different mechanisms for suppression, such as the expression of IL-10 and/or TGF-β 
(18, 19).  Induced regulatory T cells were originally described by Groux et al. in 1997 (117).  
These regulatory cells were referred to as T regulatory type 1 (TR1) cells, and they appeared 
to arise from naïve CD4+ T cells following stimulation in the presence of IL-10.  TR1 cells 
could inhibit effector T cells both in vitro and in vivo through the secretion of IL-10 and/or 
TGF-β (cells secreting only the latter are also referred to as TH3 cells).  Several types of 
induced IL-10-producing regulatory T cells distinct from the originally defined TR1 cells 
have been described, and it may be more appropriate to refer to these cells collectively as IL-
10-secreting regulatory T cells (126).  However, the conventional term “TR1” cell will be 
used hereafter. 
Because regulatory T cells were involved with maintaining tolerance to self antigens in 
peripheral tissues, it was not long before they were implicated as negative regulators of 
tumor immunity. Treg and TR1 cells can be found in tumor-draining lymph nodes and at the 
tumor site in both mice and humans (63, 165, 183).  Adoptive transfer studies in mice have 
shown that Treg can inhibit tumor specific CD8+ T cells, resulting in progressive tumor 
growth (4).  Moreover, several studies have demonstrated that pretreatment of mice with 
anti-CD25 mAb improved immune responses against transplanted tumors (221, 266, 329).  
Other methods for inhibiting and/or depleting Treg during tumor immunotherapy include 
treatment with cyclophosphamide (CY) (84) or anti-GITR antibodies (165). 
Treg can potentially inhibit immune responses against neu in both humans and mice.  In 
2004, Curiel et al. found that Treg accumulated in the tumors and ascites of ovarian cancer 
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patients, many of whom were HER-2/neu-positive (63).  Treg from these cancer patients could 
inhibit HER-2/neu-specific CD8+ T cells in vitro, although it was not shown that the Treg 
were actually specific for HER-2/neu.  In 2005, Ercolini et al. demonstrated that treatment of 
FVB/neu-N mice with CY prior to vaccination protected 10-20% of mice from subsequent 
challenge with neu+ tumor cells (84).  The enhanced protection was thought to be due to 
inhibition of Treg, since i) CY treatment reduced the number of cycling CD4+CD25+ cells; 
and ii) adoptive transfer of CD4+CD25+ T cells into vaccinated mice abrogated protection.  
Furthermore, the depletion of Treg was accompanied by an increase in neu-specific CD8+ T 
cells with high-avidity.  This suggests that high-avidity CD8+ T cells specific for tumor 
antigens may escape negative selection in tolerant mice, but are actively suppressed in the 
periphery by Treg.  Most recently, Nair et al. observed increased infiltration of spontaneous 
tumors with CD4+FoxP3+IL-10+ T cells following multiple vaccinations against neu, which 
was associated with decreased CTL activity by intratumor CD8+ T cells (211).  However, no 
depletion studies were performed to more definitively assess the role of Treg.  Overall, these 
findings suggest that Treg are likely involved with inhibiting immunity against neu, although 
the extent of their role remains to be determined. 
 
Dysfunctional or suppressive APCs.  In addition to inhibiting the effector arms of the 
immune system, tumors can also dampen the initiation of immunity by suppressing the 
activity of APCs, namely macrophages and DCs (100).  DCs found within the tumor 
microenvironment frequently exhibit functional deficits in maturation and antigen 
presentation (102, 297).  Additionally, tumors can inhibit the development of DCs from 
myeloid precursors through the secretion of soluble factors such as VEGF (101).  Tumors 
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can also cause the accumulation of myeloid precursors with suppressor function—referred to 
as immature myeloid cells (iMCs)—in bone marrow, lymphoid tissues or at the tumor itself 
(36, 323).  In mice, iMCs are characterized by expression of CD11b and Gr-1 (Ly6G), 
whereas human iMCs express CD33; both lack expression of MHC class II (100).  iMC can 
inhibit CD8+ T cell activity through a cell-contact dependent mechanism that likely involves 
the release of reactive oxygen species (176).  iMC at the tumor site have also been 
incriminated in the generation of Treg/TR1 cells (137), although other studies have failed to 
make this connection (175). 
 APC defects in humans and mice with neu-overexpressing tumors have been documented.  
Early pathological studies found a positive correlation between high-grade HER-2/neu+ 
tumors and macrophage infiltration, suggesting that macrophages may facilitate tumor 
growth (237).  More recently, tumor-associated macrophages expressing the inhibitory 
molecule B7-H4 from HER-2/neu+ ovarian cancer patients have been shown to inhibit HER-
2/neu-specific CD8+ T cells in vitro (170).  A study of BALB/neu-T mice with spontaneous 
tumors found a positive correlation between tumor multiplicity and the number of iMCs in 
the blood and spleen (198).  Furthermore, iMC could suppress T cell proliferation in response 
to anti-CD3 antibodies and IL-2.  The expansion of iMC appeared to be due to VEGF 
secretion by neu-expressing tumor cells, as transfer of iMC to tumor-free mice resulted in 
contraction of the population.  Further studies are required to more definitely assess the role 
of iMC in humans and mice bearing neu-overexpressing tumors. 
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DISSERTATION OBJECTIVES 
 
Because of their potent immunostimulatory capacity, several preclinical and clinical 
studies have evaluated the ability of DCs to induce immunity against HER-2/neu.  Although 
DC vaccines have been uniformly safe and well tolerated, their overall efficacy at inducing 
therapeutic immunity in cancer patients has been disappointing.  While the ineffectiveness of 
DC vaccines may be viewed as a deterrent for future use, it can be conversely argued that 
current peptide-pulsed DC vaccines are suboptimal, likely due to their limited secretion of 
immunostimulatory cytokines.  Thus, novel strategies for improving antigen delivery to DCs 
as well as maximizing DC function are warranted.  Transducing DCs with recombinant viral 
vectors may be an ideal approach for generating more potent DC vaccines.  As mentioned 
previously, viral vectors can be used for highly efficient delivery of intact antigen to DCs, 
resulting in processing and presentation of both MHC class I- and II-restricted epitopes.  
Moreover, viral transduction can induce robust activation of DCs through TLR-dependent 
and -independent mechanisms.  Finally, viral vectors may provide the persistent TLR 
stimulation necessary for overcoming Treg-mediated suppression and thus breaking tolerance 
against tumor antigens. 
While several viral vectors have been investigated for transduction of DCs, many are 
hampered by inefficient transduction efficiencies, potential interference with DC function, 
and questionable safety.  Viral vectors derived from VEE may successfully address several of 
these limitations.  VRPs have many appealing characteristics, including:  i) a natural tropism 
for DCs (190); ii) high-level transgene production in infected cells (238); iii) the inability to 
produce progeny virions, thus preventing potentially dangerous spread of virus in vaccinated 
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hosts; iv) an efficient in vitro production system that allows packaging of replicons in distinct 
glycoprotein coats, which can confer specific tropism and additional safety (238); v) a lack of 
preexisting anti-vector immunity in the vast majority of patients outside of certain subtropical 
regions; vi) an impeccable safety record as demonstrated in scores of studies with rodents and 
non-human primates (65, 131); and vii) an established protocol for producing the vector by 
Good Manufacturing Practices, thus expediting its use in a Phase I clinical trial. 
Vaccination with VRPs has proven highly effective at inducing both cellular and humoral 
immune responses (121, 238), and has even been shown to stimulate tumor immunity in 
some rodent models (214, 302).  The ex vivo transduction of DCs with VRPs may further 
enhance anti-tumor immune responses, as this strategy can focus antigen production in the 
cells responsible for initiating immune responses and can circumvent potential issues 
concerning anti-vector immunity.  Moreover, ex vivo transduction of DCs allows better 
control of DC quality, an important issue since endogenous DCs are frequently impaired in 
cancer patients.  The ability of VRPs to transduce DCs ex vivo, as well as their potential as 
cancer vaccines is unknown.  Therefore, the objectives of this dissertation are as follows: 
1)  To determine if VRPs can efficiently transduce human and murine DCs ex vivo, and 
characterize the resulting effects on DC phenotype and function. 
2)  To determine if VRP-transduced DC vaccines expressing a truncated neu oncoprotein 
can stimulate tumor-specific immunity in vivo. 
3)  To determine if VRP-transduced DC vaccines expressing a truncated neu oncoprotein 
can overcome tolerance in FVB/neu-N transgenic mice and consequently induce therapeutic 
tumor immunity.  
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Abstract 
Dendritic cell (DC)-based vaccines are increasingly used for the treatment of patients with 
malignancies.  While these vaccines are typically safe, consistent and lasting generation of 
tumor-specific immunity has been rarely demonstrated.  Improved methods for delivering 
tumor antigens to DCs and approaches for overcoming tolerance or immune suppression to 
self-antigens are critical for improving immunotherapy.  Viral vectors may address both of 
these issues, as they can be used to deliver intact tumor antigens to DCs, and have been 
shown to inhibit the suppression mediated by regulatory T cells (Treg).  We have evaluated 
the potential use of VEE replicon particles (VRPs) for in vitro antigen delivery to human 
monocyte-derived DCs.  VRPs efficiently transduced immature human DCs in vitro, with 
approximately 50% of immature DCs expressing a vector-driven antigen at 12 hours post-
infection (hpi).  VRP infection of immature DCs was superior to TNF-alpha treatment at 
inducing phenotypic maturation of DCs, and was comparable to LPS stimulation.  
Additionally, VRP-infected DC cultures secreted substantial amounts of the proinflammatory 
cytokines IL-6, TNF-alpha and IFN-alpha.  Finally, DCs transduced with a VRP encoding 
the influenza matrix protein (FMP) stimulated 50% greater expansion of FMP-specific CD8+ 
CTL when compared to TNF-alpha-matured DCs pulsed with an HLA-A*0201-restricted 
FMP peptide.  Thus, VRPs can be used to deliver antigens to DCs resulting in potent 
stimulation of antigen-specific CTL.  These findings provide the rationale for future studies 
evaluating the efficacy of VRP-transduced DCs for tumor immunotherapy.  
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Introduction 
There is significant interest in the use of DC vaccines as treatments for patients with 
malignancies and chronic infectious diseases (20, 43).  Following activation by inflammatory 
cytokines or microbial products, DCs possess several characteristics that are necessary for 
efficient stimulation of tumor-specific T lymphocytes, including enhanced homing to 
lymphoid tissues, high level expression of MHC class I- and II molecules in conjunction with 
costimulatory molecules, and secretion of immunostimulatory cytokines (3).  The ability of 
DCs to prime tumor-specific T cell responses has been demonstrated in various animal 
models (7, 18, 34).  These studies have led to several clinical trials evaluating the efficacy of 
DCs loaded ex vivo with tumor-associated antigens (TAAs) to initiate protective immune 
responses in cancer patients (2, 8, 10, 19, 28, 39, 49).  Multiple techniques have been 
employed for loading DCs with TAAs including pulsing with MHC class I- and/or II-
restricted peptides (41, 47, 51), incubation with tumor cell lysates (41), and electroporation 
with tumor cell RNA (23).  Unfortunately, induction of measurable and durable anti-tumor T 
cell responses have been infrequent in most clinical trials, suggesting that the stimulatory 
capacity of current DC vaccines is inadequate (42).  Therefore, alternative strategies for 
inducing optimal DC maturation and antigen presentation are warranted. 
Viral vectors that encode TAAs may provide an alternative method for delivering antigens 
to DCs.  Delivery of an entire TAA rather than TAA-derived peptides allows processing and 
presentation of multiple epitopes on both MHC class I and II molecules, resulting in a 
broader CD8+ T cell response and incorporation of CD4+ T cell help (56, 58).  In contrast to 
MHC-restricted peptide vaccines, viral vectors can be used to transduce DCs of all MHC 
haplotypes.  Viral vectors can induce DC maturation through both TLR-dependent and -
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independent pathways, resulting in up-regulation of costimulatory molecules and secretion of 
Th1-inducing cytokines (1, 13).  Additionally, viral vectors may provide stimuli that are 
required for overcoming tolerance against TAAs, specifically through the down-regulation of 
Treg activity (57).   
Several viral vectors have been utilized for transducing human DCs with TAAs (5, 14-16).  
While some of these vectors have entered clinical trials (12), their widespread use is 
hampered by inefficient transduction efficiencies, interference with DC function, and 
induction of anti-vector responses due to pre-existing immunity (25).  Because of these 
limitations, we have evaluated the potential use of vectors derived from Venezuelan equine 
encephalitis virus (VEE) for transduction of human DCs.  Nonpropagating VRPs possess 
intriguing characteristics including 1) significant expression of the inserted gene in infected 
cells (45), 2) induction of both cell-mediated and humoral immunity (6), 3) potential for 
repeated immunizations without significant induction of anti-vector immune responses (45), 
and 4) potential tropism for DCs.  While our group has shown that VRPs can infect murine 
DCs in vivo (33), their capacity to transduce human DCs is unknown.  In this report, we 
demonstrate that VRPs can infect human immature monocyte-derived DCs.  VRP-transduced 
DCs can efficiently process and present VRP-encoded antigens, leading to robust 
proliferation of antigen-specific T cells and acquisition of effector function.  Thus, vaccines 
consisting of VRP-transduced DCs may prove highly effective for the induction of tumor-
specific CD8+ T cells. 
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Materials and Methods 
Antibodies and Reagents 
PE-conjugated monoclonal antibodies specific for human CD8 (SK2), CD11c (B-LY6), 
CD14 (M5E2), CD40 (5C3), CD80 (L307.4), CD83 (HB15e) and HLA-DR (G46-6) were 
purchased from BD Pharmingen (San Diego, CA).  Anti-human CD86-PE (HA5.2B7) was 
purchased from Beckman Coulter (San Diego, CA).  Mouse anti-influenza A matrix protein 
(FMP) monoclonal antibody was purchased from Serotec (Raleigh, NC).  All isotype control 
antibodies were purchased from BD Pharmingen.  Recombinant human GM-CSF, IL-4, IL-2, 
IL-7 and TNF-α were purchased from Peprotech (Rocky Hill, NJ).  Human AB serum 
(HABS) was purchased from Gemini Bioproducts (Woodland, CA).   
 
Generation of Human Monocyte-Derived DCs 
Peripheral blood was obtained from volunteer donors by venipuncture and diluted 1:2 
with phosphate buffered saline (PBS).  Peripheral blood mononuclear cells (PBMCs) were 
isolated by centrifugation over lymphocyte separation medium (ICN Biomedicals, Aurora, 
OH), washed twice with PBS, and resuspended in serum-free AIM-V media (Invitrogen, 
Carlsbad, CA).  Monocytes were enriched by culturing 107 PBMCs/well in 6-well tissue 
culture plates for 2 hours.  Nonadherent PBMCs were removed and cryopreserved in 90% 
fetal bovine serum/10% DMSO.  In experiments evaluating cytokine secretion, highly 
purified monocytes (>90% CD14+) were obtained by immunodepletion of non-monocytic 
cells using the Monocyte Isolation Kit II (Miltenyi Biotec, Auburn, CA) according to the 
manufacturer’s instructions.  Monocytes isolated by either method were cultured at 37°C/5% 
CO2 in complete AIM-V/10% HABS supplemented with GM-CSF (800U/ml) and IL-4 
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(500U/ml).  Fresh cytokine was added on days 3 and 6 of culture.  The cells were harvested 
on day 6 as immature DCs, or further matured for 24-48 hours with lipopolysaccharide (LPS) 
(0.1 - 1µg/ml) or for 48 hours with recombinant human TNF-α (20ng/ml) added daily.  All of 
the clinical reagents were generated under protocols approved by the Committee for the 
Protection of the Rights of Human Subjects at the University of North Carolina School of 
Medicine. 
 
Generation of Recombinant VRPs 
The production of VRPs that encode the green fluorescent protein (GFP-VRP) has been 
previously described (33).  The absence of propagating recombinant virus was confirmed by 
passage in BHK cells.  VRPs were concentrated from supernatants by centrifugation through 
a 20% sucrose cushion and resuspended in PBS.  Titration of GFP-VRPs was determined by 
infecting BHK monolayers with 10-fold dilutions of VRPs for 16-18 hours at 37°C/5% CO2.  
The infected cells were fixed with 4% paraformaldehyde and GFP-expressing cells were 
directly visualized by fluorescent microscopy.  VRPs that encode FMP (FMP-VRP) were 
generated by directionally cloning the FMP cDNA (kindly provided by P. Palese, Mt. Sinai 
School of Medicine, New York, NY) immediately downstream of the 26S mRNA promoter 
of the pVR21 replicon plasmid; proper orientation was confirmed by DNA sequencing.  The 
FMP replicon plasmid was used to generate FMP-VRPs.  For titration, BHK monolayers 
were infected with 10-fold dilutions of FMP-VRPs for 16-18 hours at 37°C/5% CO2.  
Infected cells were fixed with ice-cold methanol and sequentially stained with mouse anti-
FMP monoclonal antibody, biotinylated anti-mouse IgG, and FITC-conjugated streptavidin.  
FITC-positive cells were directly enumerated by fluorescent microscopy.   
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 Infection of Human DCs with VRPs 
Immature or mature DCs were resuspended in serum-free AIM-V at 0.5-1.0 × 106 cells/ml 
and seeded at 1-2 × 105 DCs per well in 24-well ultra low attachment plates (Corning Inc., 
Corning, NY).  For infectivity experiments, 1-2 × 105 DCs were infected with VRPs at 
different MOIs over specific time intervals as indicated in the figure legends.  Infections 
were performed in serum-free conditions at 37°C/5% CO2.  After 1-2 hours, DCs were 
washed with AIM-V/10% HABS, resuspended in media supplemented with GM-CSF 
(800U/ml) and IL-4 (500U/ml), and cultured in 24-well ultra low attachment plates at 
37°C/5% CO2. 
 
Flow Cytometry Analysis 
For quantification of VRP transduction efficiency, GFP-VRP- or mock-infected DCs were 
harvested at 6, 12 or 24 hpi and washed once with cold FACS buffer (PBS/0.5% human 
serum albumin).  DCs were fixed with PBS/1% formaldehyde before FACS analysis.  In 
some experiments, DC viability was determined using the Fixation and Dead Cell 
Discrimination Kit (Miltenyi Biotec) according to the manufacturer’s instructions.  For 
phenotypic analysis, 5 × 104 DCs were incubated with 200µg/ml mouse IgG (Sigma) at 4°C 
for 20 minutes.  Following blocking, the DCs were stained with 2µl of PE-conjugated 
specific or isotype control antibodies for 30 minutes at 4°C, washed once with FACS buffer, 
and fixed with PBS/1% formaldehyde.  FACS data was acquired using a FACScan flow 
cytometer (BD Biosciences, San Jose, CA), and analyzed using FlowJo software (Tree Star, 
Ashland, OR). 
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 Cytokine Assays 
For evaluation of cytokine secretion by DCs, immature DCs were either mock-infected or 
infected with GFP-VRPs (MOI = 20) for 2 hours at 37°C/5% CO2.  Fully mature DCs were 
generated by treatment for either 24 hours with LPS (100 ng/ml) or 48 hours with TNF-α (20 
ng/ml).  Mock-infected immature DCs, VRP-infected immature DCs, or fully mature DCs 
were washed and seeded into 96-well flat bottom tissue culture plates at 105 DCs/well.  
Supernatants were harvested at 12, 24, 36 or 48 hours post-treatment and stored at -80°C.  
Quantification of IL-6, IL-8, IL-10, IL-12p70, and TNF-α in the supernatants was performed 
using the cytometric bead array (CBA) according to the manufacturer's instructions (BD 
Pharmingen, Franklin Lakes NJ).  Measurement of IFN-α was determined by ELISA 
(Biosource International, Camarillo CA) according to the manufacturer's instructions. 
 
Allogeneic Mixed Leukocyte Reactions (MLR) 
Mock- or GFP-VRP-infected (MOI = 10) DC cultures were harvested after 1 hour of 
infection, washed with media, and resuspended in AIM-V/10% HABS.  Decreasing numbers 
of DCs were added in triplicate to 1 × 105 nonadherent allogeneic PBMCs per well in 96-well 
round bottom plates and T cell proliferation assays were performed as previously described 
(55).   
 
In Vitro Expansion of FMP-Specific T Cells 
Immature DCs from HLA-A*0201-positive donors were infected for 2 hours with either 
GFP-VRPs or FMP-VRPs (MOI = 10) and washed with AIM-V/10% HABS media.  DCs 
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(0.2-2 × 105) were added to 2 × 106 autologous nonadherent PBMCs per well in 24-well 
tissue culture plates.  For comparative stimulation of T cells with peptide-pulsed DCs, TNF-
α-matured or LPS-matured DCs from the same donors were incubated with 10 µg/ml of FMP 
peptide in AIM-V/10% HABS for 2 hours.  FMP peptide-pulsed DCs were washed with 
media and added to autologous nonadherent PBMCs as described above.  PBMCs were 
incubated for 7 days in AIMV/10% HABS supplemented with IL-2 (20U/ml) and IL-7 
(10ng/ml).  Fresh cytokine was added on days 3 and 6 of culture, and cell density was 
maintained at < 2 × 106 cells/ml during the entire assay.  On day 7, the responders were 
harvested and evaluated for either antigen-specific expansion by tetramer staining, or for 
specific lysis of peptide-pulsed T2 cells by a conventional 51Cr release assay (48).  Percent 
specific lysis was determined using the following formula: 
 
Percent specific lysis = 100 × [(sample cpm - spontaneous cpm) / (total cpm - spontaneous 
cpm)]   
 
For tetramer staining, 1 × 106 responders were stained for 30 minutes with 20 µl of anti-
human CD8-FITC (Pharmingen) and 10 µl of either PE-conjugated HLA-A*0201/Influenza 
M1 peptide tetramer or HLA-A2*0201/Negative tetramer (Beckman Coulter).  Cells were 
washed with PBS, fixed with PBS/0.5% formaldehyde, and analyzed by FACS within 6 
hours.   
 
Statistical Analysis 
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Statistical differences were calculated using a Student's t-test when sample data 
distribution was parametric.  Sample data that exhibited nonparametric distribution were 
evaluated using a Mann-Whitney rank sum test.  Differences in costimulatory molecule 
expression between mock- and VRP-infected DCs from several donors were analyzed using a 
Wilcoxon signed rank test.  P values < 0.05 were considered significant.  All statistical 
analyses were performed with SigmaStat 3.0 software (Port Richmond, CA).   
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Results 
VRPs Can Efficiently Transduce Human Immature DCs 
Our group has previously demonstrated that VRPs can infect mouse DCs in vivo following 
foot pad injection (33).  To determine if human DCs could be infected with VRPs in vitro, 
immature monocyte-derived DCs were generated from normal donors.  By day 6 of culture, 
DCs exhibited a typical immature phenotype (CD11c+, HLA-DR+, CD86+, CD14-, CD40-, 
CD80-) when evaluated by flow cytometry (data not shown).  Immature day 6 DCs were 
infected with GFP-VRPs at an MOI of 10.  GFP expression in DCs was first detectable at 
around 4 hpi, and reached a maximum between 6-12 hpi (Figure 1A).   
To quantify VRP transduction efficiency, mock- or GFP-VRP-infected (MOI = 10) 
immature DCs were harvested at 6, 12 or 24 hpi and analyzed for GFP expression by flow 
cytometry.  As shown in Figure 1B, VRPs could infect human immature DCs at an MOI of 
10, with a mean of 10.8% expressing GFP by 6 hpi.  The mean percentage of GFP-positive 
immature DCs peaked at 18.4% at 12 hpi and then decreased to 15.5% by 24 hpi.  To 
determine if the maturation status of the DCs affected the transduction efficiency, immature 
DCs were stimulated with LPS for two days, resulting in marked up-regulation of CD40, 
CD80, CD83 and CD86 (data not shown).  LPS-matured DCs were minimally transduced by 
GFP-VRPs (Figure 1B).  DCs matured with TNF-α for two days were also less susceptible to 
VRP infection (mean 6.2% GFP-positive at 12 hpi), although not to the same degree as found 
using LPS-matured DCs.  Thus, VRP transduction efficiency was inversely related to the 
degree of DC maturation.   
In order to verify that the GFP-positive cells exhibited a DC phenotype, we performed 
two-color FACS analysis on infected DC cultures.  GFP-VRP-infected DCs were harvested 
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at 24 hpi and stained with PE-conjugated antibodies specific for CD11c, HLA-DR and 
CD14.  GFP-positive cells expressed high levels of CD11c and HLA-DR, and did not express 
the monocyte-marker CD14 (Figure 1C).  To demonstrate that VRPs specifically infected 
immature DCs, the ability of VRPs to transduce peripheral blood T cells, B cells and 
monocytes was determined.  We did not observe infection of CD3+ T cells and CD19+ B cells 
with GFP-VRPs (MOI = 10), and only minimal (~2%) transduction of CD14+ monocytes 
(data not shown).  Thus, VRPs specifically infected immature DCs.   
We next evaluated approaches that could enhance the efficiency of VRP transduction of 
immature DCs.  Increasing the MOI improved the transduction of immature DCs by GFP-
VRPs.  At an MOI of 100, approximately 50% of DCs expressed GFP (Figure 2A).  The 
percent of GFP-positive DCs began to plateau between an MOI of 50 and 100, suggesting 
that transduction efficiency was near maximal.  In an effort to maximize transduction 
efficiency at a lower MOI, we increased the duration of infection and the DC concentration 
during infection.  By doubling both the time of infection and the DC concentration during 
infection at an MOI of 20, the transduction efficiency increased from a mean of 22.5% to 
37.0% (n =3, p = 0.002) (Figure 2B).  Thus, immature DCs can be efficiently transduced with 
relatively small quantities of VRPs.   
The percentage of GFP-expressing DCs began to decline between 12 and 24 hpi (Figure 
1B), suggesting that VRP infection may be cytopathic to human DCs.  Alphaviruses and 
alphaviral vectors induce apoptosis in cultured cells (31), although their ability to similarly 
induce cell death in human DCs is unknown.  We therefore compared the viability of VRP-
infected (GFP-positive) DCs to uninfected (GFP-negative) DCs in the culture by exclusion of 
a vital dye.  VRP-infected DCs exhibited >90% viability between 6-12 hpi, and remained 
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~75% viable at 24 hpi (Figure 3).  However, by 48 hpi only 26% of the DCs remained viable 
compared to 66% of the uninfected DCs.  This loss in viability was associated with increased 
expression of annexin-V by VRP-infected DCs (data not shown), suggesting that VRP-
induced apoptosis was likely responsible for the death of human DCs.  In summary, the 
viability of VRP-transduced DCs remained high for 24 hours following infection, but 
steadily decreased between 24-72 hpi.     
 
VRP Infection Induces DC Maturation and Secretion of Proinflammatory Cytokines 
The studies described above indicated that immature DCs could be easily transduced with 
VRPs.  However, immature DCs are poor stimulators of antigen-specific T cells and have 
been shown to induce tolerance (11, 22).  Thus, we wanted to determine if VRP-infection 
induced maturation of immature DCs by evaluating expression of costimulatory and 
maturation surface markers (Figure 4).  At 12 hpi, the expression of various 
costimulatory/maturation markers in VRP-infected DC cultures was similar to DCs that were 
mock-infected or treated with TNF-α.  In contrast, DCs treated with a strong maturation 
stimulus (100 ng/ml of LPS) had upregulated CD80 and CD86 expression at this time.  By 24 
hpi, however, the expression of CD40, CD80 and CD86 was significantly elevated in VRP-
infected DC cultures when compared to mock-infected or TNF-α-treated DCs.  CD86 
expression in VRP-infected DC cultures at 24 hpi was comparable to that seen with LPS 
treatment, while LPS induced higher levels of CD80 and CD83.  Interestingly, VRP-infection 
induced higher levels of CD40 expression when compared to LPS treatment, a trend that was 
consistent in four different experiments.  We next determined if VRP infection induced 
maturation of both infected and uninfected bystander DCs by analyzing 
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costimulatory/maturation marker expression on GFP-positive and -negative DCs in the 
culture (Table 1).  The expression of costimulatory/maturation molecules was increased on 
both GFP-positive and GFP-negative DCs, although the latter exhibited the highest 
expression levels at 24 hpi.  These observations indicate that VRP infection resulted in 
phenotypic maturation of both infected and uninfected immature DCs within the same 
culture. 
We next evaluated secretion of proinflammatory cytokines by GFP-VRP-infected DC 
cultures (Figure 5).  Because DC cultures generated from adherent PBMCs contained a small 
but significant population of contaminating lymphocytes (15-45%), we generated highly 
purified DCs from monocytes that had been isolated by negative selection using 
immunomagnetic beads.  DC cultures generated by this method were >95% CD11c+, and 
were similar to adherent monocyte-derived DCs in both surface marker phenotype and 
susceptibility to VRP infection (data not shown).  These DCs were mock- or VRP-infected 
and supernatants were collected and assayed for proinflammatory cytokines at various time 
points post-infection.  In contrast to mock-infected DCs, VRP-infected immature DCs 
secreted significant amounts of TNF-α, IL-6 and IFN-α at 24 to 48 hours following infection.  
Low but statistically significant levels of IL-12p70 were detected at later time points (36-48 
hpi).  IL-10 was also barely detectable in the supernatants from VRP-infected DCs, but the 
levels were not significantly higher than in mock-infected DC supernatants.  By comparison, 
DCs that had been matured by either 24 hours with LPS or 48 hours with TNF-α did not 
secrete significant amounts of TNF-α, IL-6 and IFN-α.  LPS- and TNF-α-matured DCs 
secreted IL-8 (Figure 5) and displayed increased costimulatory molecule expression (Figure 
4), demonstrating that these cells had been activated.  Additionally, incubating mature DCs 
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with an MHC class I-restricted peptide (FMP peptide 58-66) did not affect cytokine secretion 
(data not shown).  In summary, VRP infection of immature human DCs induced maturation 
and proinflammatory cytokine secretion. 
 
VRP-Infected Human DCs Can Stimulate Allogeneic and Antigen-Specific T Cells 
To initially evaluate the functionality of VRP-infected DC cultures, we performed a 
standard allospecific T cell stimulation assay.  DCs infected with GFP-VRP stimulated 
substantial proliferation of allogeneic T cells, indicating that VRP infection did not have a 
detrimental effect on DC function (data not shown).  More importantly, we determined if 
VRP-transduced DCs could stimulate expansion of autologous T cells specific for a VRP-
encoded antigen.  For this set of experiments, we utilized recombinant VRPs expressing 
FMP.  When autologous PBMCs were stimulated with an irrelevant VRP expressing GFP, 
there was no significant increase in the percentage of FMP-specific CD8+ T cells (Figures 
6A-B).  However, stimulation of PBMCs with FMP-VRP-transduced DCs led to a significant 
increase in the percentage of FMP-specific CD8+ T cells (Figures 6A-B).  VRP-transduced 
DCs were highly efficient at expanding FMP-specific CD8+ T cells at even low DC numbers 
(Figure 6C).  Furthermore, the expanded FMP-specific CD8+ T cells were functional as they 
could lyse T2 cells pulsed with the FMP peptide (Figure 6D).  When we compared FMP-
VRP-transduced DCs to TNF-α-matured DCs pulsed with FMP peptide, we found that FMP-
VRPs were significantly more effective at inducing expansion of FMP-specific CD8+ T cells 
compared to FMP-pulsed DCs (Figures 6A-B).  However, peptide-pulsed DCs matured with 
a more potent stimulus (100 ng/ml of LPS) induced comparable expansion of FMP-specific 
CD8+ T cells when compared to FMP-VRP-infected DCs (42% and 38% tetramer-positive 
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cells, respectively, responder:stimulator ratio = 10:1).  VRP-infected DC can thus process 
and present vector-encoded antigens to reactive T cells, resulting in significant T cell 
expansion and acquisition of effector function.
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Discussion 
Consistent generation of tumor-specific T cell responses in patients treated with DC-based 
vaccines has remained elusive.  The shortcomings of current vaccines are due in part to 
inefficient antigen loading of DC, as well as unsatisfactory induction of DC maturation and 
proinflammatory cytokine secretion (35).  To address these issues, we evaluated the utility of 
vectors derived from VEE.  We have demonstrated that VRPs can efficiently transduce 
human immature DCs in vitro, leading to DC maturation and secretion of proinflammatory 
cytokines.  Furthermore, transduced DCs processed and presented a VRP-encoded antigen 
and stimulated significantly greater expansion of antigen-specific T cells in comparison to 
peptide-pulsed DCs matured with TNF-α. 
Several vectors have been used for transducing human DCs with TAAs (5, 14-16).  
However, the potential clinical use of these vectors is hindered by poor transduction 
efficiencies, inhibition of DC maturation, questionable safety, and induction of detrimental 
anti-vector immune responses.  The use of VRPs for DC transduction successfully addresses 
many of these concerns.  We have shown that VRP transduction efficiency is appreciable at 
an MOI of 20; efficiency can be further enhanced at higher MOIs.  VRPs have an 
outstanding safety record in thousands of animal experiments including both rodents and 
primates (9, 45).  Because VEE is only endemic to specific subtropical regions, pre-existing 
immunity to VRPs is unlikely to be present in the majority of patients.  Finally, our group 
and others have shown that VRPs can induce cell-mediated and humoral immune responses 
(6, 53).  Recent work suggests that induction of both a humoral and cellular anti-tumor 
response may increase the effectiveness of tumor vaccines (40). 
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One concern from our data was the cytopathic effect of VRPs on human DCs.  After 
terminal maturation, DCs remain viable in vitro for approximately 96 hours (54).  However, 
we found that VRP-infected DCs began to lose viability within 48 hours following infection.  
The shortened life-span of VRP-transduced DCs could limit their effectiveness in tumor 
immunotherapy.  However, studies have shown that DCs injected intradermally migrate 
rapidly (within 12-24 hours) to draining lymph nodes (37).  Additionally, several groups 
have found that DC-T cell interactions in vivo occur during the first 24 hours following 
immunization (24, 36).  As shown, the majority of VRP-infected DCs are viable during the 
first 24 hours following infection, which should allow sufficient time for infected DCs to 
migrate to regional lymph nodes and interact with T cells.  Furthermore, the induction of 
apoptosis in transduced DCs may actually be advantageous since cross-presentation of 
antigen from apoptotic DCs can effectively induce antigen-specific CD8+ T cells (30, 38, 46).  
Indeed, apoptosis was necessary for the enhanced efficacy of alphaviral replicase-based DNA 
vaccines in an in vivo tumor challenge model (30).  Our group has preliminary evidence that 
VRP-infected DCs can generate protective immunity in a tolerant breast cancer animal model 
(Moran et al, unpublished observations).  Thus, we do not believe that the shortened life-span 
of VRP-infected DCs should provide a significant impediment to their use in vivo.   
VRP infection not only resulted in production of TAAs within the cytoplasm of human 
DCs, but also induced maturation of DCs and proinflammatory cytokine secretion.  VRP 
infection resulted in up-regulation of the costimulatory molecules CD40, CD80 and CD86, 
and the maturation marker CD83.  This is consistent with previous observations that 
replicons derived from Sindbis virus, a related alphavirus, induced maturation of human DCs 
(21).  Interestingly, costimulatory/maturation marker expression was induced on both 
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infected and uninfected DCs within the same cultures.  VRP-induced maturation of bystander 
DCs is potentially advantageous, as this could enhance cross-presentation of antigen from 
infected DCs undergoing apoptosis.  In addition to phenotypic maturation, VRP infection 
resulted in secretion of proinflammatory cytokines including IFN-α, TNF-α, IL-6 and IL-
12p70.  IFN-α, TNF-α and IL-6 are important for activation of APCs, and are likely 
responsible for maturation of uninfected bystander DCs (26, 32).  IFN-α also enhances the 
efficiency of cross-presentation of antigen by DCs (29), a mechanism that is important for in 
vivo priming of tumor-specific CD8+ CTL (50).  Furthermore, recent studies suggest that IL-
6 secretion by DCs is important for inhibiting Treg activity (17, 44).  In contrast to VRP-
infected DCs, DCs that had been terminally matured with TNF-α or LPS did not secrete 
significant levels of IFN-α, TNF-α, IL-6 or IL-12p70.  This observation is in line with other 
publications describing the inability of fully matured DCs to secrete several proinflammatory 
cytokines (27, 52).  In summary, VRPs represent a novel strategy to deliver TAAs and a 
strong maturation signal simultaneously to human DCs. 
In the current study, we have shown that VRP-infected DCs could efficiently stimulate 
antigen-specific T cell responses against a VRP-encoded antigen.   Furthermore, VRP-
infected DCs were more efficient at expanding antigen specific CD8+ T cells when compared 
to TNF-α-matured DCs pulsed with an MHC class I-restricted peptide.  Increased 
costimulatory molecule expression and secretion of proinflammatory cytokines are likely 
responsible for the enhanced immunostimulatory capacity of VRP-infected DCs.  It is also 
possible that VRP-transduced DCs are presenting MHC class II-restricted epitopes to CD4+ T 
helper cells in the PBMC cultures, which would augment activation and expansion of CTL 
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(4).  The ability of VRP-transduced DCs to stimulate CD4+ T cells is under current 
investigation.    
In conclusion, we have found that immature DCs can be readily transduced with VRPs 
and these DCs can induce potent antigen-specific T cell expansion.  Our group is currently 
pursuing this strategy for vaccination of patients with cancer.   
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Table 2-1 
 
  VRP-Infected DC Cultures 
 
Mock-Infected 
DC Cultures 
GFP-positive 
DCs GFP-negative DCs
CD40 4.0 (2.6 – 12.8) 6.0 (2.6 – 14.4)a 12.4 (4.2 – 26.1)b
CD80 4.1 (2.9 – 8.8) 6.4 (3.0 – 14.9)a 10.9 (4.2 – 18.2)b
CD83 3.6 (1.7 – 9.3) 5.8 (3.5 – 7.7)a 7.6 (3.6 – 12.5)b
CD86 268.5 (64.0 – 
605.0) 
355.5 (63.7 – 
554.0) 
556.5 (83.5 – 
823.0)b
 
  
Median fluorescence intensity (MFI) of costimulatory/maturation markers following 
VRP infection of DCs.  DC cultures were mock-infected or infected with GFP-VRP (MOI = 
10-20) and evaluated 24 hours later for the expression of costimulatory/maturation markers 
with PE-conjugated antibodies.  Numbers represent the median PE fluorescence from eight 
donors (minimum – maximum).  In VRP-infected cultures, the MFI for infected and 
uninfected DCs was determined by gating on GFP-positive and GFP-negative DCs, 
respectively. ap < 0.05 compared to mock-infected DCs (Wilcoxon sign rank test); bp < 0.01 
compared to mockin-infected DCs. 
 111
Figure 2-1 
C
D
11
c
H
LA
-D
R
C
D
14
A. B.
GFP
0 6 12 18 24
0
10
20
30 Immature DC
LPS-DC
Hours Post-Infection (hpi)
%
G
FP
+
C.
 
 112
Figure 2-1:  VRPs can efficiently transduce immature human DCs.  A)  Human immature 
monocyte-derived DCs were infected with GFP-VRPs for 1 hour (MOI = 10).  Cells were 
analyzed for GFP expression at 12 hpi by fluorescent microscopy.  The white arrow indicates 
possible apoptosis of infected DCs.  B)  Infectivity of immature or LPS-matured DCs (n = 3 
donors) was quantified by FACS.  DCs were infected for 1 hour (MOI = 10) and GFP 
expression was evaluated at 6-24 hpi as indicated.  Symbols represent mean percentage of 
GFP-positive DCs +/- standard error of the mean (SEM).  C)  DCs were infected with GFP-
VRP as described above, harvested at 24 hpi, stained with PE-conjugated antibodies specific 
for CD11c, HLA-DR or CD14, and analyzed by two-color FACS. 
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Figure 2-2:  VRP infection of immature DCs is dependent upon the MOI, length of 
infection and cell density during infection.  A) Immature DCs (n = 3 donors) were infected 
for 1 hour with GFP-VRPs at increasing MOIs.  The percentage of GFP-positive cells was 
determined at 12 hpi by FACS.  B) Immature DCs (n = 3 donors) were infected with GFP-
VRPs (MOI = 20) for 1 hour at 0.5 x 106 DC/ml, or for 2 hours at 1 x 106 DC/ml.  The 
percentage of GFP-positive cells was determined at 12 hpi by FACS.  Graphs represent the 
mean percentage of GFP-positive cells +/- SEM.  *p = 0.002, Student's t test   
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Figure 2-3:  VRP-infected DCs remain predominantly viable during the first 24 hours 
following infection.  Immature DCs were infected for 2 hours with GFP-VRP (MOI =  20).  
At various times post-infection, viability of infected (GFP-positive) DCs and uninfected 
(GFP-negative) DCs was determined as described in Materials and Methods.  Graphs 
represent the mean percentage of viable cells from two experiments. 
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Figure 2-4:  VRP infection induces maturation of immature DCs.  Immature DCs were 
either mock-infected (gray histogram), infected for 2 hours with GFP-VRPs at an MOI of 20 
(heavy line), treated with TNF-α at 20 ng/ml (thin line), or treated with LPS at 100 ng/ml 
(dashed line).  DCs were harvested at 12 or 24 hpi and stained with the indicated PE-
conjugated specific antibodies.  Staining with isotype control antibodies was negative.  The 
numbers indicate the median PE fluorescence intensity.  The median 
costimulatory/maturation marker expression in VRP-infected DC cultures includes both 
GFP-positive and -negative cells.  Data is representative of four experiments.   
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Figure 2-5:  VRP-infected DCs, but not fully matured DCs, secrete high levels of 
proinflammatory cytokines.  Supernatants from immature DCs that were either mock-
infected (Mock-DC) or GFP-VRP-infected at an MOI of 20 (VRP-DC) were harvested and 
analyzed for specific cytokines by CBA (TNF-α, IL-6, IL-12p70 or IL-8) or ELISA (IFN-α).  
Supernatants from DCs that had been previously matured by 24 hours of LPS treatment 
(LPS-DC) or 48 hours of TNF-α treatment (TNF-DC) were also analyzed.  The mean 
cytokine concentration +/- SEM from three donors is shown.  Data is representative of two 
experiments.  *p < 0.05 (Student’s t test) when compared to Mock-DC, TNF-DC or LPS-DC.   
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Figure 2-6:  VRP-transduced DCs stimulate greater expansion of antigen-specific CD8+ 
CTL compared to TNF-α-matured DCs pulsed with peptide.   Immature DCs were 
transduced with either FMP-VRPs or irrelevant GFP-VRPs for 2 hours (MOI = 20).  DCs 
were washed and cocultured with autologous nonadherent PBMCs at various 
responder:stimulator ratios in the presence of IL-2 and IL-7 for 7 days.  A) Expansion of 
FMP-specific CD8+ T cells was determined by tetramer analysis.  Baseline indicates the 
percentage of FMP-specific T cells before stimulation.  The stimulatory capacity of VRP-
infected DCs was compared to TNF-α-matured DCs (TNF-DC) that had been pulsed with 
FMP peptide (10 µg/ml) for 2 hours or left untreated (responder:stimulator ratio = 20:1).  
Numbers represent the percentage of FMP-specific cells of total CD8+ T cells.  B)  Mean 
percent of FMP-specific CD8+ T cells on day 7 of stimulation from three experiments.  *p < 
0.05 (Student’s t test).  C)  Percent of FMP-specific CD8+ T cells on day 7 of stimulation at 
various responder:stimulator ratios.  One of two similar experiments is shown.  D) PBMCs 
that had been stimulated with FMP-VRP-infected DCs for 7 days were assayed for effector 
function in a standard 51Cr-release assay.  Labeled FMP peptide-pulsed (open circles) or 
unpulsed T2 cells (solid triangles) were incubated with effector cells for 4 hours and specific 
lysis was calculated as described in Materials and Methods.  Lysis of the NK-sensitive cell 
line K562 was similar to that found using unpulsed T2 cells indicating that the enhanced lytic 
activity using FMP-pulsed T2 cells was not due to NK-mediated lysis.  The graphs represent 
the mean of triplicate wells +/- SEM.  One of two similar experiments is shown. 
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CHAPTER THREE 
 
VIRAL ACTIVATION OF DENDRITIC CELLS IS INSUFFICIENT FOR 
BREAKING TOLERANCE
Abstract 
The inability of current dendritic cell (DC) vaccines to generate cytokines critical for T 
cell polarization and Treg suppression may be responsible for their limited clinical efficacy.  
Previously, we have shown that human DCs transduced with Venezuelan equine encephalitis 
virus replicon particles (VRPs) produced significant levels of proinflammatory cytokines and 
were potent stimulators of T cells.  In the current study, we have evaluated whether VRP-
transduced DCs (VRP-DCs) could overcome tolerance against the neu oncoprotein and 
induce therapeutic tumor immunity in vivo.  VRP-DCs expressing a truncated neu 
oncoprotein induced robust T cell and antibody responses in wild-type mice.  Moreover, a 
single vaccination with VRP-DCs induced regression of established neu-expressing tumors.  
However, VRP-DCs were unable to inhibit growth of the same tumor cell line in mice 
tolerant to neu, despite an accumulation of IFN-γ-producing T cells at the tumor site.  
Vaccine efficacy in tolerant mice was enhanced by depletion of CD4+CD25+ regulatory T 
cells (Treg), demonstrating that virally-activated DCs alone were incapable of overcoming 
Treg-mediated suppression.  Finally, provision of neu-specific T cells from wild-type mice did 
not improve the efficacy of VRP-DC vaccines in tolerant animals, indicating that tolerance 
was not entirely due to the absence of a high-avidity T cell repertoire.  These results 
demonstrate that while highly immunogenic, virally-activated DCs cannot break tolerance 
against self/tumor antigens.  Furthermore, our findings suggest that the ability to reject 
tumors is more dependent upon dominant immunoregulatory mechanisms within the host 
than tumor-specific inhibitory factors.
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Introduction 
Metastatic breast cancer remains a leading cause of cancer morbidity and mortality among 
women (41).  Vaccination is an attractive approach for treating metastatic breast cancer, as 
this strategy can be used not only to eliminate malignant cells but also to prevent recurrent 
disease through establishment of immunological memory (15).  A frequent target for breast 
cancer vaccines is HER-2/neu (c-erbB-2), a member of the epidermal growth factor receptor 
family that is overexpressed in 15-30% of breast cancers (4).  Amplification of the neu 
oncogene in breast cancer patients is associated with metastasis and a poor clinical prognosis 
(40).  Humoral and cell-mediated immunity against HER-2/neu have been detected in breast 
cancer patients, suggesting that tolerance against the protein may be incomplete (13).  
Therefore, several clinical studies aimed at inducing neu-specific immunity through 
vaccination with either peptides or dendritic cells (DCs) have been performed (6, 12, 22, 24, 
31, 49).  Although HER-2/neu vaccines have been safe and well tolerated, they have rarely 
yielded objective clinical responses. 
The inability of cancer vaccines to induce therapeutic responses in patients with 
macroscopic tumors is likely due to several factors.  First, tumors can secrete 
immunosuppressive cytokines or express inhibitory molecules, thus making the tumor 
environment hostile for tumor-specific T cells (1).   Second, because tumor-specific T cells 
recognize self proteins, most that evade negative selection in the thymus are of low avidity 
for their cognate antigen and are thus compromised in their ability to attack tumor cells (11, 
26, 27).  Third, tumors have been shown to recruit leukocytes with immunoregulatory 
activity, which can directly inhibit tumor-specific T cells (8, 25).  Clearly, the lack of 
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antitumor immune responses following vaccination could be due to a combination of these 
factors and others. 
Because of their role in initiating adaptive immune responses, many researchers have 
focused on utilizing DCs as therapeutic cancer vaccines (3).  DCs loaded with HER-2/neu 
derived peptides have been evaluated in clinical trials (6, 12, 24), and while they have been 
shown to stimulate HER-2/neu-specific CD8+ T cell responses, therapeutic responses have 
been infrequent.  The limited efficacy of peptide-pulsed DC vaccines may be due to the lack 
of the third signal for T cell activation—Toll-like receptor (TLR) activation and 
proinflammatory cytokine production (9, 10, 43).  Viral vectors may provide a superior 
strategy for antigen-loading of DCs, as they can efficiently deliver intact protein to the DC 
cytoplasm, thus providing multiple MHC class I and/or II epitopes (47, 51).  Furthermore, 
viral vectors can induce DC activation and provide the persistent TLR stimulation deemed 
necessary for overcoming the activity of regulatory T cells and breaking tolerance (21, 48).    
 We previously found that Venezuelan equine encephalitis virus replicon particles (VRP) 
could efficiently transduce human immature DCs, resulting in DC maturation and secretion 
of proinflammatory cytokines (30).  Furthermore, VRP-transduced DCs (VRP-DCs) were 
superior to peptide-pulsed DCs at expanding antigen-specific CTLs in vitro, arguing that 
VRP-DCs may be an ideal vaccine for breaking tolerance.  To expand upon our in vitro 
findings, we have examined the efficacy of VRP-DCs as therapeutic cancer vaccines in mice 
bearing neu-expressing tumors.  We demonstrate that VRP-DCs are highly immunogenic in 
wild-type FVB/N mice, and can induce regression of established tumors.  In contrast, 
therapeutic vaccination with VRP-DCs alone was unable to inhibit tumor growth in neu 
transgenic (neu-N) mice, which exhibit a profound tolerance against neu (35).  Depletion of 
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Treg with cyclophosphamide (CY) enhanced the effectiveness of VRP-DC vaccines, 
demonstrating that VRP-DCs could not independently circumvent Treg-mediated suppression.  
Adoptive transfer of T cells from FVB/N mice into neu-N mice did not improve vaccine 
efficacy, indicating that the inadequacy of VRP-DC vaccination was not purely due to a lack 
of high-avidity T cells.  Taken together, these results suggest that viral activation of DCs is 
insufficient to overcome immune regulation and break tolerance to a self protein, even in the 
presence of high-avidity T cells.  Additionally, our data support a model in which tumor 
immunity is not directly inhibited by the tumor itself, but rather by dominant suppressive 
mechanisms present in the host. 
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Materials and Methods 
Mice 
FVB/N mice (age 6-7 weeks) were purchased from Jackson Laboratories.  Homozygous 
neu-N transgenic on the FVB/N background (19) were purchased from Jackson Laboratories 
and maintained in our animal breeding facility.  All mice used were 6-12 weeks of age. 
 
Cell lines and peptides 
NIH-3T3 (American Type Culture Collection), 3T3neu and NT2 cells have been 
previously described (35).  RNEU420-429 (PDSLRDLSVF) and NP118-126 (RPQASGVYM) 
peptides were purchased from New England Peptide (Gardner, MA) at >95% purity.  
RNEU420-429 is the immunodominant H2-Dq-restricted epitope from rat neu (17), while NP118-
126 peptide is an H2-Dq-restricted epitope from the LCMV nucleoprotein and served as an 
irrelevant peptide control. 
 
VEE replicon particles (VRP) 
VRP encoding GFP (GFP-VRP) or VRP lacking a functional transgene (null-VRP) have 
been previously described (42).  VRP encoding the extracellular-transmembrane domains 
(amino acids 1-697) of rat neu (neuET-VRP) were generated by cloning the neuET cDNA 
into the pVR21 replicon plasmid as previously described (30).  VRP titer was determined by 
infection of baby hamster kidney (BHK) cells as previously described (30).  All VRPs were 
packaged in the wild type (V3000) viral envelope. 
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Generation of VRP-DC vaccines 
DCs were derived from bone marrow as previously described (33).  Briefly, bone marrow 
from female FVB/N or neu-N mice was harvested by flushing femurs and tibias with 
complete R-10 media.  Following treatment with ACK lysis buffer, bone marrow progenitor 
cells were plated at 1 x 106 cells per well in 6-well ultra low attachment plates (Costar, 
Corning, NJ) in 1.5ml of R-10 supplemented with 20 ng/ml murine GM-CSF (Peprotech, 
Rocky Hill, NJ).  On day 3, 1.5 ml of R-10 was added along with GM-CSF and murine IL-4 
(Peprotech) to a final concentration of 10 ng/ml for each cytokine.  On day 5, 3 ml of R-10 
was added along with GM-CSF and IL-4 to a final concentration of 5 ng/ml of each cytokine. 
On day 7, immature DCs were harvested and cryopreserved in 90% FBS/10% DMSO at a 
concentration of 5 x 106 cells per ml.  DCs were stored in liquid nitrogen and used within 3 
months of cryopreservation. 
To generate VRP-transduced DC (VRP-DC) vaccines, cryopreserved DCs were quickly 
thawed at 37ºC and washed twice with R-10.  DCs were plated in 6-well ultra low attachment 
plates at 106 cells/ml in R-10 supplemented with 5 ng/ml GM-CSF and 5 ng/ml IL-4, and 
cultured overnight at 37ºC/5% CO2.  The next morning, DCs were harvested, washed and 
diluted in RPMI-1H infection media (RPMI-1640, 1% FBS, 10mM HEPES) to 106 cells/ml.  
DCs were plated at 106 cells/well in 6-well ultra low attachment plates and infected with 
VRP at a multiplicity of infection (MOI) of 10 for 2 hours at 37ºC/5%CO2 as previously 
described (30).  Infected DCs were washed three times and suspended in 0.9% sterile saline.  
Prior to vaccination, female FVB/N or neu-N mice were anesthetized by i.p. injection of 1.3 
mg ketamine HCl / 0.38 mg xylazine.  VRP-DC (106) were injected s.c. in the mammary fat 
pad. 
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 Antibodies and flow cytometric analysis 
Anti-CD8-FITC (53.6.7), anti-CD25-FITC (PC61), anti-CD40-PE (1C10), anti-CD62L-
APC (MEL-14), anti-MHC class I-PE (28-14-8), anti-MHC class II-PE (M5/114.15.2), anti-
IFN-γ-PE (XMG1.2), and anti-FoxP3-PE (FJK-16s) monoclonal antibodies were purchased 
from eBioscience (San Diego, CA).  Anti-CD4-PerCP (RM4-5), anti-CD80-PE (16-10A1), 
anti-CD86-PE (GL1), and anti-IL-10-PE (JES5-16E3) monoclonal antibodies were 
purchased from BD Pharmingen (San Diego, CA).  Anti-c-ErbB2/neu (Ab4) monoclonal 
antibody was purchased from Calbiochem (San Diego, CA).  PE-conjugated H-
2Dq/RNEU420-429 tetramers were synthesized by the NIH Tetramer Facility (Emory 
University, Atlanta, GA).  For phenotypic analysis of DCs, cells were washed with FACS 
buffer (PBS/2% FBS), stained with the indicated antibodies for 30 min at 4ºC, and fixed with 
1% formaldehyde prior to analysis.  For tetramer staining of lymphocytes, cells were 
incubated with PE-conjugated H-2Dq/RNEU420-429 tetramers (1:200) for 1 hour at room 
temperature; anti-CD8, anti-CD3 and anti-CD62L antibodies were added during the last 15 
min of incubation.  Cells were then washed and suspended in 0.5% formaldehyde prior to 
analysis.  Analysis of intracellular FoxP3 expression was performed according to the 
manufacturer’s instructions.  FACS data were acquired using a FACSCalibur flow cytometer 
(BD Biosciences), and analyzed using FlowJo software (TreeStar, Ashland, OR). 
 
Cytokine secretion assays 
Murine DCs were infected with GFP-VRP as described.  Two hours post infection, the 
DCs were washed and plated into 96-well tissue-culture plates at 105 cells/well in a total 
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volume of 200 µl of R-10 supplemented with GM-CSF (5 ng/ml) and IL-4 (5 ng/ml).  
Supernatants were harvested at 6, 12, 24 and 48 hours post-infection.  Analysis of IL-6, TNF-
α and IL-10 was performed using the Murine Inflammation Cytometric Bead Array (CBA) 
kit (BD Pharmingen) according to the manufacturer’s instructions.  Analysis of IL-12p70 
was performed using the BD OptEIA™ Mouse IL-12p70 ELISA Set (BD Pharmingen) 
according to the manufacturer’s instructions.  Analysis of IFNα/β was determined by a type I 
interferon (IFN) bioassay as previously described (45). 
 
Detection of neu-specific CD8+ T cells 
Female FVB/N or neu-N mice were vaccinated with 106 VRP-DC as described.  Mice 
were boosted with VRP-DC two weeks later.  At one week post-boost, spleens were 
harvested and dissociated into single-cell suspensions.  After treatment with ACK lysis 
buffer, splenocytes were suspended in R-10 (2 x 106 cells/ml) and stimulated with 5 µg/ml of 
either RNEU420-429 or irrelevant NP118-126 peptide for 12 h at 37ºC/5% CO2 in the presence of 
3 µg/ml brefeldin A (eBioscience).  The cells were then stained for surface expression of 
CD8, CD3 and CD62L, fixed and permeabilized, and stained for intracellular IFN-γ.  
Enumeration of neu-specific CD3+CD8+ T cells was determined by subtracting the 
percentage of IFN-γ+ cells in samples treated with irrelevant NP118-126 peptide from the 
percentage of IFN-γ+ cells in samples treated with RNEU420-429 peptide. 
 
Detection of serum anti-neu IgG 
3T3 or 3T3neu cells were harvested with trypsin and blocked with 20 µg/ml goat IgG 
(Sigma) for 15 min at 4ºC.  The cells were stained with two-fold dilutions of serum from 
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vaccinated FVB/N or neu-N mice for 1 hour at 4ºC.  Cells were washed twice with FACS 
buffer and stained with goat anti-mouse IgG-FITC (Sigma) at a 1:200 dilution for 30 min at 
4ºC.  Cells were subsequently washed twice, suspended in 1% formaldehyde and transferred 
to 96-well V-bottom plates.  The median FITC fluorescence intensity (MFI) was measured 
using a Guava EasyCyte cell analysis system (Guava Technologies, Hayward, CA).  Specific 
staining of neu was determined by subtracting the MFI of 3T3 cells from the MFI of 3T3neu 
cells.  The concentration of neu-specific IgG in sera was calculated using a standard curve 
generated with Ab4 monoclonal antibody. 
 
Therapeutic vaccination with VRP-DC 
For each tumor challenge experiment, a fresh vial from the same lot of cryopreserved NT2 
tumor cells was thawed and passaged in vitro for 5-10 days.  NT2 cells were harvested with 
trypsin, washed twice with HBSS, and suspended to an appropriate concentration in HBSS.  
FVB/N or neu-N mice were challenged with 2 x 106 or 5 x 104 NT2 cells, respectively, in the 
mammary fat pad.  FVB/N or neu-N mice were vaccinated 7 or 3 days post-tumor challenge, 
respectively, with VRP-DC as described above.  In some experiments, mice were boosted 
every 14 days for a total of three vaccinations.  Tumor growth was monitored 2-3 times 
weekly by measuring the major and minor axes with metric calipers.   
In Treg-depletion experiments, neu-N mice received i.p. injections of CY (100 mg/kg) two 
days after tumor challenge.  Mice were vaccinated two days later with VRP-DCs as 
described.  For adoptive transfer experiments, CD25-depleted splenic T cells (>95% purity) 
were isolated from FVB/N mice as previously described (46).  Two days following CY 
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treatment, neu-N mice received i.v. injections of 1-2 x 107 CD25-depleted T cells.  Mice 
were then vaccinated the next day with VRP-DCs. 
 
In vivo depletion of lymphocytes 
CD4+ or CD8+ T cells were depleted by i.p. injection of 0.5 mg of GK1.5 or 53.6.72 (Bio 
Express, West Lebanon, NH), respectively.  Control mice received i.p. injections of 0.5 mg 
rat IgG (Sigma).  Injections were given on days -6, -4 and -2 prior to tumor challenge, and 
depletions were maintained by antibody injections every 4-5 days thereafter.  Depletion of 
specific T cell populations was verified by FACS analysis of splenocytes from select mice 
(data not shown). 
 
Isolation of tumor-infiltrating lymphocytes (TILs) 
Tumors from vaccinated mice were excised, disrupted with a razor blade, and incubated 
under constant agitation for 1 h with collagenase A (2.5 mg/ml), DNase I (17 µg/ml) and 
glass beads at 37ºC.  Undigested material was removed using a 100 µm nylon cell strainer.  
The single cell suspension was washed, suspended in 44% Percoll (Sigma), layered on a 
Lympholyte-M density gradient (Cedarlane Laboratories, Hornby, ON, Canada), and 
centrifuged for 30 min at 2500 rpm, 25ºC.  TILs banding at the Percoll-Lympholyte interface 
were removed and washed.  For intracellular cytokine staining, TILs were stimulated for 4 h 
with PMA (5 ng/ml) and ionomycin (500 ng/ml).  TILs were stained for surface expression 
of CD4 and CD8, fixed and permeabilized, and stained for intracellular expression of IFN-γ 
or IL-10.  For evaluation of CTL activity, CD8+ TILs were isolated using anti-CD8 magnetic 
beads (Miltenyi Biotec, Auburn, CA) according to the manufacturer’s instructions.  The 
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CD8+ TILs were then used as effectors in a standard 51Cr-release assay as previously 
described (39). 
 
Statistical analysis 
Statistical differences for costimulatory molecule expression, cytokine expression, T cell 
and antibody responses and cellular tumor infiltrates were calculated by a two-tailed 
Student’s t test.  Differences in tumor delay and survival were determined by Kaplan-Meier 
survival analysis.  All statistical analyses were performed with GraphPad Prism® 3.0 
software.  For all analyses, a P value ≤ 0.05 was considered significant. 
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Results 
Characterization of VRP-DC vaccines 
We initially investigated the ability of VRPs to transduce murine bone marrow-derived 
DCs in vitro.  Preliminary studies using GFP-VRP demonstrated that transgene expression in 
VRP-transduced murine DCs exhibited similar kinetics as in VRP-transduced human 
monocyte-derived DCs, with expression peaking at 6-12 hours post-infection (data not 
shown).  Interestingly, the transduction efficiency for murine DCs was enhanced in 
comparison to human DCs.  40-60% of murine DCs were transduced at an MOI of 10, 
whereas only 35-40% of human DCs could be transduced at an MOI of 20 (30).  We also 
determined if murine DCs could be efficiently transduced with a VRP encoding the tumor 
antigen neuET.  At 12 hours post-infection, 59% of murine DC expressed high levels neuET 
as determined by staining for surface and intracellular expression of the antigen (Figure 1A). 
We next characterized the phenotype of murine DCs following VRP transduction.  VRP-
DCs exhibited increased expression of the costimulatory molecules CD40, CD80 and CD86 
in comparison to mock-infected DCs (Figure 1B).  VRP-induced expression of CD40 and 
CD86 was comparable to treatment with 100 ng/ml LPS, whereas induction of CD86 by 
VRPs was slightly less than that seen with LPS.  We also evaluated cytokine secretion by 
DCs following VRP infection (Figure 1C).  At 24 hours post infection, VRP-transduced and 
LPS-treated DCs secreted comparable levels of TNF-α, whereas LPS-treated DCs secreted 
significantly more IL-6 over a 48 hour period.  Neither LPS-treated nor VRP-infected DCs 
secreted appreciable levels of IL-10.  Surprisingly, VRP infection of murine DCs did not 
induce significant IL-12p70 secretion, which is in contrast to our previous studies with 
human DCs (30).  However, VRP infection was a potent inducer of type I IFN, as VRP-
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transduced DCs secreted nearly 1000-fold more IFN-α/β than LPS-treated DCs.  DCs treated 
with VRP that had been inactivated with ultraviolet light were similar to mock-infected DCs 
in terms of phenotype and cytokine secretion (data not shown), indicating that the effects of 
VRP infection were not due to a contaminant in the VRP preparation.  Overall, VRP 
infection of murine DCs resulted in high-level transgene expression, phenotypic maturation, 
and secretion of several proinflammatory cytokines, which are all important characteristics of 
a potent DC vaccine. 
 
VRP-DC vaccines induce neu-specific immunity in FVB/N mice 
 To validate the immunogenicity of VRP-DC vaccines in vivo, we immunized FVB/N 
mice with DCs transduced with neuET-VRP (neuET-DCs).  At seven days post-boost, 
spleens were harvested and evaluated for neu-specific CD8+ T cells by intracellular IFN-γ 
staining.  Mice vaccinated with neuET-DCs had a significant population of CD8+CD62L- 
cells specific for the immunodominant peptide RNEU420-429 (Figure 2A-B).  The lack of 
reactivity against the irrelevant peptide NP118-126 confirmed the specificity of the CD8+ T 
cells for neu.  CD8+ T cells specific for RNEU420-429 were absent in untreated mice (data not 
shown) and mice vaccinated with DCs transduced with null-VRP (null-DCs) (Figure 2A-B).   
Because humoral immunity is important for controlling the growth of neu-expressing 
tumors (36), we evaluated the ability of neuET-DC vaccines to induce neu-specific antibody 
responses.  Mice vaccinated with neuET-DCs had significant levels of serum anti-neu IgG, 
whereas anti-neu IgG was undetectable in mice vaccinated with null-DCs (Figure 2C).  Thus, 
VRP-DC vaccines have the capacity to induce both humoral and cell-mediated immunity 
against neu in vivo. 
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 VRP-DC vaccines induce therapeutic immunity against established tumors in FVB/N mice 
While DC vaccines can frequently protect mice from subsequent tumor challenge or 
spontaneous tumor development (7, 38), few studies have evaluated their efficacy after 
therapeutic vaccination of mice with preexisting tumors.  The ability of DC vaccines to 
inhibit the growth of established tumors is arguably more relevant for determining potential 
clinical efficacy, since the majority of cancer patients present with existent disease.  
Therefore, we sought to evaluate the ability of VRP-DC vaccines to inhibit the growth of 
established tumors in FVB/N mice.  Mice were challenged with 2 x 106 NT2 tumor cells and 
then vaccinated with neuET-DCs seven days later when tumor size was approximately 50 
mm2.  A single vaccination with 1 x 106 neuET-DCs resulted in inhibition of tumor growth, 
and induced regression in the majority of treated mice (Figure 3A).  Vaccination with neuET-
DCs significantly prolonged survival of tumor-bearing FVB/N mice when compared to 
vaccination with null-DCs (p = 0.0045).   
Because effective tumor immunity has been associated with increased lymphocytic 
infiltration of tumors (14), we characterized the TILs isolated from the tumor site (Figure 
3B).  Mice vaccinated with neuET-DCs had an increased percentage of RNEU420-429-specific 
CD8+ T cells as determined by tetramer staining in comparison to mice receiving null-DCs.  
Mice vaccinated with neuET-DCs also had an increase in the percentage of IFN-γ+ CD8+ and 
CD4+ T cells at the tumor site, indicating a possible mechanism for tumor clearance. 
To more specifically evaluate the role of T cells in mediating inhibition of tumor growth, 
we depleted mice of either CD4+ or CD8+ T cells prior to vaccination (Figure 3C).  We found 
that CD4+ T cells were crucial for effective tumor immunity, as all CD4-depleted mice 
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experienced rapid tumor growth and had to be euthanized within four weeks of tumor-
challenge (Figure 3C).  Interestingly, tumor immunity was only partially dependent upon 
CD8+ T cells, as 62.5% of CD8-depleted mice survived to day 60 post-tumor challenge (p = 
0.0002 v. rat IgG-treated mice).  Because CD4+ T cells are important for the development of 
antibodies against neu, we analyzed serum anti-neu IgG responses in mice depleted of either 
CD4+ or CD8+ T cells (Figure 3D).  CD4-depleted mice had no detectable serum anti-neu 
IgG, indicating that CD4 help was critical for the development of neu-specific humoral 
immunity.  Interestingly, CD8-depleted mice had a modest but significant decrease in serum 
anti-neu IgG levels (p = 0.042).  Taken together, the presence of tumor-specific CD8+ T cells 
does not appear to be an absolute requirement in our vaccination model, whereas CD4+ T 
cells are essential for inhibition of tumor growth. 
 
VRP-DC vaccines fail to induce therapeutic immunity against neu in tolerant neu-N mice 
The previously described experiments demonstrated that a single vaccination with VRP-
DCs induced therapeutic tumor immunity in nontolerant mice.  We next explored the ability 
of VRP-DC vaccines to induce neu-specific immunity under conditions of immunological 
tolerance in neu-N transgenic mice.  In contrast to FVB/N mice, neu-N mice did not develop 
CD8+ T cells specific for RNEU420-429 following vaccination with neuET-DCs (Figure 4A).  
Vaccination with neuET-DCs also did not induce neu-specific CTL as determined by a 
standard 51Cr-release assay using 3T3neu cells as targets, suggesting that CD8+ T cells 
specific for subdominant neu epitopes were not present (data not shown).  Vaccination of 
neu-N mice with neuET-DCs did induce very modest anti-neu IgG responses (Figure 4B), 
which was over 20-fold less than that seen in nontolerant FVB/N mice (Figure 2C). 
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As previous investigators had suggested that the generation of proinflammatory cytokines 
was critical in the immune rejection of tumors, we evaluated the ability of VRP-DC vaccines 
to inhibit the growth of tumors in neu-N mice.  Female neu-N mice were vaccinated with 
neuET-DCs three days following tumor challenge, and were boosted every two weeks for a 
total of three vaccinations.  Tumor growth in neu-N mice vaccinated with neuET-DCs was 
nearly identical to that seen in mice vaccinated with null-DCs or left untreated, indicating 
that VRP-DC vaccines could not induce therapeutic immune responses against neu (Figure 
4C).  Given the poor therapeutic responses in neu-N mice, we investigated if VRP-DCs could 
induce an immune response at the tumor site.  Surprisingly, we found that neu-N mice 
vaccinated with neuET-DCs had a significantly increased percentage of CD8+ TIL producing 
IFN-γ following stimulation with PMA/ionomycin in comparison to untreated mice (p = 
0.0162) or mice vaccinated with null-DCs (p =  0.0197) (Figure 4D).  However, no RNEU420-
429-specific CD8+ T cells were detectable by tetramer staining, indicating that CD8+ TIL 
specific for the immunodominant neu epitope were absent (data not shown).  Furthermore, 
the CD8+ TIL were incapable of specifically lysing 3T3neu cells in a standard 51Cr-release 
assay, demonstrating that the CTLs were functionally impaired (Figure 4E).  Interestingly, 
IFN-γ+CD4+ TIL were elevated in both null-DC- and neuET-DC-vaccinated mice in 
comparison to untreated mice, although the increase was not statistically significant (4D).  
Overall, these results demonstrate that VRP-DC vaccines alone are incapable of overcoming 
tolerance to neu in neu-N transgenic mice, despite the induction of IFN-γ-producing CD8+ T 
cells at the tumor site. 
 
Depletion of CD4+FoxP3+ Treg with CY enhances the efficacy of VRP-DC vaccines 
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The ineffectiveness of VRP-DC vaccines in neu-N mice suggested that DC therapy alone 
was unable to overcome tolerogenic mechanisms.  Previous studies have demonstrated that 
regulatory T cells, including CD4+FoxP3+ T cells (Treg), play an important role in mediating 
tolerance against neu in neu-N mice (16).  Because Treg have been shown to preferentially 
migrate to the tumor site in HER-2/neu+ ovarian cancer patients (8), we investigated whether 
Treg similarly accumulate in NT2 tumors following vaccination.  We found increased 
numbers of CD4+FoxP3+ T cells but not CD4+IL-10+ T cells (Figure 5A) at the tumor site in 
mice vaccinated with neuET-DC, suggesting that Treg may be recruited to suppress immune 
responses within the tumor.   
We next sought to determine if inhibiting Treg function would enhance the efficacy of 
VRP-DC vaccines.  Interestingly, treatment of tumor-bearing neu-N mice with anti-CD25 
monoclonal antibody prior to vaccination did not result in decreased tumor growth 
(Supplemental Figure 1).  However, the use of anti-CD25 antibodies for Treg depletion is 
likely suboptimal, since this approach would also deplete recently activated CD4+ effector T 
cells that are clearly necessary for efficient induction of tumor immunity in our model 
(Figure 3C).  Therefore, we attempted to inhibit Treg activity by treating mice with low-dose 
CY, which preferentially decreases the number and function of Treg (16, 28).  We found that 
tumor-bearing mice treated with CY (100 mg/kg) exhibited a significant decrease in the 
percentage of CD4+FoxP3+ T cells in the tumor-draining lymph node (TDLN) (Figure 6B), 
whereas total numbers of CD4+, CD8+ and CD19+ cells were unaffected (data not shown).  
Tumor-bearing mice were treated with CY and vaccinated with VRP-DCs two days later.  
Mice pretreated with CY and vaccinated with neuET-DCs demonstrated a significant delay in 
formation of palpable tumors in comparison to CY-treated mice vaccinated with null-DCs 
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(Figure 5C, p = 0.036).  However, CY-treatment did not significantly increase overall 
survival of vaccinated mice due to late rapid growth of tumors (p = 0.1375, Figure 5D).  The 
rapid tumor growth was accompanied by a significant rebound of CD4+FoxP3+ T cells in the 
tumor-draining lymph node and at the tumor site of CY-treated mice, indicating that Treg-
depletion with CY was transient (Figure 5E).  A second injection of CY two-weeks after 
vaccination did not improve survival.  We were unable to identify RNEU420-429-specific 
CD8+ T cells in the tumors of CY-treated animals vaccinated with neuET-DCs (data not 
shown).   In summary, depletion of Treg with CY treatment prior to therapeutic VRP-DC 
vaccination significantly inhibits early tumor growth.  However, long-term control of tumor 
growth is not improved, likely due a resurgence of Treg at the tumor site. 
 
Provision of tolerant mice with a neu-specific T cell repertoire does not improve VRP-DC 
vaccination 
Peripheral neu-specific T cells in neu-N mice are generally of low avidity, which could 
significantly inhibit the efficacy of VRP-DC vaccination (27).  In contrast, FVB/N mice 
possess high-avidity neu-specific T cells that can be effectively expanded following 
vaccination (17 and Figure 2A-B).  Therefore, we sought to determine if supplying neu-N 
mice with a naïve T cell repertoire containing high-avidity neu-specific T cells would 
improve the efficacy of VRP-DC vaccines.  Two days following CY treatment, tumor-
bearing neu-N mice were infused with either saline or 1 x 107 CD25-depleted T cells and 
vaccinated with neuET-DCs on the following day.  Tolerant mice receiving adoptively 
transferred T cells exhibited neither a significant delay in tumor formation (p = 0.234) nor 
significantly increased survival (p = 0.358) (Figures 6A-B).  Increasing the T cell dose to 2 x 
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107 did not alter survival, indicating that the lack of vaccine efficacy was not due to 
insufficient numbers of adoptively transferred T cells (data not shown).  These results 
demonstrate that vaccine efficacy cannot be improved by providing tolerant mice with high-
avidity T cells specific for neu, and suggest that in our model, regulatory mechanisms 
dominantly suppress the activity of effector T cells. 
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Discussion 
 The optimal DC vaccine would generate significant quantities of antigen allowing 
expansion of functional antigen-specific T and B cells in concert with the production of 
polarizing proinflammatory cytokines.  Our previous studies with human DCs demonstrated 
that VRP-transduction resulted in DC activation and secretion of immunostimulatory 
cytokines, leading to efficient stimulation of antigen-specific T cells.  Thus, we were 
interested in determining if this platform would break tolerance in neu-N transgenic mice and 
inhibit the growth of existing tumors.   
Here, we demonstrate that VRPs efficiently transduce murine bone marrow-derived DCs, 
resulting in maturation and cytokine production by infected cells.  VRP-DC vaccines were 
highly immunogenic in wild-type FVB/N mice, and were capable of inducing both cellular 
and humoral immunity against neu.  A single vaccination with VRP-DCs expressing neuET 
could induce therapeutic immune responses against established tumors, resulting in tumor 
regression.  However, VRP-DC vaccines were incapable of generating robust CD8+ T cell 
and antibody responses against neu in tolerant neu-N transgenic mice, which was associated 
with an inability to inhibit tumor growth in these mice.  Thus, the same tumor and vaccine 
induced significantly different immune responses in tolerant and nontolerant animals, which 
differ only in the transgenic expression of neu.   
Yang et al. had previously shown that viral infection alone or lentiviral transduced DCs 
given with anti-CD25 mAb could break tolerance to influenza HA in C3H-BALB/c F1 mice 
and that breaking tolerance using DCs without Treg depletion required persistent LPS 
exposure and TLR stimulation (48).  Given these findings and our previous data 
demonstrating significant proinflammatory cytokine induction by DCs following viral 
 144
transduction, we sought to determine if vaccination with VRP-DCs could break tolerance 
against neu.  Despite the generation of proinflammatory cytokines by our virally-transduced 
DCs, we were unable to overcome tolerance in neu-N transgenic mice. VRP-DCs differed 
from LPS-treated DCs in the production of IL-12 and in the quantity of IL-6 generated.  
Thus, it is conceivable that the VRP-DCs could not overcome tolerance due to insufficient 
production IL-6, which is necessary for inhibiting Treg-mediated suppression (34).   
Alternatively, the generation of IL-12 may be critical to overcoming immune regulation, 
although studies have shown that IL-12 production by the DC vaccine itself was not 
necessary for activation of CTLs in vivo (44).  Regardless, our data suggests that type I IFN 
production by DCs vaccines is insufficient to break tolerance, since VRP-transduced DCs 
secreted copious amounts of IFN-α/β.   
Since neu-specific T cells in neu-N mice are of low frequency and avidity (17, 27), we 
reasoned that VRP-DC vaccination was ineffective due to the absence of a high-avidity 
effector T cell repertoire.  If this were true, we would expect to find that the administration of 
naïve splenocytes from nontolerant mice followed by immunization would induce tumor 
regression.  However, the administration of a significant number of CD25-depleted naïve T 
cells from nontolerant mice did not break tolerance in vaccinated mice.  These data suggest 
that tolerance in neu-N mice is an active process that blocks the expansion of naïve T cells.  
Moreover, our data is consistent with tolerance being mediated by dominant 
immunoregulatory mechanisms rather than the absence of a T cell repertoire specific for a 
self/tumor antigen.  While our findings suggest that tolerogenic mechanisms can inhibit the 
priming of naïve high-avidity T cells, the ability to inhibit the effector function of activated 
neu-specific CD8+ T cells is currently unknown.  Treg can effectively suppress the activity of 
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adoptively transferred melanoma-specific CTL that had been previously activated, indicating 
that tolerance may dominate over effector function (2).  Nonetheless, future studies need to 
evaluate the ability of Treg to inhibit neu-specific effector T cells in neu-N mice.   
We investigated potential mechanisms for the active suppression of an immune response 
to neu in neu-N mice.  There are several populations of cells that may mediate immune 
suppression in vivo including thymus-derived CD4+CD25+FoxP3+ Treg (37), peripherally-
induced Tr1 cells (18) and myeloid suppressor cells (5).  Although VRP-DC vaccines alone 
were incapable of inhibiting tumor growth in tolerant mice, their efficacy was enhanced 
when combined with CY treatment.  Low-dose CY can decrease the number and function of 
Treg (16, 28), and can unmask high-avidity T cells specific for neu (16).  As seen in other 
studies, Treg depletion by CY was transient in tumor-bearing mice (28).  Furthermore, the 
immune-modulating effects of CY were most evident when the drug was given prior to 
vaccination, which is consistent with previous reports (29).  Because Treg numbers can 
rebound quickly in tumor-bearing mice, better methods for long-term Treg depletion are 
needed.  The use of anti-CD25 antibodies for durable inhibition of Treg is unlikely to be 
effective, since these antibodies can also abrogate the activity of CD25+ effector T cells (23).  
The use of agonistic antibodies specific for glucocorticoid-induced tumor necrosis factor 
receptor family-related protein (GITR) may be a better strategy for overcoming Treg activity 
during the course of tumor immunotherapy (23).   
 It is interesting that although tumor growth was unaffected, vaccination with neuET-DCs 
resulted in increased numbers of IFN-γ-producing CD8+ and CD4+ T cells at the tumor site, 
suggesting that vaccination was inducing some degree of antitumor immunity.  However, the 
CD8+ T cells were dysfunctional as they were not able to lyse neu-expressing cells in a 
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standard CTL assay, indicating that IFN-γ production by TILs is not an accurate predictor of 
tumor immunity.  In addition, the elevated numbers of IFN-γ+ CD8+ T cells at the tumor site 
was accompanied by a concomitant increase in CD4+FoxP3+ T cells.  These observations are 
consistent with a recent report by Nair et al., who witnessed an increased number of IFN-γ-
secreting CD8+ T cells with impaired cytolytic activity within spontaneous tumors of neu-N 
mice that had been repeatedly vaccinated against neu (32).  Moreover, the authors reported a 
parallel increase in the number of CD4+CD25+FoxP3+ T cells at the tumor site.  The study by 
Nair et al. and the results of this current report suggest that vaccination against neu in 
tolerant mice results in concurrent activation of both effector and regulatory T cells within 
the tumor environment.  These observations are in line with studies showing that tumor-
specific effector cells and regulatory cells are simultaneously activated in tumor-bearing 
mice (20, 50).  Altogether, these findings have serious implications for cancer vaccines, as 
they suggest that vaccination can unintentionally induce expansion of regulatory T cells that 
will impede tumor immunity and may actually expedite tumor growth. 
In conclusion, we have shown that VRP-DC vaccines are highly immunogenic in wild-
type mice, eliciting effective therapeutic immunity against established tumors.  
Unfortunately, VRP-DC vaccines alone were incapable of inhibiting tumor growth in tolerant 
mice, even when mice were provided with a repertoire of high-avidity T cells specific for 
neu.  Depletion of Treg with CY enhanced the efficacy of VRP-DC vaccines in tolerant mice, 
although the effect was transient due to resurgence in Treg numbers following vaccination.  
These results are consistent with the pervasive failure of DC vaccines at consistently 
inhibiting tumor growth in the setting of established disease, and indicate that viral activation 
of DCs cannot independently overcome Treg activity.  Therefore, future studies should 
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combine DC vaccination with therapies that either reduce Treg activity or decrease the 
sensitivity of effector T cells to Treg-mediated suppression.
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Figure 3-1:  VRP transduction results in high-level transgene expression and DC 
activation.  A.  DCs were transduced with neuET-VRP at an MOI of 10.  At 12 h post-
infection, DCs were stained for surface and intracellular expression of neuET.  B.  DCs were 
infected with either GFP-VRP (solid bars) or mock-infected with viral diluent (open bars).  
DCs treated with 100 ng/ml LPS (hatched bars) were included as a positive control for 
maturation.  At 24 h post-infection, DCs were stained for CD40, CD80, and CD86.  
Expression of costimulatory molecules on VRP-infected DCs was determined by gating on 
GFP+ DCs.  Bars represent the mean +/- SEM (n = 4 per group).  One of four similar 
experiments is depicted.  C.  DCs were either mock-infected (open squares), infected with 
GFP-VRP at an MOI of 10 (closed circles), or treated with 100 ng/ml LPS (open triangles).  
Cytokine levels were evaluated at the indicated times post-infection as described in Materials 
and Methods.  *p<0.0005 v. mock-DCs, Student’s t test. 
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Figure 3-2:  Vaccination of FVB/N mice with VRP-DCs induces neu-specific T cell and 
antibody responses.  A-B.  Female FVB/N mice (n = 6 mice per group) were vaccinated s.c. 
in the mammary fat pad with 1 x 106 DCs that had been transduced with either null-VRP 
(null-DCs) or neuET-VRP (neuET-DCs).  Mice were similarly boosted two weeks later.  At 
seven days post-boost, splenocytes were isolated and stimulated with either RNEU420-429 
peptide or irrelevant NP118-126 peptide for 12 h, and then assayed for intracellular IFN-γ 
expression.  A.  Representative staining of gated CD3+CD8+ T cells from mice vaccinated 
with either null-DC or neuET-DCs.  B.  The frequency of RNEU420-429-specific CD8+ T cells 
was determined by subtracting the frequency of NP118-126 specific T cells.  Bars represent the 
mean +/- SEM.  Data is representative of two experiments.  C.  Serum levels of anti-neu IgG 
were determined as described in Materials and Methods.  Bars represent the mean +/- SEM.  
*p<0.001, Student’s t test. 
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Figure 3-3:  Therapeutic VRP-DC vaccination of tumor-bearing FVB/N mice inhibits 
tumor growth and induces tumor-infiltrating effector T cells.  A.  Female FVB/N mice (n 
= 6 mice per group) were challenged with 2 x 106 NT2 tumor cells s.c. in the mammary fat 
pad on day 0.  Seven days later, mice received a single vaccination of either 1 x 106 null-DCs 
or 1 x 106 neuET-DCs in the contralateral mammary fat pad (solid arrow).  Tumor growth 
was monitored 2-3 times weekly throughout the experiment.  Mice were euthanized when the 
tumor exceeded >2 cm2 or became ulcerated.  Mice vaccinated with neuET-DC demonstrated 
a significantly prolonged 60-day survival (p = 0.0045, Kaplan-Meier survival analysis). One 
of two similar experiments is shown.  B.  Tumor-infiltrating lymphocytes (TIL) were isolated 
at 21 days post-vaccination.  neu-specific CD8+ T cells were determined by staining with H2-
Dq/RNEU420-429 tetramers.  For assessment of IFN-γ production, TIL were stimulated for 4 h 
with PMA/ionomycin prior to intracellular IFN-γ staining.  C.  Female FVB/N mice (8-10 
mice per group) were treated with rat IgG, 53.6.72 or GK1.5 antibodies as described in 
Materials and Methods.  Mice were then challenged with 2 x 106 NT2 cells and vaccinated 
with 1 x 106 neuET-DC seven days later (solid arrow).  Tumor growth was monitored 2-3 
times weekly, while T cell depletions were maintained by injection of antibody every 4-5 
days.  Cumulative data from two experiments is shown.  Survival of mice receiving rat IgG 
was significantly increased when compared to GK1.5-treated mice or 53.6.72-treated mice (p 
= 0.0001 and 0.0002, respectively, Kaplan-Meier survival analysis).  D.  Sera was collected 
from mice treated with rat IgG, 53.6.72 or GK1.5 at 2 weeks post-vaccination with neuET-
DCs and analyzed for the presence of neu-specific IgG as described in Materials and 
Methods.  Bars represent the mean +/- SEM (n = 3-6 mice per group).  *p<0.05, Student’s t 
test. 
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Figure 4:  Therapeutic VRP-DC vaccination fails to inhibit tumor growth in tolerant 
neu-N mice, despite an accumulation of IFN-γ-producing T cells at the tumor site.  A-B.  
Female neu-N mice (n = 6 mice per group) were vaccinated s.c. in the mammary fat pad with 
either 1 x 106 null-DCs or 1 x 106 neuET-DCs.  Mice were similarly boosted two weeks later.  
At seven days post-boost, splenocytes and sera were harvested and evaluated for RNEU420-
429-specific CD8+ T cells (A) or anti-neu IgG (B), respectively.  Bars represent the mean +/- 
SEM.  C.  Female neu-N mice (n = 9 mice per group) were challenged with 5 x 104 NT tumor 
cells s.c. in the mammary fat pad.  Three days later, mice were vaccinated with either 1 x 106 
null-DCs, 1 x 106 neuET-DCs or saline only, with vaccinations repeated on days 17 and 31 
post-tumor challenge (solid arrows).  Tumor growth was monitored 2-3 times weekly and 
animals were sacrificed when tumors were >2 cm2 or became ulcerated.  Cumulative data 
from two experiments is depicted.  D.  TIL from mice receiving saline (white bars), null-DCs 
(black bars) or neuET-DCs (hatched bars) were isolated at 5-6 weeks post-tumor challenge.  
TIL were stimulated for 4 h with PMA/ionomycin and then analyzed by intracellular IFN-γ 
staining.  Bars represent the mean +/- SEM (n = 3 mice per group).  One of two similar 
experiments is depicted.  E. TIL were isolated from vaccinated neu-N mice at 28 days post-
tumor challenge.  CD8+ TIL were purified by magnetic selection and used as effectors cells 
in a standard 51Cr-release assay with 3T3 or 3T3neu cells serving as targets.  neu-specific 
lysis was determined by subtracting the specific lysis of 3T3 target cells from the specific 
lysis of 3T3neu target cells.  *p = 0.01, Student’s t test. 
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Figure 3-5:  Treatment of neu-N mice with cyclophosphamide enhances the efficacy of 
VRP-DC vaccines.  A.  CD4+FoxP3+ cells are increased within NT2 tumors in neu-N mice 
vaccinated with neuET-DCs.  TIL were isolated from vaccinated or untreated neu-N mice at 
5-6 weeks post-tumor challenge and stained for intracellular expression of either FoxP3 or 
IL-10.  Bars represent mean +/- SEM (n = 3 mice per group).  One of two similar 
experiments is depicted.  B.  Female neu-N mice were inoculated with 5 x 104 NT2 cells in 
the mammary fat pad.  Two days later, mice received i.p. injections of either PBS (open bars) 
or 100 mg/kg CY (solid bars).  Lymphocytes from TDLN were then harvested after 2 days 
and stained for intracellular expression of FoxP3.  C-D.  Female neu-N mice (n = 6-9 per 
group) were challenged with 5 x 104 NT2 tumor cells and then treated with either CY (100 
mg/kg) or PBS two days later (dashed arrow).  On day 4 post-tumor challenge, mice were 
vaccinated with either neuET-DCs or null-DCs; vaccinations were repeated on days 18 and 
32 (filled arrows).  Mice were monitored 2-3 times weekly for the formation of palpable 
tumors (>9 mm2).  Animals were sacrificed when tumors were >2 cm2 or became ulcerated.  
There was a significant delay in tumor formation (C) for mice receiving neuET-DCs and CY 
in comparison to mice receiving null-DCs and CY (p = 0.036, Kaplan-Meier survival 
analysis). There was a modest trend that was not significant for improved survival (D) 
between mice receiving CY and vaccinated with either neuET-DCs or null-DCs (p = 0.1375, 
Kaplan Meier survival analysis).  E.  TDLN cells and TIL from neuET-vaccinated neu-N 
mice treated with either PBS (open bars) or CY (solid bars) were isolated 4 weeks post-tumor 
challenge and analyzed for expression of intracellular FoxP3.  Bars represent the mean +/- 
SEM (n = 3-6 per group).  *p<0.05, Student’s t test. 
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Figure 3-6 
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Figure 3-6:  Provision of tolerant mice with a neu-specific T cell repertoire does not 
improve VRP-DC vaccination.  Female neu-N mice (n = 8 mice per group) were challenged 
with 5 x 104 NT2 tumor cells on day 0 and then treated with CY (100 mg/kg) on day 2 
(dashed arrow).  On day 4, mice received i.v. injections of either saline (neuET/CY+S) or 1 x 
107 CD25-depleted splenic T cells from FVB/N mice (neuET/CY+T) as indicated by the 
open arrow.  The following day, mice were vaccinated with 1 x 106 neuET-DCs, with 
vaccination repeated on days 19 and 33 (solid arrows).  Mice were monitored 2-3 times 
weekly for the formation of palpable tumors (>9 mm2).  Animals were sacrificed when 
tumors were >2 cm2 or became ulcerated.  Cumulative data from two experiments is 
depicted.  There was no significant difference in tumor delay (A) or survival (B) between the 
two groups (p = 0.234 and 0.358, respectively, Kaplan-Meier survival analysis). 
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Supplemental Figure 3-1:  Antibody depletion of CD25+ T cells does not enhance the 
efficacy of VRP-DC vaccines in tolerant mice.  Female neu-N mice (n = 3 per group) 
received i.p. injections of 0.5 mg of either rat IgG or anti-CD25 monoclonal antibody (PC61) 
on days -7 and -4.  On day 0, mice were challenged with 5 x 104 NT2 tumor cells.  Three 
days later, mice were vaccinated with 1 x 106 neuET-DCs and boosted on days 17 and 31 
post-tumor challenge (solid arrows).  Tumor growth was measured 2-3 times weekly. 
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CHAPTER FOUR 
 
DISCUSSION 
We hypothesized that unlike current DC vaccines, virally-transduced DCs would be 
capable of inducing antitumor immunity and overcoming tolerance against tumor antigens.  
The advantages of using viral vectors include the potential for highly efficient transduction 
leading to copious production of tumor antigen (5); the capacity to deliver intact antigens 
which can be processed into multiple epitopes and presented on all haplotypes of MHC class 
I and/or II molecules (8, 106); and the provision of a simultaneous activation signal resulting 
in optimal DC maturation through TLR-dependent or independent pathways (1, 41).  
Furthermore, viruses have been shown to activate signaling pathways that are required for 
inhibiting the activity of Treg, which play an important role in maintaining tolerance against 
tumor antigens (103).  While several viral vectors have been evaluated for ex vivo 
transduction of DCs, many of them are marred by low transduction efficiencies, interference 
with DC maturation and questionable safety (45 and Table 4-1).  Because of these 
limitations, we have evaluated the feasibility of using DCs transduced with VRPs as cancer 
vaccines.  We demonstrated that VRP could efficiently transduce human immature mono-
DCs ex vivo, resulting in high-level transgene expression.  VRP transduction induced DC 
maturation and the secretion of proinflammatory cytokines.  Most importantly, human DCs 
could process and present a VRP-encoded antigen to CD8+ T cells, resulting in robust T cell 
expansion and acquisition of effector function.  Thus, VRP-transduced human DCs possessed 
several characteristics associated with potent DC vaccines. 
Based upon the results with human DCs, we proceeded to examine the feasibility of VRP-
DCs as cancer vaccines in vivo.  As observed with human DCs, VRPs could efficiently 
transduce murine bone marrow-derived DCs, resulting in a similar level of maturation and 
proinflammatory cytokine production.  Vaccination of wild-type mice with VRP-DCs 
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expressing a truncated neu oncoprotein induced neu-specific CD8+ T cell and antibody 
responses.  Furthermore, VRP-DC vaccines could induce regression of established neu-
expressing tumors in wild-type mice, indicating that VRP-DC vaccines are highly 
immunogenic.  However, VRP-DC vaccination of neu-N transgenic mice, which exhibit a 
profound immunological tolerance against neu, did not result in robust anti-neu T cell and 
antibody responses.  Moreover, therapeutic vaccination with VRP-DCs was incapable of 
inhibiting the growth of existing tumors in neu-N mice.  The efficacy of VRP-DC vaccines 
could be temporarily enhanced if mice were pretreated with CY to deplete Treg.  However, 
transfer of naïve T cells from FVB/N mice, which contain a repertoire of high-avidity T cells 
specific for neu, to tolerant mice was ineffective at augmenting vaccine efficacy.  Taken 
together, these results demonstrate that while highly immunogenic in nontolerant hosts, 
VRP-DC vaccines cannot independently overcome Treg-mediated suppression of tumor 
immunity in tolerant animals.  These findings have broad implications for cancer 
immunotherapy, arguing that monotherapy with potent DC vaccines is unlikely to induce 
effective tumor immunity in patients with established disease.  Therefore, DC vaccines 
should be evaluated in the context of a multimodality treatment strategy, which includes 
tactics for inhibiting immunoregulatory mechanisms. 
 
Feasibility of VRP-DCs as cancer vaccines 
VRP-transduced DCs appeared to possess several characteristics associated with potent 
DC vaccines, including high-level transgene expression, upregulation of costimulatory 
molecules and secretion of proinflammatory cytokines.  In comparison to other vectors 
commonly used for DC transduction, VRPs are generally equivalent if not superior in certain 
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areas (Table 4-1).  VRPs could transduce a mean of 37% of human immature mono-DCs at 
an MOI of 20 (Figure 2-2).  While this transduction efficiency is relatively efficient, there are 
at least two different strategies for further enhancement.  The first approach would involve 
packaging VRPs with glycoprotein coats harboring specific mutations that enhance tropism 
for DCs.  This can be accomplished rather easily by providing the specific mutant 
glycoprotein gene in trans during the VRP packaging process.  Several different VEE 
glycoprotein mutations have been identified in attenuated isolates or by mutagenesis (4, 7, 
18, 37, 64).  While these mutations have been characterized in regards to pathogenesis, their 
ability to confer tropism for human DCs in vitro remains to be fully assessed.  A preliminary 
study has suggested that VRPs packaged in the 3014 glycoprotein coat are greater than 2-fold 
more efficient at transducing human DCs in vitro when compared to VRPs packaged in the 
wild-type 3000 coat (K. Davis, T. Moran, J. Serody and R. Johnston, unpublished 
observations).  Thus, packaging VRPs in different glycoprotein coats can have dramatic 
effects on DC transduction efficiency.  Increasing the transduction efficiency would conserve 
a significant amount of resources, since large-scale production of VRPs is a costly venture.  
A second strategy for enhancing DC transduction efficiency would be to package the VRPs 
in cell lines that differentially glycosylate the viral glycoproteins, such as invertebrate cell 
lines or mammalian cell lines that are deficient in certain glycosylation enzymes.  Packaging 
replicon particles in these cell lines would result in preferential addition of high-mannose 
carbohydrate residues to the glycoproteins, which in turn results in enhanced binding to and 
infection of cells expressing the c-type lectin DC-SIGN.   This approach has been used to 
increase the tropism of Sindbis virus (49) and Ross River virus (R. Shabman and M. Heise, 
personal correspondence) for DCs.  However, enhancing the binding of VRPs to DC-SIGN 
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may have the deleterious repercussion of negatively modulating DC function, as interaction 
of pathogens with DC-SIGN can inhibit DC activation (36, 95). 
A potential issue with using VRPs for tumor antigen delivery is their propensity for 
inducing cell death.  Alphaviruses are cytopathic in vitro and in vivo (57).  VRP-induced cell 
death of DCs was likely due to apoptosis, as infected DCs stained positive for the apoptosis 
marker annexin-V (Figure A-1).  Although VRP-induced apoptosis could be detrimental, 
VRP-DCs remained predominantly viable for 12-24 hours pi in vitro, and it is conceivable 
that the half-life of DCs may be extended in vivo following adoptive transfer.  VRP-DCs 
should have sufficient time to migrate to regional lymph nodes and interact with T cells, as 
recent studies using two-photon microscopy have shown that priming of T cells by antigen-
bearing DCs occurs within the first 24 hours following vaccination (43, 68).  While DC 
apoptosis is generally viewed as detrimental for immune induction, it is possible that 
apoptosis of VRP-DCs may actually enhance activation of T cells through the process of 
cross-presentation.  In support of this idea, tumor antigens from human DCs infected with 
canarypox vectors can be efficiently cross-presented in vitro (73).  Another study by 
Racanelli et al. demonstrated that DCs transfected with a cytopathic self-replicating RNA 
were capable of eliciting potent T cell responses by cross-presentation of DC-associated 
antigen by endogenous APCs (78).  Moreover, apoptosis was necessary for the enhanced 
immunogenicity of a self-replicating DNA vaccine derived from SIN in vivo (54).  Apoptotic 
vesicles released from VRP-transduced DCs appear to be loaded with VRP-encoded antigen 
(Figure S-1), and it is likely that they also contain double-stranded RNA associated with viral 
replication.  This could result in enhanced cross-presentation of antigen within apoptotic 
vesicles via a TLR3-dependent pathway in endogenous APCs, as previously shown for cells 
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infected with SFV replicons (90).  Regardless of the potential negative effects of VRP-
induced apoptosis, it is obvious that VRP-DC vaccines have the capacity to stimulate 
antigen-specific T cells both in vitro and in vivo (Figures 2-6 and 3-2).  Nonetheless, the DC 
lifespan following VRP transduction could possibly be extended by using double-promoter 
VRPs expressing both the tumor antigen and an antiapoptotic protein such as bcl-2, which 
has been shown to inhibit alphaviral-induced cell death (56).  
Similar to vectors derived from Ad and SIN, VRP transduction induced phenotypic 
maturation of human DCs (Table 4-1 and Figure 2-4).  While transduction of human DCs 
with retroviral or lentiviral vectors does not interfere with the potential for maturation, 
transduction alone rarely activates the DCs and thus requires an additional maturation 
stimulus.  On the other hand, transduction with vectors derived from VV or HSV inhibits 
subsequent maturation of DCs unless certain viral genes are deleted from the vectors.  VRP 
transduction was similar to LPS treatment at inducing expression of CD40 and further 
upregulating CD86 expression in human DCs, yet was inferior at inducing CD80 and CD83 
expression.  Because upregulation of CD80 following DC activation is relatively slow in 
comparison to CD86 (38), VRP-mediated inhibition of host-cell translation may prevent 
maximal production of CD80.  Interestingly, CD80 expression has been associated with 
attenuation of immune responses (55, 101), and therefore reduced CD80 expression 
following VRP transduction could conceivably be advantageous.  It may be possible to 
further enhance maturation by simultaneously stimulating DCs with CD40L (12), although 
any negative effects of this strategy upon transgene expression would need to be evaluated. 
Another hallmark of VRP transduction was the copious secretion of proinflammatory 
cytokines, including TNF-α, IL-6 and IFN-α.  These cytokines are important for activation of 
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both the innate and adaptive immune systems.  TNF-α, IL-6 and IFN-α can induce activation 
of other APCs, and are likely responsible for the observed maturation of uninfected bystander 
DCs in the cultures (Table 2-1) (46, 60).  The production of type I IFN is generally 
considered advantageous for tumor immunity, as these cytokines can enhance NK cell 
activity (40), increase cross-presentation of tumor antigen (52), augment clonal expansion of 
CD4+ and CD8+ T cells (39, 51), and directly induce apoptosis of cancer cells (92).  Although 
type I IFN can be induced via TLR-dependent recognition of viral components, preliminary 
studies suggest that VRP induction of IFN-α/β is largely independent of signaling mediated 
by MyD88 or TLR-3 (R. Shabman and M. Heise, personal correspondence).  Since VRPs 
replicate in the cytoplasm of infected cells, it is likely that the viral recognition proteins RIG-
I and/or Mda5 are responsible for sensing VRP replication and initiating the IFN-α/β 
response (48).  The production of IL-6 following VRP transduction may assist in 
circumventing Treg function, as this cytokine has been shown to decrease the sensitivity of 
effector T cells to Treg-mediated inhibition (31, 77).  One potential shortcoming of VRP 
transduction was the limited induction of IL-12p70.  IL-12p70 promotes the production of 
IFN-γ and development of TH1 immune responses (50), which are often deemed necessary 
for effective tumor immunity.  Nevertheless, studies have shown that IL-12 production by 
DC vaccines is not necessary for induction of antigen-specific CTL responses in vivo (97), 
which is consistent with our observations that VRP-DC vaccines could induce neu-specific 
CD8+ T cells (Figure 3-2).  Although IL-12 production by VRP-DC vaccines does not appear 
to be required for activation of CD8+ T cells, IL-12p70 secretion could be enhanced either by 
codelivery of IL-12-expressing VRPs or by treatment with CD40L (13, 15). 
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VRP-DC vaccines had the capacity to stimulate T cell responses against foreign antigens 
both in vitro and in vivo.  Human DCs transduced with a FMP-VRP were very potent 
stimulators of FMP-specific CD8+ T cells, and were superior to TNF-α-matured DCs pulsed 
with an HLA-A2-restricted FMP peptide (Figure 2-5).  Moreover, VRP-transduced DCs 
could stimulate both CD8+ T cells and antibodies specific for neu in wild-type mice, resulting 
in the clearance of established tumors (Figures 3-2 and 3-3).  The ability of VRP-DCs to 
induce antibody responses is a significant advantage over classical peptide-pulsed DC 
vaccines, as humoral immunity often collaborates with T cell responses for complete 
clearance of tumor cells (83).  While the in vitro studies using human DCs demonstrated that 
VRP-DCs could stimulate antigen-specific memory T cells, the in vivo studies clearly show 
that VRP-DC vaccines can activate naïve T cells.  It is likely that the elevated costimulatory 
molecule expression and secretion of proinflammatory cytokines associated with VRP 
transduction contributed to the enhanced immunogenicity of VRP-DC vaccines.  However, 
future studies using DCs from mice deficient in various costimulatory molecules or cytokines 
need to be performed to support this postulation.  Although it was proposed that DCs 
transduced with whole tumor antigens have the capacity to stimulate both CD4+ and CD8+ T 
cells, the ability of VRP-DCs to directly stimulate CD4+ T cell remains to be determined.  
However, the observation that CD4-depleted animals fail to develop anti-neu antibodies 
following vaccination suggests that VRP-DCs have the capacity to activate TH cells (Figure 
3-3). 
While VRP-DCs caused tumor regression in nontolerant wild-type mice, they alone were 
unable to induce therapeutic tumor immunity in mice tolerant to HER-2/neu (Figure 3-4).  
The failure to induce tumor immunity was associated with an inability to stimulate robust T 
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cell and antibody responses specific for neu in tolerant neu-N mice (Figure 3-4).  These 
results are in striking contrast to results obtained in wild-type FVB/N mice, and emphasize 
the importance of validating vaccine efficacy in tolerant animal models.  Tolerance in neu-N 
mice has been most thoroughly characterized by Jaffee and colleagues, and is likely mediated 
by a combination of central and peripheral mechanisms (28, 82).  In the original paper 
describing tolerance in neu-N mice (82), Reilly et al. reported that newborn neu-N mice 
exhibited low expression of the neu transgene in the thymus, which could lead to central 
deletion of neu-specific T cells.  However, thymic neu expression was not detected in fetal or 
adult virgin mice, suggesting that there may be a window for high-avidity neu-specific T 
cells to escape central deletion.  Indeed, neu-specific T cells were detected following 
vaccination with irradiated 3T3neuGM cells, but at extremely low numbers.  A subsequent 
study, though, was unable to detect CD8+ T cells specific for the immunodominant epitope 
RNEU420-429 in neu-N mice, suggesting that these cells are likely deleted in the thymus (29).  
We similarly were unable to detect RNEU420-429-specific CD8+ T cells following vaccination 
with VRP-DCs.  To determine if tolerance in neu-N transgenic mice is primarily due to the 
absence of high-avidity effector T cells, we adoptively transferred CD25-depleted naïve T 
cells from FVB/N mice, which contain a repertoire of neu-specific T cells that have not been 
centrally deleted.  Provision of naïve T cells from nontolerant mice to did not enhance 
vaccine efficacy in tolerant animals (Figure 3-6).  This observation strongly argues that 
tolerance in neu-N mice is mediated by dominant regulatory mechanisms that actively 
suppress the expansion of neu-specific T cells.  It is possible that regulatory mechanisms may 
not inhibit the effector function of primed neu-specific T cells, although studies in a 
melanoma model would suggest otherwise (3).  We are currently planning experiments to 
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evaluate the ability of Treg to inhibit the activity of adoptively transferred effector T cells 
specific for neu in neu-N mice. 
There are many mechanisms that can mediate suppression of tumor immunity, including 
tumor-derived factors and regulatory T cells.  The observation that the same tumor cell line 
could be rapidly rejected in nontolerant mice but not in tolerant animals suggested that NT2 
tumors were not inherently immunosuppressive, and argued that suppression of tumor 
immunity was likely mediated by regulatory T cells.  In support of this argument, Ercolini et 
al. reported that CD8+ T cells specific for RNEU420-429 could be detected in about 10-20% of 
vaccinated neu-N mice that had been depleted of Treg with CY (28).  This study indicated that 
high-avidity neu-specific CD8+ T cells could escape thymic deletion in a minority of mice, 
but were actively suppressed in the periphery by Treg.  Adopting a similar strategy, we treated 
tumor-bearing neu-N mice with CY prior to vaccination with VRP-DCs.  This approach 
resulted in inhibition of early tumor growth, as indicated by the significant delay in the 
formation of palpable tumors (Figure 3-5).  There was also a trend for a prolonged survival, 
although this was not statistically significant.  The temporary inhibition of tumor growth was 
likely due to a transient depletion of Treg in the draining lymph node following CY treatment.  
Unfortunately, Treg numbers appeared to rebound quickly, as the number of CD4+FoxP3+ T 
cells in the tumor and in the tumor-draining lymph node was similar in either untreated or 
CY-treated mice by four weeks after tumor challenge (Figure 3-5).  A second treatment with 
CY two weeks after vaccination did not significant affect tumor growth, which is consistent 
with a previous report (65).  Altogether, these results suggest that dominant regulatory 
mechanisms in tolerant hosts actively inhibit tumor immunity, and that this suppression may 
be difficult to overcome by vaccination alone. 
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We argued that ex vivo transduction of DCs is an ideal vaccination strategy because it 
delivers antigen directly to the cell responsible for initiating adaptive immunity.  Ex vivo 
transduction with viral vectors is typically the preferable method for delivering antigens to 
DCs, since most vectors do not target DCs in vivo.  Consistent with this notion, studies have 
shown that vaccination with DCs transduced ex vivo with Ad vectors induced superior tumor 
immunity compared to direct vector inoculation (84, 96).  On the other hand, VRPs have 
been shown to target DCs in vivo, suggesting that direct inoculation of VRPs may not be 
inferior to VRP-transduced DCs at inducing tumor immunity.  Indeed, a preliminary study 
found that vaccination of nontolerant FVB mice with 106 infectious units of neuET-VRP3000 
was slightly superior to neuET-VRP3000-transduced DCs at inducing neu-specific CD8+ T 
cells, but was dramatically better at inducing neu-specific antibody responses (Figure A-2).  
Furthermore, tumor-bearing mice vaccinated with neu-VRP3000 had a similar 60-day survival 
compared to mice vaccinated with neuET-DCs, but tumor growth was more significantly 
inhibited in the former.  These results may cause some to question the use of VRP-DC 
vaccines since direct inoculation of VRPs was better at inducing tumor immunity in 
nontolerant mice.  However, there are certain instances where the use of VRP-transduced 
DCs would be preferable to direct VRP inoculation.  First, virally-transduced DCs can be 
used in persons that have preexisting anti-vector antibodies, which can neutralize directly 
injected viral vectors (47, 87).  While VRPs do not induce significant anti-vector immunity at 
low doses, vaccination with larger quantities of VRPs can result in appreciable antibody 
responses against the viral structural proteins, which can potentially decrease the efficacy of 
repeated VRP vaccinations (17).  Second, direct VRP inoculation may not stimulate maximal 
immunity in cancer patients since many exhibit defects in DC development and function 
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(32).  Therefore, ex vivo differentiation of DC precursors into functionally optimized DCs 
may help circumvent issues with cancer-mediated inhibition of DC activity.  Regardless of 
their greater immunogenicity in nontolerant mice, VRPs alone could not induce regression of 
preexisting tumors in tolerant animals (27 and B. Long and R. Tisch, personal 
correspondence), which ultimately makes them no better than VRP-DC vaccines with regards 
to breaking tolerance. 
Why do VRP-DC vaccines lack the ability to induce therapeutic tumor immunity under 
conditions of tolerance?  The reason is likely due to a combination of factors.  First, because 
tumor-specific CD8+ T cells recognize self proteins, most that evade negative selection in the 
thymus are of low affinity or avidity for their cognate antigen and are thus compromised in 
their ability to proliferate and kill tumor cells (19, 58, 61, 72).  Some studies have 
demonstrated that low-avidity CD8+ T cells can be coaxed into mediating tumor rejection 
(61, 63, 72).  However, most of these studies involved tumor cells expressing highly 
immunogenic viral antigens (i.e. influenza HA) or used adoptive transfer of TCR transgenic 
T cells into tolerant mice, thus artificially enhancing the tumor-specific T cell precursor 
frequency (63, 72, 103).  Second, although deletion of high-avidity CD8+ T cells specific for 
tumor antigens is not absolute, those that do escape into the periphery are of low frequency 
and are often anergic or are actively suppressed by regulatory T cells (3, 9, 21, 28, 53, 71, 75, 
80).  The case for active suppression is supported by our studies showing that provision of 
high-avidity T cells did not enhance vaccine efficacy.  Third, VRP-DC vaccines may not 
provide an adequate amount of neu antigen for activation of low-avidity T cells.  Activation 
of low-avidity T cells requires a significantly higher concentration of MHC-peptide 
complexes than needed for stimulation of high-avidity T cells (2).  Increasing the VRP 
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transduction efficiency or the number of injected DCs may remedy this issue.  Fourth, VRP-
DC vaccines may not secrete the appropriate types or amounts of proinflammatory cytokines 
needed for optimal activation of T cells and subversion of Treg activity.  Fifth, it is possible 
that the vaccine itself may be activating regulatory T cell populations.  Studies have shown 
that mature DCs are potent stimulators of Treg expansion both in vitro and in vivo (6, 100).  
Furthermore, Zhou et al. have shown that vaccination against a model tumor antigen can 
activate both effector and suppressor T cells, with the suppressor T cells eventually 
dominating (105).  Sixth, the tumors may recruit inhibitory cell populations other than Treg to 
dampen immune responses.  This is supported by our observation of large numbers of 
CD11b+Gr-1+ iMC within the tumors and spleens of vaccinated mice (Figure A-3).  A similar 
finding was reported by Melani et al., who described the presence of iMCs in the spleens of 
BALB/neu-T mice bearing spontaneous tumors (67).  Immune suppression mediated by Treg 
and iMC may not be mutually exclusive, as studies have reported that iMC may be 
responsible for induction of Treg in the periphery (42, 101).  Taken together, it is obvious that 
several factors may conspire against successful vaccination with VRP-DCs. 
Our data suggest that virally-transduced DCs can function as potent vaccines, yet still fail 
to overcome tolerance.  This was surprising, since studies have shown that viruses can break 
tolerance against self antigens and induce autoimmune disease (74, 76).  Furthermore, studies 
by Yang et al. have shown that viral vectors were capable of breaking CD8+ T cell tolerance 
and inducing tumor immunity, reportedly through persistent TLR stimulation (103).  
However, these studies were performed with highly immunogenic viral proteins used as 
tumor antigens.  Moreover, the study by Yang et al. also involved adoptive transfer of high-
avidity TCR transgenic T cells, which artificially inflates the precursor frequency of tumor-
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specific T cells and consequently lowers the threshold for inducing tumor immunity (66).  
Transgenic neu-N mice are likely a much more stringent model for tolerance, since the rat 
neu transgene is closely related to its murine counterpart and the neu-specific T cell 
repertoire is of low avidity.  Therefore, the mechanisms involved with maintaining tolerance 
in neu-N mice are likely more rigorous than those in transgenic mice expressing highly 
immunogenic antigens, and in turn require more than just a potent vaccine for their 
inhibition.  Indeed, a recent study has shown that TLR stimulation combined with viral 
vaccination was unable to induce tumor regression in transgenic mice that develop 
autochthonous melanomas (93).  Our studies also have an extra degree of difficulty in that we 
are trying to inhibit the growth of established tumors, which we feel is a more clinically 
relevant scenario than prophylactic vaccination.  The ability of prophylactic neu vaccines to 
protect mice from subsequent tumor challenge or spontaneous tumor development has been 
demonstrated in several models (14, 15, 82, 87, 98).  We were also able to demonstrate that 
prophylactic vaccination with VRP-DCs could significantly delay the growth of adoptively 
transferred tumors (Figure A-4).  However, we found that tumor growth was inhibited 
equally by both null-DCs and neuET-DCs, indicating that protection was independent of 
transgene expression and was likely due to an adjuvant effect of VRP-DC vaccination on 
innate immunity.  These observations suggest that the requirements for inducing prophylactic 
immunity are likely different and less stringent than those needed for inducing therapeutic 
immunity, which explains why vaccines in general have been unsuccessful in patients with 
existing disease. 
In summary, transduction of DCs with VRPs is a feasible strategy for inducing immune 
responses against foreign antigens both in vitro and in vivo.  The transduction efficiency of 
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human DCs with VRPs is appreciable, and there is the possibility for further enhancement.  
VRP transduction results in activation of DCs as illustrated by the increased expression of 
costimulatory molecules and the secretion of proinflammatory cytokines.  Moreover, VRP-
DCs expressing foreign antigens are potent stimulators of humoral and cellular immunity in 
vivo.  Unfortunately, therapeutic vaccination with VRP-DCs alone is incapable of inhibiting 
tumor growth in tolerant mice.  The reasons for this are likely multifactorial, but depend 
more heavily upon the dominant activity of Treg rather than inhibitory factors expressed by 
the tumor itself.  Taken together, our findings demonstrate that while potent vaccines 
composed of virally-activated DCs may be necessary for optimal tumor immunity, they alone 
are insufficient to break tolerance against tumor antigens.  These findings have broad 
implications for tumor immunotherapy, as they imply that vaccination alone is not a practical 
strategy for inducing regression of established tumors in cancer patients.  Altogether, 
effective immunotherapy will likely require:  i) a potent vaccine capable of stimulating both 
CD4+ TH cells and CD8+ CTLs; ii) a substantial number of high-avidity effector T cells; and 
iii) a strategy for inhibiting cellular mediators of tolerance.   
 
Future directions for VRP-DC vaccines 
Adjunct chemotherapy or mAb therapy.  Because the immune responses generated by VRP-
DC vaccines in tolerant mice are limited, it may be necessary to use adjunct chemotherapy or 
mAb treatment to inhibit tumor growth and allow time for the development of effective anti-
tumor immunity.  Several chemotherapeutic drugs have been evaluated for their ability to 
augment tumor immunotherapy (16, 25).  Most notably, CY has been frequently combined 
with cancer vaccination due to its ability to deplete Treg (28, 62, 85, 94)  Other studies have 
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shown that adjunct treatment with doxorubicin or paclitaxel can enhance the efficacy of 
vaccination with either irradiated tumor cell vaccines (65) or VRPs encoding neu (98).  
Doxorubicin has the additional advantage of causing immunogenic death of tumor cells, thus 
resulting in enhanced presentation of tumor antigens by DCs (11).  Gemcitabine has also 
proven effective in augmenting tumor immunotherapy, possibly due to its ability to eliminate 
immunosuppressive iMC in tumor-bearing animals (91).   The use of mAb against neu can 
further augment the activity of neu-specific vaccines, possibly by inducing proteosome-
dependent degradation of neu in tumor cells and consequently increasing MHC class I 
presentation of neu-derived epitopes (99).  Taken together, these studies suggest that adjunct 
chemotherapy or mAb treatment may be a straightforward and efficient approach for 
enhancing the efficacy of VRP-DC vaccines. 
 
Adoptive cell therapy (ACT) and VRP-DC vaccination.  Because the endogenous T cell 
repertoire is often suboptimal for effective tumor immunity, several researchers have tried to 
circumvent this issue through adoptive transfer of tumor-specific T cells that had been 
expanded ex vivo (35).  ACT can provide large numbers of tumor-specific effector T cells 
capable of inducing therapeutic regression of metastatic tumors (23).  However, ACT does 
have some limitations including the frequent deletion of transferred cells and an inverse 
relationship between the in vivo function of T cells and the length of ex vivo expansion (22, 
34).  Furthermore, adoptively transferred cells can still be inhibited by Treg in vivo, which 
likely explains why some patients have progressing tumors despite the presence of large 
numbers of tumor-specific T cells (86).  In support of the dominant nature of Treg, we found 
that providing tolerant mice with a naïve repertoire of T cells containing neu-specific 
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precursors was ineffective at overcoming Treg activity and consequently enhancing vaccine 
efficacy (Figure 3-6).  This is consistent with studies showing that tumor-specific CD8+ T 
cells fail to inhibit tumor growth when cotransferred with 10-fold fewer Treg, even when mice 
received concurrent injections of CD4+ TH cells (3).   
Despite our failure to augment vaccine efficacy through adoptive transfer of naïve T cells, 
it may be possible to use VRP-DCs to enhance the efficacy of ACT using large numbers of 
activated neu-specific T cell clones.  Concurrent DC vaccination has been shown to 
significantly improve the effectiveness of ACT, resulting in prolonged survival and enhanced 
antitumor activity of adoptively transferred CD8+ T cells specific for melanoma (59).  
However, this study was performed with TCR transgenic T cells that had only undergone one 
round of stimulation.  In reality, it would be extremely difficult if not impossible to generate 
a large number of antigen-specific T cells without multiple rounds of ex vivo stimulation, 
which can negatively affect the in vivo antitumor activity of these cells.  Therefore, further 
studies are required to evaluate the effectiveness of ACT using T cell clones generated from 
wild-type or tolerant mice that have been expanded ex vivo.  Incidentally, VRP-DCs may also 
be suitable for ex vivo expansion of T cell clones, as VRP-DCs were extremely efficient at 
expanding antigen-specific T cells in vitro (Figure 2-6).  Because VRP-DCs could present 
both MHC class I- and II-restricted epitopes, they may be useful for expanding CD4+ TH and 
CD8+ CTL.  The ability of VRP-DCs to expand antigen-specific T cells ex vivo may be 
useful for the treatment of other chronic diseases, such as human immunodeficiency virus or 
hepatitis C virus infection. 
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Concluding remarks 
The ability to exploit the immune system for elimination of malignant tumors remains the 
primary goal of tumor immunotherapy.  While the immune system performs remarkably well 
at protecting the body from foreign invaders, its ability to attack native cells expressing self 
antigens is, for good reason, unsatisfactory.  However, the immune system does have the 
capacity to mount effective and sometimes destructive immune responses against self-
proteins, as evident during autoimmune diseases such as type I diabetes and multiple 
sclerosis.  Furthermore, undeniable immune responses against tumors have been recorded in 
cancer patients, albeit at a very low frequency.  These observations suggest that cancer 
immunotherapy is an achievable yet daunting goal. 
Many researchers, including ourselves, have proposed that enhancing the efficacy of DC 
vaccines will lower the threshold for overcoming tolerance against tumors.  We hypothesized 
that virally-transduced DCs would be an ideal vaccine platform, as viral vectors can be used 
to efficiently deliver tumor antigens to DCs while simultaneously providing potent immune-
activating signals that may be necessary for breaking tolerance.  Based on this rationale, we 
evaluated the use of DCs transduced with VRPs as cancer vaccines.  We found that VRP-
DCs possessed several putative characteristics of an ideal DC vaccine, namely high-level 
transgene expression, increased expression of costimulatory molecules, secretion of 
proinflammatory cytokines and efficient presentation of antigen to reactive T cells.  
Moreover, VRP-DC vaccines expressing neuET were highly immunogenic in nontolerant 
mice, capable of stimulating both cellular and humoral immune responses and inducing 
tumor regression.  Despite their immunogenicity, VRP-DCs were unable to initiate effective 
tumor immunity against neu under conditions of tolerance.  Depletion of Treg prior to 
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vaccination enhanced the efficacy of VRP-DC vaccines in tolerant mice, suggesting that 
vaccination alone was incapable of overcoming tolerogenic mechanisms.  Furthermore, Treg 
activity in tolerant mice could not be overcome through provision of high-avidity naïve T 
cells specific for neu.  These results have significant implications for DC vaccines, as they 
imply that simply increasing the potency of the vaccine will be inadequate for circumventing 
tolerance unless additional measures are undertaken to inhibit regulatory mechanisms. 
We feel that it is time to move beyond the unilateral approach of increasing DC vaccine 
potency for the sake of overcoming tolerance, as immunoregulatory mechanisms appear to 
pose a barrier too formidable for success.  A paucity of high-avidity effector T cells and the 
dominant action of regulatory T cells collude against the induction of robust tumor immunity.  
These obstacles cannot be consistently surmounted by exclusively increasing the strength of 
DC vaccines, but also require strategies for increasing the repertoire of high-avidity T cells, 
such as through ACT, while concurrently inhibiting the activity of regulatory T cells through 
pharmacological intervention.  Unfortunately, these strategies are not without risk, as broadly 
inhibiting Treg can potentially lead to harmful autoimmunity.  Therefore, extensive research 
needs to be performed to identify the antigenic targets of regulatory T cells so that more 
selective elimination of tumor-specific Treg can be possible.  Moreover, better methods for 
isolating tumor-specific T cells and expanding them ex vivo while maintaining their function 
will be necessary for effective ACT.  Thus, the future directions for improving the efficacy of 
cancer vaccines are relatively clear, although the ability to reach the goal of curative 
immunity remains elusive. 
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Table 4-1:  Comparison of different viral vectors used for transduction of human DCs 
 
Vector 
MOI = Transduction 
Efficiency (Reference) 
Interference 
with DC 
maturation? 
Antigen 
presentation 
to T cells? Cytopathic? 
VRP 20 = 37.0% No Yes Yes 
Adenovirus 100 = >90% (104) 
1000 = 38-100% (20) 
1000 = >90% (10) 
10,000 = >95% (5) 
No (79, 104) Yes (10, 20) No (104) 
Vaccinia 
virus 
2.5 = 26-67.9% (44) 
10 = 30% (102) 
10 = 50-85% (8) 
Yes (8, 26, 
44) 
Yes (8, 102) Yes (26, 44) 
Retrovirusa 1-10 = 22-28% (81) 
1-10 = 15% (69) 
No (69) Yes (69, 81) No (69) 
Lentivirus 20 = 30-40% (24) 
150 = 30% (30) 
No (24, 30) Yes (24) No (24) 
SIN 
replicons 
50 = 18% (33) No (33) ND ND 
Herpesvirus 6 = >95% (88) 
10 = 60% (70) 
Yes (70, 88) 
Nob (89) 
Yesb (89) Yes (88) 
 
aInfects CD34-derived DCs only 
bHerpes simplex virus vectors with deleted IE and vhs genes 
ND, not determined 
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APPENDIX A 
 
ADDITIONAL DATA CHARACTERIZING VRP-TRANSDUCED DC VACCINES
Figure A-1 
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Figure A-1:  VRP infection induces apoptosis of DCs.  A.  Fluorescent micrograph of 
VRP-infected murine DCs at 12 hours post-infection.  Arrows indicate apparent apoptosis of 
infected DCs as demonstrated by membrane blebbing and release of GFP-filled vesicles.  B.  
Immmature DCs from neu-N mice were either mock-infected with PBS or infected with 
neuET-VRP (MOI = 10).  Some DCs were treated with camptothecin (10uM) as a positive 
control for apoptosis induction.  At various times post-infection, DCs were harvested and 
stained with FITC-conjugated annexin V and propidium iodide (PI).  DCs were then gently 
fixed with 0.5% formaldehyde and immediately analyzed by FACS. 
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Figure A-2:  Direct vaccination of FVB/N mice with neuET-VRP induces more effective 
tumor immunity compared to vaccination with neuET-DCs.   A-B.  For vaccination with 
VRP-transduced DCs, female FVB/N mice were vaccinated s.c. in the mammary fat pad with 
1 x 106 DCs that had been transduced with either null-VRP3000 (null-DCs) or neuET-VRP3000 
(neuET-DCs) at an MOI of 10.  For direct vaccination with VRPs, mice were inoculated in 
the footpad with 106 BHK infectious units (IU) of either null-VRP3000 (null-VRP) or neuET-
VRP3000 (neuET-VRP).  Mice were similarly boosted two weeks later.  At seven days post-
boost, splenocytes and sera were isolated and assayed for RNEU420-429-specific T cells (A) or 
anti-neu IgG (B), respectively, as described in Chapter 3.  Bars represent the mean +/- SEM 
(n = 6 mice per group).  C-D.  Female FVB/N mice (n = 6 mice per group) were challenged 
with 2 x 106 NT2 tumor cells s.c. in the mammary fat pad on day 0.  Seven days later, mice 
received a single vaccination of either 1 x 106 null-DCs, 1 x 106 neuET-DCs, 1 x 106 IU of 
null-VRP3000, or 1 x 106 IU of neuET-VRP3000.   VRP-DC vaccines were given s.c. in the 
contralateral mammary fat pad, while VRPs were injected into the footpad.  C.  Tumor 
growth of individual vaccinated mice.  D.  60-day survival of vaccinated mice.  *p<0.05 in 
comparison to neuET-DCs, Student’s t test.
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Figure A-3:  Transgenic neu-N mice bearing NT2 tumors have dramatically increased 
numbers of CD11b+Gr-1+ immature myeloid cells in the spleen and at the tumor site.  
Female neu-N mice were challenged with 5 x 104 NT2 tumor cells.  At 6-7 weeks post-tumor 
challenge, spleens from unchallenged mice or tumor-bearing mice were harvested, disrupted 
into a single-cell suspension, and analyzed for expression of CD11b and Gr-1 by FACS.  
Tumors were likewise excised, disrupted into a single-cell suspension, and then layered over 
a Percoll-Lympholyte M density gradient.  After centrifuging for 30 min at 2500 rpm, 25ºC, 
mononuclear cells at the Percoll-Lympholyte interface were harvested and analyzed for 
expression of CD11b and Gr-1 by FACS.  Representative data from a tumor-free (tumor-) 
mouse and a tumor-bearing (tumor+) mouse are depicted. 
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Figure A-4:  Prophylactic vaccination of tolerant mice with VRP-DCs nonspecifically 
prolongs survival following tumor challenge.  Female neu-N mice (n = 6 mice per group) 
were vaccinated with either saline, 1 x 106 null-DCs, or 1 x 106 neuET-DCs s.c. in the 
mammary fat pad.  Mice were boosted in a similar manner two weeks later.  At seven days 
post-boost, mice were challenged with 5 x 104 NT2 tumor cells.  Tumor growth was 
measured 2-3 times per week, and mice were euthanized when tumor area was >2 cm2 or 
when tumors became ulcerated.  Mice vaccinated with neuET-DCs had a significantly 
prolonged survival in comparison to saline-treated mice but not mice vaccinated with null-
DCs (p = 0.008 and 0.16, respectively, Kaplan-Meier survival analysis).  
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